

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The risk of invasive candidiasis with prolonged duration of ICU stay and broad-spectrum antibiotic use: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036452
Article Type:	Original research
Date Submitted by the Author:	11-Sep-2019
Complete List of Authors:	Zhang, Zhidan Zhu, Ran Luan, Zhenggang Ma, Xiaochun; the First Hospital of China Medical University,
Keywords:	ACCIDENT & EMERGENCY MEDICINE, INTENSIVE & CRITICAL CARE, Adult intensive & critical care < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **The risk of invasive candidiasis with prolonged duration of ICU stay and broad-**
4 **spectrum antibiotic use: a systematic review and meta-analysis**
5
6
7
8
9
10

11 **Running title:** Duration of ICU prior to candidemia
12
13
14
15
16

17 Zhidan Zhang MD,^a Ran Zhu MD,^a Zheng gang Luan MD,^a Xiao chun Ma MD^{a,*}
18
19

20 a Department of Critical Care Medicine, the First Hospital of China Medical
21 University, Shenyang 110001, Liaoning, China
22
23
24
25
26
27

28 ***Corresponding author:** Xiao chun Ma
29
30

31 Department of Critical Care Medicine, the First Hospital of China Medical University,
32 Shenyang 110001, Liaoning, China
33
34
35

36 Tel: 008613840192939;
37
38

39 E-mail: xiaochun06@yeahmca.cn
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: This study aimed to evaluate the duration of intensive care unit (ICU) stay prior to onset of invasive candidiasis (IC)/candidemia.

Design: Systematic review and meta-analysis.

Data Sources: Pubmed, Cochrane, Embase, and Web of Science databases were searched through June, 2019 to identify the relevant studies.

Eligibility Criteria: Adult patients who had been admitted to the ICU and developed an invasive candidiasis infection.

Data extraction and synthesis: Duplicate data extraction and quality assessment were conducted. Meta-analysis and meta-regression were conducted in Comprehensive Meta-Analysis statistical software.

Results: The mean age of patients ranged from 28.2 to 76 years across studies. The pooled mean duration of ICU stay before the onset of candidemia was 12.93 days (95% confidence interval [CI]: 11.70 – 14.15). The pooled mean duration of ICU admission prior to the onset of candidemia ranged from 4 to 47 days. IC patients had a higher proportion of broad-spectrum antibiotic use (89.13%, 95% CI: 82.68 – 93.37%) before the onset of IC, which was higher than that observed in non-IC patients (77.36%, 95% CI: 52.25 – 91.43%). The pooled mean duration of hospital stay was 36.26±5.32 days (95% CI: 25.84 – 46.67) and the pooled mean mortality rate was 49.25±2.16% (95% CI: 45.02 – 53.48%). There was no significant difference in duration of hospital stay or overall mortality between patients with or without *C. albicans*, yet a significant difference was demonstrated in mean length of ICU stay (2.82 days, $P < 0.001$). The meta-regression analysis found that South American

1
2
3 countries had significantly longer mean duration of ICU admission prior to
4
5 candidemia onset compared with Asian, European, Australian, and North American
6
7 countries.
8
9

10 **Conclusions:** The current findings demonstrate that a more proactive strategy for the
11
12 diagnosis of IC should be considered in these patients, especially relevant for Asian
13
14 physicians.
15
16

17
18
19
20
21
22 **KEYWORDS:** Invasive candidiasis, candidemia, intensive care unit, length of stay,
23
24 antibiotic, mortality
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This was a systematic review to indicate that patients with IC were associated with the use of broad-spectrum antibiotics and the length of ICU stay.
- Meta-regression was used to test differences in regional subgroups, and statistical significance was found.
- Two independent reviewers performed a methodological quality assessment, with a third reviewer consulted for any uncertainties, but this systematic review lacked a pre-specified protocol and its preliminary registration.
- High heterogeneity had existed in some overall and subgroup analyses; in addition to regional differences found in this study, there may be other potential factors that may explain heterogeneity that need to be further explored.
- Due to lack of data, the possible correlation between prolonged exposure to broad-spectrum antibiotics and the time of candidemia onset after ICU admission could not be assessed.

INTRODUCTION

Candida species account for 70% to 90% of invasive fungal infections and are the most frequent cause of fungal infections in patients admitted to the intensive care unit (ICU) [1]. Invasive candidiasis (IC) is associated with a high mortality rate (range: 40% to 60%) [1, 2]. Over recent decades, the incidence of IC has been gradually increasing in most regions [3], ranging from 0.5 to 32 cases per 1,000 ICU admissions. It has been found that there is a significant difference in the incidence of IC among several countries in Latin America and North America; however, data from Asia-Pacific countries are still relatively rare [4]. Candidemia has been described as the most common manifestation of IC, and the further infection of the liver, spleen, heart valves, or eye might also occur after a bloodstream infection [5]. In the past, the main *Candida* species isolated from patients with IC was *C. albicans*. However, non-*C. albicans* species has seen a rising proportion and now account for approximately 50% of all cases of IC in the past two decades [1,6-8].

Diagnosis and management of IC remains challenging for physicians in the ICU [1, 2]. The early initiation of empiric antifungal treatment has been demonstrated to improve the prognosis of invasive candidiasis [2, 9]. However, there is difficulty in the diagnosis of IC which can delay timely antifungal treatment [2, 10]. Blood culture remains the gold standard for the diagnosis of invasive candidiasis, but its sensitivity is variable (21% to 71%) [11].

In order to improve the diagnosis of IC, and to identify the patients who may best benefit from prophylactic, preemptive, or empirical therapy prior to, or at an early stage of ICU admission several methods in predicting the development of IC based on their associated risk factors have been developed [12, 13]. The risk factors in the various predictive models include broad-spectrum antibiotic use, central venous

1
2
3 catheter placement, total parenteral nutrition, hemodialysis (days 1–3 in the ICU), any
4
5 surgery, immunosuppressive use, pancreatitis prior to ICU admission, and steroid use.
6
7 However, different risk factors are included in the different predictive models. In
8
9 addition, potential risk factors such as *Candida* colonization [14] and mechanical
10
11 ventilation [15] have not been included in these models.
12
13

14
15 Long-term ICU stay has been reported as a risk factor for IC [11, 14-16]. Only a
16
17 few studies have examined the interval between ICU admission or initiation of broad-
18
19 spectrum antibiotics and the diagnosis of IC. However, the specific duration of long-
20
21 term ICU stays and the prolonged use of broad-spectrum antibiotics are often
22
23 arbitrarily defined and inconsistent among studies [6, 12, 15, 17-19]. Furthermore, a
24
25 large majority of severe candidiasis cases are caused by endogenous colonization.
26
27 This may be the primary reason for causing a delay of 7 to 10 days between exposure
28
29 to risk factors and the development of IC [20].
30
31

32
33 Thus, the objective of this systematic review was to evaluate the risk factors
34
35 associated with the development of candidemia, specifically the length of ICU stay
36
37 and the use of broad-spectrum antibiotics.
38
39

40 41 42 **METHODS**

43 44 **Search strategy**

45
46
47 The study was performed in accordance with guidance from the Preferred
48
49 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed,
50
51 Cochrane, Embase, and Web of Science databases were searched through June, 2019
52
53 using the following search terms: invasive candidiasis, critical care, critical illness,
54
55 candidemia, and antibiotic agents. A detailed search strategy for the Medline database
56
57 is shown in Figure 1.
58
59
60

1
2
3 Randomized controlled trials (RCTs), cohort studies, case-controlled, and cross-
4 sectional studies were included. All studies included adult patients who were critically
5 ill, who had been admitted to the ICU, and who tested positive for *Candida* species
6 using blood culture analyses. Studies had to have reported quantitative outcomes of
7 interest and no author was contacted. Letters, comments, editorials, case reports,
8 proceedings, personal communications, and case series were excluded. Studies in
9 which patients were diagnosed with candidiasis prior to ICU admission were
10 excluded. Studies that did not evaluate the incidence of candidiasis as a primary
11 objective, or that were not designed to evaluate risk factors/prognostic factors of
12 patients with candidiasis were also excluded.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Patients and/or members of the public were not involved in this study; therefore,
ethical approval and informed consent were not necessary as meta-analyses do not
involve human subjects and does not require institutional review board review.

Study selection and data extraction

Studies identified by the search strategy were reviewed for inclusion and data
was extracted by two independent reviewers. Where there was uncertainty regarding
study eligibility, a third reviewer was consulted. The following information / data was
extracted from studies that met the inclusion criteria: the name of the first author, year
of publication, country, study design, type of ICU, number of participants in each
group, participants' age and gender, the presence of *C. Albicans*, the presence of
neutropenia, and antifungal treatment (especially the use of broad-spectrum
antibiotics). The following data were also extracted from each article: length of stay in
hospital/ICU, length of stay prior to ICU admission, duration of ICU stay prior to
candidemia onset, antibiotic therapy prior to candidemia onset, duration of antibiotic

1
2
3 therapy prior to candidemia onset, and overall mortality.
4
5
6
7

8 **Quality assessment**

9
10 We used the Risk of Bias In Non-randomized Studies of Interventions (ROBINS-
11 I) tool to assess the quality of the included studies [21]. ROBINS-I is based on the
12 Cochrane RoB tool and is suited for evaluating non-randomized studies that compare
13 the health effects of different interventions. ROBINS-I covers 7 different bias
14 domains: bias due to confounding, bias in selection of participants into the study, bias
15 in classification of interventions, bias due to deviations from intended interventions,
16 bias due to missing data, bias in measurement of outcomes, and bias in the selection
17 of reported results [22-23]. In this systematic review, 2 independent reviewers
18 performed the quality assessment, with a third reviewer consulted for any
19 uncertainties.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

36 **Statistical analysis**

39 Study characteristics were summarized as mean \pm standard deviations (SD),
40 mean (range), median (range), or median (IQR) for age or duration of antifungal
41 treatment; and percentage (%) for sex, rate of *C. Albicans* isolated, neutropenia, and
42 antifungal treatment used in each study.
43
44
45
46
47

48 Clinical outcomes, including hospital stay, ICU length of stay, length of stay
49 prior to ICU admission, duration of ICU admission prior to candidemia onset, and
50 duration of antibiotic therapy prior to candidemia onset were represented as mean
51 (range: [min. – max.]), median (range), or median (IQR [interquartile range: 1st – 3rd
52 quartiles]). The rate of antibiotic therapy prior to candidemia onset and overall
53 mortality rate were presented as a percentage (%), according to the data extracted
54
55
56
57
58
59
60

1
2
3 from the study. All the clinical outcomes were further summarized for overall studies,
4 or subgroups of studies (with studies' number ≥ 2) given type of study, presence of
5 neutropenia, type of ICU, type of *C. Albicans* isolated, presence of IC/candidemia,
6 and region/country, and meta-regression analyses were further used to investigate
7 statistical importance of the potential moderators. Before summarizing, studies that
8 reported quantitative data with median (range) and/or median interquartile range
9 (IQR) were transformed into mean \pm SD according to Wan et al. [24]
10
11
12
13
14
15
16
17
18

19 The effect size for the following meta-analysis were set as length of hospital
20 stay, ICU length of stay, duration of ICU admission prior to candidemia onset, and
21 overall mortality compared between subgroups, *C. Albicans* and non-*C. Albicans*. The
22 effect size was calculated as mean difference with 95% CI (Lower, Upper limit) and
23 significance of *p*-values in length of days or rate ratio with 95%CI and *p*-values in
24 overall mortality for each given study and then a pooling effect was derived
25 thereafter. A difference in means of length days < 0 (or rate ratio of overall mortality
26 rate > 1) indicated the pooling effect favored non- *C. Albicans* subgroup; difference in
27 means of length days > 0 (or rate ratio of overall mortality rate < 1) indicated the
28 pooling effect favored *C. Albicans* subgroup; difference in means of length days = 0
29 (or rate ratio of overall mortality rate = 1) indicated the pooling effect was similar
30 between *C. Albicans* and non-*C. Albicans* subgroups. Heterogeneity was evaluated
31 using a χ^2 -based Cochran's Q statistic and I^2 , that the random effect model
32 (DerSimonian-Laird method) and meta-regression analyses with potential moderators
33 were considered for the meta-analysis if either Q statistic with P values < 0.10 or
34 $I^2 > 50\%$ were derived; otherwise, a fixed effect model (Mantel-Haenszel method) was
35 considered for the meta-analysis. For the Q statistic, P values < 0.10 were considered
36 statistically significant for heterogeneity. For the I^2 statistic, heterogeneity was
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 assessed as follows: no heterogeneity ($I^2 = 0 - 25\%$), moderate heterogeneity ($I^2 = 25 -$
4
5
6 50%), large heterogeneity ($I^2 = 50 - 75\%$), and extreme heterogeneity ($I^2 = 75 - 100\%$).

7
8 A two-sided P value of <0.05 was considered significant.
9

10 Countries were classified according to their continent, but since the meta-
11
12 analysis of this research topic from China has not yet been seen, in following
13
14 discussions, research from China will be selected and specifically examined.
15

16
17 The publication bias was assessed by funnel plot with Egger's test and Classical
18
19 fail-safe N test for all the enrolled studies (except for subgroups). The absence of
20
21 publication bias was indicated by the data points forming a symmetric funnel-shaped
22
23 distribution and a 1-tailed significance level of $P > 0.05$ in Egger's test.[24] All
24
25 analyses were performed using Comprehensive Meta-Analysis statistical software,
26
27 version 3.3.070 (Biostat, Englewood, NJ, USA).
28
29
30
31
32

33 **RESULTS**

34 **Literature search results**

35
36
37 A total of 1875 articles were retrieved by the primary search, and 1800 articles were
38
39 excluded after the title and abstract were screened based on the inclusion/exclusion
40
41 criteria (Figure 1). Seventy-five articles underwent full-text review, and 34 articles
42
43 were excluded due to irrelevant objectives or study designs ($n=19$), reporting
44
45 predictor/prognostic factors for mortality ($n=4$), neonatal or pediatric intensive care
46
47 unit ($n=5$), not designed for invasive candidiasis ($n=4$), and not reporting outcomes of
48
49 interest ($n=6$). Thus, 41 articles were included in the systematic review.
50
51
52
53
54
55
56
57

58 **Study characteristics**

1
2
3 The characteristics of the 41 studies are summarized in Table 1 and Table 2 [14-16,
4 25, 27-29, 31-50]. A total of 10,692 patients were included across the studies, with the
5 number of patients in each study ranging from 12 to 1,400. The mean age of the
6 patients ranged from 28.2 to 76 years. The majority of the patients were males (range:
7 40% to 75.9%). These studies were conducted in different countries: 19 in Europe, 14
8 in Asia, 1 in the US, 4 in South America, 2 in Australia and 1 multinational study
9 (Australia, Belgium, Greece, Brazil).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1. Characteristics of studies included in this systematic review

Studies 1 st Author (year)	Country	Study design	Type of ICU	Total number of patients	IC and Candidemia	No. of patients	Age (years)	Male (%)	<i>C.Albica</i> isolated (%)	Neutropen ia (%)	Antifungal treatment	
											Duration of treatment	Antifungal treatment used
Zhao H (2018)	China	retrospective cohort	ICU		Candidemia	95	69.3±16.5	57.90%	59	—	—	17.90%
Ding R (2018)	China	retrospective cohort	ICU	72	Candidemia	72	62.5 (49.8, 77.0)§	62.50%	15	—	—	Fluconazole 30.6% Voriconazole 9.70% Echinocandin 44.4%
Yang et al. (2017) ^[25]	China	Retrospective cohort study (China-SCAN)	ICU	306	Early-onset IC	105	56.9 (19.94)§	64.80%	47.7	1.90%	—	Fluconazole (39.3%) Caspofungin(21.3%) Voriconazole (19.1%) Micafungin(10.1%) Itraconazole(5.6%) Amphotericin B (3.4%) Combined therapy (1.1%)
						201	64.0 (19.67)§	70.60%	36.1	1.50%	—	Fluconazole (36.9%) Caspofungin(25.1%) Voriconazole (17.9%) Micafungin(7.8%) Itraconazole(9.5%) Amphotericin B (1.7%) Combined therapy (1.1%)

1													
2													
3													
4													
5	Tukenmez	Turkey	Case-	ICU	73	Candidemia	36	65 (52-	52.80	75	17.6 ±	Caspofungin	
6	Tigen E (2017)		control					73)†	%		11.7	Posaconazole	
7			study								days	Voriconazole	
8												Itraconazole	
9												Fluconazole	
10												Amphotericin B	
11													
12													
13													
14													
15	Baldesi O	France	Case-	ICU	246,45	Candidemia	851	65 [54;	62.60	61.40	5.10%	—	—
16	(2017)		control					75]§	%				
17			study										
18													
19													
20													
21													
22	Rudramurthy	India	prospective	MICU, SICU	1161	Candidemia (C.	74	39 (16 -	62.20	—	—	—	fluconazole (20.3)
23	SM (2017)		cohort			auris)		58.5)§	%				echinocandin(9.5)
24													
25													
26													
27													
28													
29	Kawano Y	Japan	retrospectiv	ICU	4,136	Candidemia	25	69 (24 -	56.00	52	0	—	antifungal treatment: 32%
30	(2017)		e cohort					88)†	%				
31													
32	OrtizRuiz et al.	Colombi	Case-	Polyvalent,	243	Candidemia	81	64.5 (51-	51.85	42	—	—	—
33	(2016) [16]	a	control	cardiovascularI				78) §	%				
34			study	CU									
35													
36													
37													
38													
39													
40													
41													
42													
43													
44													
45													
46													

1													
2													
3													
4													
5	Gong et al.	China	Prospective, MICU, SICU, 306	Integrated ICU	306	Candidemia	98	62.2±17.2	62.20	100	3.10%	12.85	Triazole (64.7%)
6	(2016) [47]		cohort			(<i>C. albicans</i>)		6	%			days	Echinocandin (31.8%)
7			study										Polyenes (0%)
8			(China-SCAN)										
9													
10													
11						Candidemia	146	61.4±21.3	72.60	—	1.40%	20.4	Triazole (62.8%)
12						(Non- <i>Candida albicans</i>)		6	%			days	Echinocandin (34.1%)
13													Polyenes (2.3%)
14													
15	Playford EG	Australia	prospective cohort	MICU, SICU	6,714	ICU-acquired IC	96	—	—	66	—	—	—
16	(2016)					Control (no IC)	6618	—	—	—	—	—	—
17													
18													
19													
20	Pinhati HM	Brazil	cross-sectional	ICU	40	fluconazole-resistant <i>C. parapsilosis</i> (FRCP)	21	70 (23–91)†	66.70	—	—	—	any: (33.3)
21	(2016)												fluconazole: (19.0)
22													
23													
24													
25						fluconazole-susceptible <i>Candida</i> species (FSC)	19	76 (35–90)†	57.90	—	—	—	any: (15.8)
26													fluconazole: (15.8)
27													
28													
29													
30	Aguilar et al.	Spain	Prospective cohort study	SICU	22	IC	22	66 (53.7–74.2) §	72.70	59.1	—	10 (5.0–16.5)	Echinocandins (86.4%)
31	(2015) [15]											days	Fluconazole (13.6%)
32													
33													
34	Fochtman et al.	Austria	Retrospective cohort study	Burn ICU	174	Candidemia	20	39 (17–88) †	60%	60	—	—	Triazoles (70%)
35	(2015) [27]												
36						Control	154	58 (17–94) †	61%	—	—	—	Echinocandins (30%)
37													
38													
39													
40													
41													
42													
43													
44													
45													
46													

1													
2													
3													
4													
5	Klingsporet al.(2015) [28]	14 countries in Europe	Prospective cohort study	SICU	807	IC	779	63(0–91)†	62.50%	54	—	—	Fluconazole (60%) Caspofungin (18.7%) Amphotericin B (13%) Voriconazole (4.8%)
6													
7													
8													
9													
10	Chakrabarti et al. (2015) [29]	India	Prospective cohort study	MICU, SICU	1400	Candidemia	1400	49.7 ± 17.7	—	20.9	1.30%	9.0 (5-15)§	Azoles (72.0%) Echinocandins (18.3%) Amphotericin B (14.4%)
11													
12													
13													
14	Liao et al. (2015) [14]	China	Prospective cohort study (China-SCAN)	MICU, SICU, Mix ICU	306	Flu-S	129	62.4±19.5	68.20%	60.5	3.10%	—	Monoantifungaltherapy (64.5%) Fungal drug adjustment (35.7%) Completely improved(34.6%)
15													
16													
17													
18													
19													
20													
21													
22													
23													
24													
25													
26	Kautzky S (2015)	Austria	prospective cohort	MICU	65	IC (invasive candida infection)	5	28.2 ± 9.7	20%	—	0%	15.40 ± 13.9	100%
27													
28													
29													
30													
31													
32													
33													
34													
35	Karacaer et al. (2014) [31]	Turkey	Prospective cohort study	ICU service	burn 2362	IC	63	70.2 ± 19.5 (14-95)	54%	64	—	—	—
36													
37													
38													
39													
40													
41													
42													
43													
44													
45													
46													

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Colombo et al. (2014) ^[32]	Brazil	Retrospective cohort study	ICU	1,392	Candidemia	647	66 (18–97) †	50.7	44	2.50%	—	Amphotericin B (period 1:27.8%; period 2: 13.4%) Echinocandins(period 1: 5.9%; period 2: 18.0%)
Hu et al.(2014) ^[48]	China	Prospective cohort study (China-SCAN)	ICU	294	CRCBSI	29	69.4 ± 19.1	75.90 %	28.6	—	19.0 ± 13.3 days	Fluconazole (39.3%) Caspofungin(25.0%) Voriconazole(14.3%) Micafungin (10.70%) Itraconazole(10.7%) Amphotericin B (0%) Two-drug combination (0%)
					Non-CRCBSI	265	60.7±20.2 %	68.30	40.3	—	16.7 ± 13.3 days	Fluconazole (36.7%) Caspofungin(23.6%) Voriconazole(19.2%) Micafungin (8.7%) Itraconazole(7.9%) Amphotericin B(2.2%) Two-drugs combination(1.7%)
Lortholary O (2014)	France	prospective cohort	ICU	2507	ICU-acquired candidemia	1206	60 ± 17	62.00 %	57.10	—	—	Fluconazole(55.4 %) Echinocandins(26.2 %) Others (including combination)(12.6 %)
					non-ICU acquired candidemia	1301	60 ± 17	58.70 %	54.90	—	—	Fluconazole(59.9 %) Echinocandins(19.1 %) Others (including combination)(13.3 %)
Yapar N (2014)	Turkey	retrospective cohort	ICU	1076	Candidemia	66	54.4 ± 23.9	53%	53	—	—	9%

						Control (non-Candidemia)	1010	53.2 ± 23.0	63%	—	—	—	6.30%
Guo et al.(2013) ^[49]	China	Prospective cohort study (China-SCAN)	MICU SICU General Emergency Neurologic ICU	306	Candidemia	306	61.5±20.0	68.60%	40.2	1.60%	14 (0-104)† days	Fluconazole (37.7%) Caspofungin (23.9%) Voriconazole (18.3%)	
Giri S (2013)	India	prospective cohort	ICU	5,976	Candidemia	39	35.14 (3days-79y)	61.50%	4				
Tortorano et al.(2012) ^[33]	Italy	Prospective cohort study	MICU, SICU	384	Candidemia	276	—	—	60.9	—	—	Fluconazole (63%) Amphotericin B (22%) Caspofungin (7%) Voriconazole (6%)	
Ylipalosaari et al. (2012) ^[34]	Finland	Retrospective cohort study	MICU,SICU	82	ICU-acquired candidemia	38	63 (45-69) §	71%	76.3	—	Median: 22 days	Fluconazole (73%) Amphotericin B (34%) Echinocandins (31%)	
					non-ICU-acquired candidemia	44	64 (56-75) §	61%	68.9	—	Median: 24 days	Fluconazole (77%) Amphotericin B (35%) Echinocandins (40%)	
Pasero D et al. (2011) ^[35]	Italy	Prospective cohort study	SICU	349	Candidemia	26	60±21	61.50%	73	—	—	—	

						Control	323	67±16	65.30 %	—	—	—	
	Han SS et al. (2010) [36]	Korea	Case-control study	MICU	52	Candidemia	49	57.6±14.1	—	65	25%	11 (1-45)† days	Amphotericin B (71.4%) Fluconazole (28.6%)
						Control	147	57.4±14.0	—	—	8%		
	Pratikaki M et al. (2009) [37]	Greece	Case-control study	Multi-disciplinary ICU	855	Candidemia	33	57±18	64%	33.3	0%		Amphotericin B (57.1%)
						Control	132	58±18	70%	—	0%	>14 days	Voriconazole(17.9%), Caspofungin (14.3%) Fluconazole (10.7%)
	Playford et al.(2009) [38]	Australia	Prospective cohort study	MICU, SICU	615	IC	15	NA	NA	73.3	0%	—	—
	Holleyetal.(2009) [39]	Australia, Belgium, Greece, Brazil	Retrospective cohort study	Multi-disciplinary ICU	189	Candidemia (<i>C. albicans</i>)	104	56.5±17.1	63.50 %	100	—	1(1-32)†days	Fluconazole (37%) Amphotericin B (31%)
						Candidemia (Non- <i>Candida albicans</i>)	85	58.9±16.3	44.70 %	—	—		Fluconazole and amphotericin B (15%)
	Choi et al. (2009) [40]	Korea	Retrospective cohort study	ICU	497	Candidemia (<i>C. albicans</i>)	54	49±23	44.40 %	100	13%	—	Amphotericin B (77.8%) Fluconazole (16.7%)
						Candidemia	27	48±25	44.40 %	—	19%	—	Fluconazole and amphotericin B (5.6%)

Author (Year)	Country	Study Design	Setting	n	Infection	n	APACHE II	Mortality %	Survival %	LOS (days)	Cost (€)	Treatment	
Yap et al (2009) [50]	China Hong Kong	Retrospective cohort study	MICU SICU	128	Candidemia (<i>C. glabrata</i> , <i>C. krusei</i>)	128	54 (43-68) §	63.30 %	56	11%	—	Amphotericin B (39.1%) Fluconazole (38%) Amphotericin B+fluconazole (13%) Caspofungin or voriconazole (9.8%)	
Chow et al. (2008) [41]	US	Case-control study	MICU, SICU	926	Candidemia (Non- <i>Candida albicans</i>)	67	62.3±14.5	57%	—	—	—	—	Fluconazole (84.8%) Amphotericin B (23.9%) Caspofungin (10.9%) Voriconazole (4.3%)
					Candidemia (<i>C. albicans</i>)	79	57±17.0	60%	100	—	—	—	Fluconazole (63%) Amphotericin B (33.3%) Caspofungin (11.1%) Voriconazole (0%)
					Control	780	62.3±17.4	56%	—	—	—	—	Fluconazole (100%) Amphotericin B (14.3%) Caspofungin (0%) Voriconazole (0%)
Bougnoux et al. (2008) [42]	France	Prospective cohort study	MICU SICU HU BU	290	Candidemia	57	56.1±18.2	67%	54.2	19.30%	13.2±10.3 days	Fluconazole (78.3%) Amphotericin B (52.2%) Flucytosine (15.2%)	

1												
2												
3												
4												
5	Girãoet	Brazil	Prospective ICU	73	Candidemia	40	51(12-	60%	—	—	—	—
6	al.(2008) [43]		cohort study		(Non- <i>Candida</i>		86)*					
7					<i>albicans</i>)							
8					Candidemia (C.	33	51(15-	40%	100	—	—	—
9					<i>albicans</i>)		86)*					
10												
11	Dimopoulos et	Greece	Prospective MICU, SICU	56	Candidemia (C.	36	60.5 ±	44.40	100	0%	Respon	Fluconazole as prophylaxis:
12	al. (2008) [44]		cohort study		<i>albicans</i>)		14.9	%		(excluded)	e rate:	Amphotericin B (75%)
13											(80.6%)	Caspofungin (25%)
14												
15												
16												No fluconazole as
17												prophylaxis:
18												Amphotericin B (60%)
19												Caspofungin (40%)
20					Candidemia	20	64.5±	55%	—		Respon	Amphotericin B (100%)
21					(Non- <i>Candida</i>		16.8				e rate:	
22					<i>albicans</i>)						(45%)	
23												
24												
25	Dimopouloset	Greece	Prospective MICU, SICU	24	Candidemia	24	—	—	62.5	—	16.5 (14-	C. albicans: fluconazole
26	al.(2007) [45]		cohort study								24)*days	Non-albicans: amphotericin B
27												
28												
29	Jordà-Marcos	Spain	prospective MICU, SICU	1765	Candidemia	63	63 (48 -	71.40	57.10	6.30%	—	7.90%
30	R (2007)		cohort				70)†	%				
31												
32												
33					Control (non-	1072	63 (46 -	66.50	—	2.80%	—	5.60%
34					Candidemia)		71)†	%				
35												
36												
37												
38												
39												
40												
41												
42												
43												
44												
45												
46												

Piazza O (2004)	Italy	retrospective ICU cohort	478	Candidemia	12	57.58±22.07	58.30 %	67	—	—	—
Michalopoulos et al. (2003) ^[46]	Greece	Prospective case-control study	150	Candidemia	30	63.2±9.7	73.30 %	70	—	—	—
				Control	120	64.3±9.9	73.30 %	—	—	—	—

Abbreviations: CICU, cardiothoracic ICU; CRCBSI, Catheter-related Candida bloodstream infection; Flu-R, fluconazole-resistant; Flu-S, fluconazole-sensitive; IC, Invasive candidiasis; MICU, medical ICU; SICU, surgical ICU.

Total number of enrolled patients: 7,982.

* Data were presented as mean (range).

† Data were presented as median (range).

§ Data were presented as median (IQR).

Dash indicates no available data.

Table 2. Length of stay, antibiotic therapy prior to candidemia onset, and overall mortality

Studies 1 st Author (year)	Hospital stay (days)	ICU length of stay (days)	Length of stay prior to ICU admission (days)	Duration of ICU admission prior to candidemia onset (days)	Rate of antibiotic therapy prior to candidemia onset	Duration of antibiotic therapy prior to candidemia onset (days)	Overall mortality rate
Zhao H (2018)	N/A	24 (12-57) [†]	N/A	N/A	N/A	N/A	58%
Ding R (2018)	N/A	N/A	N/A	N/A	Broad-spectrum antibiotics: 98.6%	N/A	31.90%
Yang et al. (2017) ^[26]	(prior to IC diagnosis) Early-onset IC:4 (2, 7) [§] Late-onset IC: 26 (16, 50) [§]	N/A	N/A	Early-onset IC: 4 (1, 7) [§] Late-onset IC: 17 (10, 33) [§]	Early-onset IC: 62 (59.0%) Late-onset IC: 179 (89.1%)	N/A	Early-onset IC: 28.6% Late-onset IC: 40.8%
Tukenmez Tigen E (2017)	N/A	22 (18-30) [†] 5.5 (2.25-15.75) [†]	N/A	N/A	Broad-spectrum antibiotic: 100% Broad-spectrum antibiotic: 59.5%	100% N/A	83.30%
Baldesi O (2017)	N/A	29 (18; 49) [§] 7 (4; 13) [§]	N/A	N/A	antimicrobials: 82.2% antimicrobials: 55.1%	N/A	52.40% 17.80%
Rudramurt hy SM (2017)	N/A	N/A	N/A	10 (4.7 – 22.2) [§] 7 (3 – 13) [§]	N/A	N/A	41.90% 27%

1								
2								
3								
4								
5	Kawano Y (2017)	N/A	N/A	N/A	13 (1 – 73)†	Broad-spectrum antimicrobial: 84%	N/A	72%
6								
7	OrtizRuiz et al. (2016) [16]	35.4±3.0	21.9±1.7	N/A	Median 25	Broad-spectrum antibiotic: 93.8 vs. 69.8% (case vs. control)	N/A	39.51%
8								
9								
10								
11	Gong et al. (2016) [47]	<i>Candida albicans</i> : Median: 32 Non- <i>albicans</i> : Median: 44	<i>Candida albicans</i> : Median: 18 Non- <i>albicans</i> : Median: 29	N/A	N/A	<i>Candida albicans</i> (before diagnosis): 76 (77.6%) Non- <i>albicans</i> (before diagnosis): 121 (82.9%)	N/A	<i>Candida albicans</i> (before diagnosis): 29.6% Non- <i>albicans</i> (before diagnosis): 26.7%
12								
13								
14								
15								
16								
17								
18	Playford EG (2016)	51 (34 – 89)§ 23 (13 – 40)§	21 (14 – 32)§ 8 (5 – 12)§	N/A	10 (5 – 15.25)†	N/A	N/A	26% 18.3%
19								
20								
21	Pinhati HM (2016)	N/A	N/A	N/A	22 (0 – 83)† 25 (7 – 134)†	any: 47.6% any: 42.1%	N/A	42.9% 47.4%
22								
23								
24	Aguilar et al. (2015) [15]	N/A	N/A	N/A	20 (5, 37.5) §	Antibiotic therapy:21 (95.4 %)	10 (5.0–16.5)†	13.60%
25								
26								
27								
28	Fochtman et al. (2015) [27]	N/A	60 (13–176) †	N/A	16 (6–89) †	Broad-spectrum antibiotic treatment in most patients	16 (6–89)†	30%
29								
30								
31	Klingspore t al.(2015) [28]	N/A	23 (0–329) †	2 (0-744) †	12 (0–190) †	Broad-spectrum antibiotics in the last 2 weeks: 511 (78.4%)	N/A	38.80%
32								
33								
34								
35	Chakrabart i et al. (2015) [29]	N/A	N/A	N/A	8 (4, 15) §	Candidemia patients received: antibiotics:93.0%	16.0 (7–36) days§	44.70%
36								
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Liao et al. (2015) [14]	Flu-S: 34.5 (18, 65) Flu-R: 48.0 (21, 90)	Flu-S: 22.5 (10.0, 40.0) Flu-R: 29.0 (17, 59)	N/A	Flu-S: 8.0 (3.0, 17.0)§ Flu-R: 10.5 (4.0, 27.0)§	≥5 d before diagnosis: Flu-S: 101 (78.3%) Flu-R: 73 (81.1%)	N/A	Flu-S: 31.8% Flu-R: 41.1%
Kautzky S (2015)	N/A	46 (14 - 74)† 21 (10 - 77)†	17 (1 - 21)† 3 (1 - 66)†	17.4 ± 14.5	100% 90%	N/A	80% 21.7%
Karacaer et al. (2014) [31]	46.8±36.7 (5-190)	32.9±36.9 (0-190)	N/A	N/A	N/A	15 ± 13.8	77.70%
Colombo et al. (2014) [32]	N/A	N/A	N/A	20 (0-188) †	Prior antibiotic expose: 96.1%	N/A	70.30%
Hu et al.(2014) [48]	54.0 (26.0-91.0) §	34.0 (18.0-71.0) §	N/A	11.0 (4.0, 26.0)§	CRCBSI: 100% N CRCBSI:99.5%	CRCBSI: 11.4 ± 4.2 days; N CRCBSI:10.6 ±6.5 day	44.80%
Lortholary O (2014)	N/A	N/A	N/A	N/A	N/A	N/A	51.00% 30.70%
Yapar N (2014)	N/A	30.9±33 12.9±13	N/A	N/A	96.9% 78.3%	N/A	43.9% 32.2%
Guo et al.(2013) [49]	N/A	N/A	N/A	10 (0-330)†	Treatment before diagnostic confirm: 74 (27.6%)	N/A	36.60%
Giri S (2013)	N/A	mean 26.4 (range 9-86) days	N/A	N/A	66.70%	mean 19.45 (range 4-31) days	24%

1								
2								
3								
4								
5	Tortorano N/A	N/A	N/A	22.8 (2–190)†	broad spectrum antibiotic	N/A	46.20%	
6	et al.(2012)				treatment: 85%			
7	[33]							
8	Ylipalosaar 38.0 (22- 59) §	16.0 (11-30) §	1 (0-2) §	8.0 (1.0, 12.0) §	Previous antibacterial treatment	N/A	65.80%	
9	i et al.				(%): 97.4-95.5%			
10	(2012) [34]							
11								
12	Pasero D et N/A	21±7	N/A	20 (8, 49) §	A significantly higher	N/A	47%	
13	al. (2011)				administration of > 2 antibiotics			
14	[35]				for >72 hours.			
15								
16	Han SS et 38 (2-141)§	22 (1-141)§	8 (0-92) §	17 (0-117) †	All patients were treated with	16 (1-92) †	96.00%	
17	al. (2010)				antibiotics prior to candidaemia			
18	[36]				onset			
19								
20	Pratikaki N/A	25 (14-46)§	14 (1-20) §	10 (3, 22) §	All patients received	N/A	60.60%	
21	M et al.				antimicrobial agents prior to			
22	(2009) [37]				candidaemia onset			
23								
24	Playford et N/A	NA	N/A	10 (4, 16) §	Antibiotic receipt on days 1–3:	N/A	10.60%	
25	al.(2009)				83.4%;			
26	[38]				Broad-spectrum antibiotic receipt			
27					on days 1–3: 82.0%			
28								
29	Holleyetal. N/A	<i>C. albicans</i> : 29.0±18.5	N/A	N/A	All patients received	<i>C. albicans</i> : 13 (median)	<i>C. albicans</i> : 52.9%	
30	(2009) [39]	non- <i>C. albicans</i> : 29.2			antimicrobial agents prior to	non- <i>C. albicans</i> : 15	non- <i>C. albicans</i> :	
31		±28.2			candidaemia onset	(median)	64.7%	
32								
33	Choi et al. (prior to fungemia)	<i>Candida albicans</i> :	N/A	<i>Candida albicans</i> : 11±25	N/A	N/A	<i>Candida albicans</i> :	
34	(2009) [40]	<i>Candida albicans</i> :		Non- <i>albicans</i> : 15±31			48%	
35		42±47					Non- <i>albicans</i> : 67%	
36		Non- <i>albicans</i> :						
37		38±33						
38								
39								
40								
41								
42								
43								
44								
45								
46								

1								
2								
3								
4								
5	Yap et al (2009) [50]	28 (17-54) §	14 (5-23) §	N/A	6 (1-13)§	Antibiotics > 48 hours before candidaemia: <i>C. albicans</i> : 70 (97.0%) <i>non-C. albicans</i> : 56 (100%)	N/A	70%
6								
7								
8								
9	Chow et al. (2008) [41]	<i>Candida albicans</i> : 28 (20–42)§ Non- <i>albicans</i> : 37 (24–57)§	<i>Candida albicans</i> : 22 (15–33)§ Non- <i>albicans</i> : 25 (14–40)§	N/A	<i>Candida albicans</i> : 11 (9, 17) § Non- <i>C. albicans</i> : 10 (4, 21) §	Non- <i>C. albicans</i> : 0.75 (0–2) §	2.21 (1.4–2.7)§	<i>Candida albicans</i> : 58% Non- <i>albicans</i> : 57%;
10								
11								
12								
13								
14	Bougnoux et al.(2008) [42]	N/A	43.1 ± 45.2	N/A	19.0 ± 2.9 or (13.0; 2-145)§	No antibiotic treatment is reported	N/A	61.80%
15								
16								
17								
18	Girãoet al.(2008) [43]	N/A	N/A	N/A	<i>C. albicans</i> : 15 (mean) Non- <i>C. albicans</i> : 18 (mean)	The hospital is restricted the use of several antibiotics	N/A	<i>C. albicans</i> : 72% non- <i>C. albicans</i> : 80%
19								
20								
21								
22	Dimopoulos et al. (2008) [44]	<i>C. albicans</i> : 22 ± 7.6 non- <i>C. albicans</i> : 25 ± 8.4	N/A	N/A	<i>C. albicans</i> : 12 ± 2.2 non- <i>C. albicans</i> : 10 ± 2.4	100% of patients received broad spectrum antibiotic treatment for >3 days during the ICU stay.	N/A	<i>C. albicans</i> : 52.8% non- <i>C. albicans</i> : 90%
23								
24								
25								
26								
27	Dimopoulos et al.(2007) [45]	N/A	N/A	N/A	9 (5–11) †	100% of patients received broad spectrum antibiotic treatment	N/A	N/A
28								
29								
30								
31	Jordão-Marcos R (2007)	48 (26 – 69)	28 (17 – 45)	N/A	23.5 ± 54.7	100%	N/A	17.2%
32		35 (22 – 57)	18 (12 – 28)			96.5%		13.2%
33								
34								
35	Piazza O (2004)	N/A	N/A	N/A	median 13 days	N/A	N/A	67%
36								
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

1						
2						
3						
4						
5	Michalopo	N/A	27.1 ± 7.5	N/A	15 (11-23) †	Empiric antibiotic therapy with 2 N/A
6	ulos et al.					or more broad-spectrum agents
7	(2003) [46]					for all patients
8						

9 Abbreviation: ARDS, acute respiratory distress syndrome; CPB, cardiopulmonary bypass; CRCBSI, Candida catheter-related bloodstream infection; Flu-R, fluconazole-resistant; Flu-S, fluconazole-sensitive; IC, invasive candidiasis; IMV, invasive mechanical ventilation; N/A, not available; SAPS II, Simplified Acute Physiology Score II; TPN, total parenteral nutrition.

12 § Data are presented as median (interquartile range; IQR).

14 † Data are presented as median (range).

For peer review only

1
2
3 Five studies reported the mean ICU stay prior to onset of candidemia. In 4 studies,
4
5 the median ICU stay was ≤ 10 days, including the early-onset group in the study by
6
7 Yang et al [25] and Flu-S group in the study by Liao et al. [14] with the overall
8
9 mortality ranged from 28.6% to 70.0%. Three studies reported that the median ICU
10
11 stay was >10 days prior to candidemia onset with the overall mortality ranged from
12
13
14
15 40.8% to 44.8%.
16

17 Similar to other countries, most of the patients with IC in China received
18
19 antibiotic treatment prior to candidemia onset in the ICU, which was ranged from
20
21 59.0% of patients in the early-onset group [25] to 100% in the CRCBSI group and
22
23 non-*C. albicans* group [49, 51]. Only one study reported the median duration of
24
25 antibiotic therapy prior to candidemia onset, which was ranged from 10.6 to 11.4 days
26
27
28 [49].
29
30
31
32

33 **Meta-analysis**

34 ***Summary of the clinical outcomes for overall studies or given subgroups***

35
36 The summary of variables such as hospital length of stay, ICU length of stay, duration
37
38 of ICU admission prior to candidemia onset, length of stay prior to ICU admission,
39
40 and overall mortality was presented in Table 3. Five studies [14, 25, 47-49] were from
41
42 China by using China-SCAN patient data, in which four studies were excluded to
43
44
45 avoid using repeating data.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Summary for length of hospital stay, length of ICU stay, duration of ICU admission prior to candidemia onset, and overall mortality for overall or given subgroups^{†‡}

Comparison	Length of hospital stay, days	ICU length of stay, days	Duration of ICU admission prior to candidemia onset, days	Length of stay prior to ICU admission, days	Overall mortality
	Mean (95%CI.)	Mean (95%CI.)	Mean (95%CI.)	Mean (95%CI.)	Rate (95%CI.)
Overall	36.26(25.84, 46.67)	25.83(23.58, 28.07)	12.93(11.70, 14.15)	11.71(0.37, 23.05)	49.25(45.02, 53.48)
Overall optional^{abcd}	^a 37.49(33.33, 41.64)	^b 25.90(23.48, 28.33)	^c 13.73(12.46, 15.00)	—	^d 50.99(46.57, 55.41)
Subgroups					
Type of study					
Prospective	41.01(32.93, 49.09)	27.43(24.59, 30.27)	12.92(11.47, 14.37)	19.21(17.15, 21.27)	42.65(37.89, 47.40)
Retrospective/ Cross-sectional	31.86(18.22, 45.50)	23.85(21.12, 26.57)	13.70(11.16, 16.24)	7.39 (-3.65, 18.44)	56.50(47.95, 65.04)
Presence of neutropenia					
Neutropenia	34.93(19.79, 50.07)	25.42(19.33, 31.50)	11.64(9.53, 13.75)	—	49.55(40.80, 58.30)
Non-neutropenia	22.94(20.88, 25.00)	—	10.00(9.26, 10.74)	—	41.32(7.94, 74.71)
Type of ICU					
ICU	37.73(21.74, 53.71)	27.28(24.89, 29.67)	14.32(5.66, 5.98)	17.17(11.90, 22.44)	49.78(44.285, 55.27)
SICU	—	21.66(19.45, 23.86)	17.31(11.93, 22.70)	—	33.12(15.16, 51.07)

1						
2						
3						
4						
5	MICU	—	32.74(10.25, 55.23)	17.00(16.22, 17.78)	—	88.44(72.78, 104.10)
6	MICU+SICU	34.64(28.17, 41.11)	22.50(18.41, 26.59)	10.93(9.55, 12.31)	—	45.71(36.42, 55.00)
7						
8	C. Albicans					
9						
10	C. Albicans	34.17(33.08, 35.26)	25.91(22.29, 29.53)	11.00(10.71, 11.29)	—	52.19(40.01, 64.38)
11						
12	Non C. Albicans	27.01(24.25, 29.78)	24.97(18.02, 31.92)	—	—	—
13						
14	Presence of					
15	IC/candidemia					
16	Candidemia	36.34(32.89, 39.79)	25.76(23.23, 28.28)	13.24(11.96, 14.53)	10.84(-1.96,23.64)	51.43(47.05, 55.82)
17						
18	IC	33.85(-3.74, 71.43)	26.42(20.71, 32.13)	11.47(7.63, 15.31)	—	38.94(27.77, 50.10)
19						
20	Region					
21						
22	Asia	36.88(22.95, 50.80)	24.95(20.92, 28.98)	17.39(14.62, 20.15)	19.31(17.21, 21.42)	51.16(44.65, 57.67)
23						
24	Europe/US/Australia	33.26(20.74, 45.79)	27.67(23.27, 32.07)	18.51(15.28, 21.74)	9.61 (-1.20, 20.4)	48.58(42.43, 54.73)
25						
26	South America	—	—	45.76(27.84, 63.69) *	—	54.37(38.02, 70.72)
27						
28						
29						
30						
31						
32						
33						
34						
35						
36						
37						
38						
39						
40						
41						
42						
43						
44						
45						
46						

Note: Certain subgroups have only 1 study (degree of freedom = 0).

^a Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^b Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^c Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

^d Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

Dash indicates no available

[†] The range width of 95% CI is related to the accuracy of the estimation. The narrower the range, the higher the accuracy of the estimation. If both the upper and lower limits are positive, the clinical outcome estimate for this group of participants is obviously positive, if the lower limit negative and the upper limit is positive, indicating that the clinical outcome estimate for this type of participants is not significantly greater than 0.

[‡]Meta-regression is used to assess the relationship between study level covariates and effect size when obvious heterogeneity in subgroups.

* Meta-regression analysis illustrated the South American countries were significantly longer than the Asian, European, Australian, and North American countries in the mean of duration of ICU admission prior to candidemia onset (Asia as reference group, South America $\beta = 25.83$, $p = 0.0308$, $R^2 = 0.097$). Other meta-regression analysis in subgroups in this table did not reach statistical significance.

For overall studies, the length of hospital stay, length of ICU stay, duration of ICU admission prior to candidemia onset, length of stay prior to ICU admission and overall mortality rate were derived as a mean of 36.26 days (95% CI: 25.84 - 46.67), 25.83 days (95% CI: 23.58 - 28.07), 12.93 days (95% CI: 11.70 - 14.15), 11.71 days (95% CI: 0.365 - 23.05), and rate of 49.25% (95% CI: 45.02% - 53.48%), respectively. When the four China-SCANE studies were excluded from the analysis, length of hospital stay, length of ICU stay, duration of ICU admission prior to candidemia onset were derived as a mean of 37.49 days (95% CI: 33.33 - 41.64), 25.90 days (95% CI: 23.48 - 28.33), 13.73 days (95% CI: 12.46 - 15.00), and the overall mortality was 50.99% (95% CI: 46.57% - 55.41%), respectively (Table 3). The clinical outcomes were also summarized for subgroups of studies (with studies' number ≥ 2) given the type of study, presence of neutropenia, type of ICU, type of *C. Albicans* isolated, presence of IC/candidemia, and region of countries. The interval estimate showed the summarized statistics of subgroups were all significant except for

1
2
3 length of hospital stay of patients with IC present, length of stay prior to ICU
4 admission of patients selected from retrospective or cross-sectional type of studies and
5 patients with candidemia presents (95% CI included zero) (Table 3).
6
7
8
9

10 According to the summarized statistics, those studies with neutropenic patients
11 had a greater length of hospital stay (mean=34.93 vs. 22.94 days), a longer duration of
12 ICU admission prior to candidemia onset (mean=11.64 vs. 10.0 days), and a higher
13 overall mortality rate (rate: 49.55% vs. 41.32%) compared to those with non-
14 neutropenic patients. The duration of ICU admission prior to candidemia onset had a
15 mean of 17.31 days, 17 days, 14.32 days, and 10.93 days for studies with patients in
16 surgical ICU (SICU), medical ICU (MICU), ICU, and MICU+SICU, respectively.
17 Patients with candidemia had a greater length of hospital stay (mean=36.34 vs. 33.85),
18 longer duration of ICU admission prior to candidemia onset (mean=13.24 vs. 11.47),
19 and a higher overall mortality rate (51.43% vs. 38.94%) compared with patients
20 without IC. However, patients with candidemia had a shorter length of ICU stay
21 (mean=25.76 vs. 26.42 days) and length of stay prior to ICU admission (mean=10.84
22 vs. 15.20 days) than patients with IC. Furthermore, patients with *C. albicans* also had
23 a higher duration of ICU admission prior to candidemia onset compared to patients
24 with other species of *C. albicans* (mean=11 vs. 10 days). The mean duration of ICU
25 admission prior to candidemia onset in patients in hospitals was 18.51 days (95%
26 CI=15.28 – 21.74 days) in Europe, 17.39 days (95% CI: 14.62 – 20.15 days) in Asia,
27 and 45.77 days (95% CI: 27.84 – 63.69 days) in South America. Data from Giro et
28 al.[43] and Gong et al.[47] were excluded from the summarized analysis due to a lack
29 of standard deviations for mean values and unavailability of data ranges.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ***Broad-spectrum antibiotic use prior to candidemia onset, length of stay prior to***
4
5 ***ICU admission, and overall mortality***
6
7

8 In order to compare whether there is a differences in the proportion of broad-spectrum
9 antibiotic use between IC patients and non-IC patients, we reviewed the identified
10 publications and excluded studies containing control groups (non-invasive candida
11 infection) and studies with a clear number of broad-spectrum antibiotics utilized.
12
13
14

15
16 After pooling the study data, IC patients were found to have utilized a higher
17 proportion of broad-spectrum antibiotics (89.13%, 95% CI: 82.68%-93.37%) before
18 IC onset, which was higher than non-IC patients (77.36%, 95% CI: 52.25%-91.43%),
19 even if it has not yet reached statistical significance. The mean duration of antibiotic
20 therapy prior to candidemia onset was 17.77 days (95% CI: 9.30 - 26.25), but the
21 duration of broad-spectrum antibiotic use prior to the infection was not included due
22 to the limitation of data. Only five studies reported length of stay prior to ICU
23 admission and the mean was 11.71 days (95% CI: 0.37 - 23.05). The overall mortality
24 rate was increased from 49.25% to 50.99% after excluding four China-SCAN studies
25 (Table 3).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 ***Comparing the effect between *Candida albicans* vs. non-*Candida albicans****
43

44 A meta-analysis was performed to compare the effect of length of hospital stay, ICU
45 length of stay, and overall mortality between studies of patients infected with *C.*
46 *albicans* and different strains of *Candida*. Three studies examined length of hospital
47 stay (Choi et al 2009, Chow et al. 2008, Dimopoulos et al 2008), three studies
48 examined ICU length of stay (Holley et al 2009, Choi et al 2009, Chow et al. 2008),
49 and six studies examined overall mortality (Gong et al 2016, Holley et al 2009, Choi
50 et al 2009, Chow et al. 2008, Giral et al 2008, Dimopoulos et al 2008) and were
51
52
53
54
55
56
57
58
59
60

1
2
3 selected for the meta-analysis. According to the heterogeneity test, a random effect
4 model was applied for length of hospital stay (Q value=25.47, I-squared value =
5
6 92.1%, $p<0.001$) and overall mortality rate (Q-value=399, I-squared value=98.7%,
7
8 $p<0.001$) and a fixed effect model for ICU length of stay (Q value = 1.56, I-squared
9
10 value = 0%, $p=0.458$). The pooled effect demonstrated that there was no significant
11
12 difference in length of stay and overall mortality between patients with and without *C.*
13
14 *albicans* (Figure 2A, 2C; both $p>0.05$). However, there was a significant difference in
15
16 mean length of ICU stay between patients with and without *C. albicans* (difference in
17
18 means = 2.82 days, Figure 2B, $P<0.001$).
19
20
21
22
23
24
25
26

27 ***Quality assessment***

28
29 The results of the quality assessment are shown in Table 4. For the results of
30
31 ROBINS-I, 9 studies had serious bias due to confounding because no baseline
32
33 confounding or appropriate analysis methods were used to adjust for important
34
35 baseline confounding. Five studies had serious bias in the selection of participants due
36
37 to unclear inclusion and exclusion criteria. Most of studies had low or moderate bias
38
39 in classification of interventions. No studies provided the information of systematic
40
41 differences between experimental intervention and comparator groups due to lack of
42
43 comparison of two intervention groups. All studies had low or moderate bias due to
44
45 missing data, bias in measurement of outcomes and bias in selection of the reported
46
47 result. Overall, 28 studies had moderate risk of bias, thirteen had serious risk of bias,
48
49 and one had unclear information regarding the risk of bias.
50
51
52
53
54

55 ***Meta-regression of clinical outcomes***

56
57 A meta-regression analysis demonstrated that South American countries were
58
59 significantly longer than the Asian, European, Australian, and North American
60

1
2
3 countries for mean duration of ICU admission prior to candidemia onset (Asia as
4 reference group, South America $\beta = 25.83$, $p = 0.0308$, $R^2 = 0.097$). Other meta-
5 regression analysis in subgroups did not reach statistical significance (Table 3). The
6 level of risk of bias (moderate/serious or no information) was also included in the
7 meta-regression analysis and the coefficient was not found to achieve statistically
8 significant results.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 4. Quality assessment of included studies using ROBINS-I

1st Author (year)	Bias due to confounding	Bias in selection of participants into the study	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported result	Overall risk of bias
Ding et al. (2018)	low	moderate	low	no information	moderate	low	low	moderate
Zhao et al. (2018)	low	low	no information	no information	low	low	low	moderate
Baldesi et al. (2017)	low	moderate	no information	no information	low	low	low	moderate
Kawano et al. (2017)	serious	moderate	low	no information	low	low	low	serious
Rudramurthy et al. (2017)	low	low	low	no information	low	low	low	moderate
Tukenmez Tigen et al. (2017)	serious	moderate	low	no information	low	low	low	serious
Yang et al. (2017)	low	low	low	no information	low	low	moderate	moderate
Gong et al. (2016)	serious	moderate	low	no information	low	low	low	serious
OrtizRuiz et al. (2016)	low	low	low	no information	low	low	low	moderate
Pinhati et al. (2016)	moderate	moderate	low	no information	low	low	low	moderate
Playford et al. (2016)	low	moderate	no information	no information	low	low	low	moderate
Aguilar et al. (2015)	no information	moderate	low	no information	low	low	low	moderate
Chakrabarti et al. (2015)	serious	low	low	no information	low	low	low	serious

1									
2									
3									
4									
5	Fochtmann et al. (2015)	low	moderate	low	no information	low	low	low	moderate
6									
7									
8	Kautzky et al. (2015)	serious	low	no information	no information	low	low	low	serious
9									
10	Klingspor et al.(2015)	low	moderate	low	no information	low	low	low	moderate
11									
12	Liao et al. (2015)	low	moderate	low	no information	low	low	low	moderate
13									
14	Karacaer et al. (2014)	moderate	moderate	low	no information	low	low	low	moderate
15									
16	Colombo et al. (2014)	low	moderate	low	no information	low	low	low	moderate
17									
18	Hu et al.(2014)	low	moderate	low	no information	low	low	low	moderate
19									
20	Lortholary et al. (2014)	low	serious	low	no information	low	low	moderate	serious
21									
22	Yapar et al. (2014)	moderate	moderate	low	no information	low	low	low	moderate
23									
24	Giri et al. (2013)	serious	moderate	low	no information	low	low	low	serious
25									
26	Guo et al.(2013)	low	low	low	no information	low	low	low	moderate
27									
28	Tortorano et al.(2012)	serious	moderate	low	no information	low	low	low	serious
29									
30	Ylipalosaari et al. (2012)	moderate	moderate	low	no information	low	low	low	moderate
31									
32	Pasero et al. (2011)	low	low	low	no information	low	low	low	moderate
33									
34	Han et al. (2010)	low	serious	no information	no information	low	low	low	serious
35									
36	Pratikaki et al. (2009)	moderate	low	low	no information	low	low	low	moderate
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Playford et al.(2009)	no information	low	no information	no information	low	low	low	no information
Holley et al.(2009)	low	serious	low	no information	low	low	low	serious
Choi et al. (2009)	low	serious	low	no information	low	low	low	serious
Yap et al. (2009)	no information	moderate	low	no information	low	low	low	moderate
Chow et al. (2008) ^a	low	low	low	no information	low	low	low	moderate
Chow et al. (2008) ^b	low	moderate	low	no information	low	low	low	moderate
Bougnoux et al. (2008)	no information	low	low	no information	low	low	low	moderate
Girãoet al. (2008)	no information	serious	low	no information	low	low	low	moderate
Dimopoulos et al. (2008)	low	low	low	no information	low	low	low	moderate
Dimopoulos et al. (2007)	serious	low	low	no information	low	low	low	serious
Jordà-Marcos et al. (2007)	low	moderate	low	no information	low	low	low	moderate
Piazza et al. (2004)	serious	low	moderate	no information	moderate	low	low	serious
Michalopoulos et al. (2003)	low	low	no information	no information	low	low	low	moderate

^a, Chow JK¹, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008 Apr 15;46(8):1206-13. doi: 10.1086/529435.

^b, Chow JK¹, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, Chawla V, Young JA, Hadley S. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med. 2008 Jul;36(7):1993-8. doi: 10.1097/CCM.0b013e31816fc4cd.

Publication bias

Egger's test showed potential publication bias for length of hospital stay (1-tailed $P < 0.001$) and duration of ICU admission prior to candidemia onset (1-tailed $P = 0.004$), and no significant publication bias for length of ICU stay (1-tailed $P = 0.37$) and overall mortality (1-tailed $P = 0.38$). The classic fail-safe N tests indicated that the number of missing studies which would be needed to make the P-values of the summary effect become insignificant was 65,685 for length of stay, 2,304 for ICU length of stay, 89,242 for duration of ICU admission prior to candidemia onset, and 34,263 for overall mortality. These results indicated that the significance of the observed effects of the meta-analyses would not be influenced by the inclusion of additional studies (Figure 3A-C).

DISCUSSION

The current meta-analysis demonstrated that the pooled mean of duration of ICU admission prior to candidemia varied from approximately 17 days within hospital settings in Asia, to 19 days in Europe, to 46 days in South America. Most of the ICU patients had received broad-spectrum antibiotics (89%), and the mean duration of antibiotic therapy prior to candidemia onset was nearly 18 days. The pooled mean mortality rate was approximately 49%. There was no significant difference in length of stay or overall mortality between patients with and without *C. albicans*, but the mean length of ICU stay was greater for patients with *C. albicans* compared to those patients without *C. albicans*.

Seven studies were performed in hospitals in China (Table 1). Two studies evaluated patients with *Candida albicans* vs. non-*Candida albicans* candidemia. One study compared patients with catheter-related *Candida* bloodstream infection

(CRCBSI) vs. non-CRCBSI, and the other study compared patients with a fluconazole-resistant vs. fluconazole-sensitive (Flu-S) infection. The mean length of hospital stay ranged from 4 (early-onset group) to 54 days, and the mean length of ICU stay ranged from 14 to 34 days. The majority of studies (n=29) were performed in countries other than China [14, 25, 48-51]. Of these, 7 were case-control or cross-sectional studies, and 34 were retrospective or prospective cohort studies. Eleven were designed to compare patients with and without candidemia. Five studies compared patients with candidemia based on *C. Albicans* vs. another *Candida* strain, and only 1 study compared ICU-acquired candidemia vs. non-ICU acquired candidemia [34]. Most of the studies (n=24) were conducted in general ICUs, and the others in SICUs or in cardio-surgical/cardiothoracic ICUs (CICU) [47], or medical ICUs [36], suggesting that invasive candidiasis is a common problem in critically ill patients regardless of the type of ICU. The mean length of hospital stay ranged from 22 to 51 days, and the mean length of ICU stay ranged from 7 days to 60 days (Table 2). In 9 studies, the median length of ICU stay was ≤ 10 days prior to onset of IC, and the overall mortality in ICU patients with candidemia in those studies ranged from 10.6% to 65.8%. In the other studies with a median ICU length of stay > 10 days prior to onset of IC, the overall mortality ranged from 13.6% to 96.0%.

The duration of ICU stay varied widely prior to candidemia onset which indicated that the onset of IC may be initiated by distinct risk factors in the ICU, and the time point to encounter these risk factors was different among critically ill patients. As we have mentioned previously, the major cause of severe candidiasis has been the endogenous colonization of *Candida* species that requires a 7 to 10-day period for the development of IC after exposure to risk factors [20]. In addition, the median time for obtaining positive blood cultures was 2–3 days (possibly up to ≥ 7

1
2
3 days) [2]. Therefore, for patients with a confirmed diagnosis of candidemia onset at 8
4
5 days after ICU admission, the endogenous colonization of *Candida* species may have
6
7 occurred in patients on the first day of ICU admission. Similarly, for the patients with
8
9 a confirmed diagnosis of candidemia at 12-13 days after ICU admission, the
10
11 endogenous colonization of *Candida* species may have also occurred 3-5 days after
12
13 ICU admission.
14
15

16
17 The main risk factor for candidemia was systemic antibiotic use [16]. In a
18
19 previously reported study in pediatric ICUs, it was reported that treatment with
20
21 vancomycin or anti-anaerobic antibiotics for >3 days were independently associated
22
23 with the development of candidemia [2], but only in an unadjusted analysis [16].
24
25 Overuse and prolonged exposure to broad-spectrum antibiotics have been found that
26
27 closely associates them with candidemia in both China and India [52, 53]. Therefore,
28
29 it may be suggested that overuse of broad-spectrum antibiotics may be associated with
30
31 early-onset of candidemia after ICU admission in China. A study in Hong Kong found
32
33 that candidemia occurred in patients within 6 days of being admitted to the ICU, and
34
35 more than 97.0% of patients infected with fungi of *Candida* species had received >48
36
37 hours of antibiotic treatment [51]. Regardless of geographical differences, most
38
39 patients with IC received broad-spectrum antibiotic treatment prior to candidemia
40
41 onset in the ICU. However, due to a lack of sufficient data, any potential correlation
42
43 between prolonged exposure to broad-spectrum antibiotics and the time of candidemia
44
45 onset after ICU admission and the further explanation of the longer duration of ICU
46
47 admission prior to candidemia onset in South America than in
48
49 Asia/Europe/US/Australia could not be assessed in this systematic review.
50
51
52
53
54
55

56 The current results demonstrated that there was no significant difference in length
57
58 of hospital stay prior to the development of IC or overall mortality between patients
59
60

1
2
3 with and without *C. albicans* IC. This may be due to the clinical presentation and the
4
5 treatment of patients with candidemia caused by *C. albicans* and non-*C. albicans* were
6
7 indistinguishable [54]. Although it was found that the mortality rates in patients with
8
9 *C. albicans* and non-*C. albicans* was similar, the susceptibilities of these strains to
10
11 anti-fungal agents were different [21, 55, 56]..
12
13

14
15 This systematic review had several limitations. This systematic review was
16
17 lacking a pre-specified protocol and its preliminary registration, the biased post hoc
18
19 decisions in review methods may occur. A number of the trials reported outcomes
20
21 using median (range) and/or median (IQR). In order to combine results, the sample
22
23 mean and standard deviation for such trials was estimated using a method proposed by
24
25 Wan et al. [24]. This method was based under the assumption that the data were
26
27 normally distributed. Across the meta-analysis, however, medians and quartiles were
28
29 often reported when data did not follow a normal distribution [23]. This possibility
30
31 may have confounded the results. The results of the quality assessment indicated that
32
33 potential biases from confounders may be present. High heterogeneity had existed in
34
35 the overall and subgroup analyses, suggesting the complexity of the risk factors
36
37 causing IC and candidemia (Supplementary Table S1).
38
39
40
41

42
43 Although meta-regression analysis in different design, country, and risk of bias et
44
45 al, which may be find the heterogeneity between groups were assessed in this study,
46
47 there may still be other potential factors that explain heterogeneity that requires
48
49 further study. Besides the factors analyzed in the subgroup analyses, there may be
50
51 other factors influencing heterogeneity such as comorbidities, severity of illness, and
52
53 invasive procedures (e.g., hemodialysis, invasive mechanical ventilation, total
54
55 parenteral nutrition, surgery, and immunosuppression), which were not taken into
56
57 account in this analysis. Publication bias may have also possibly existed in some
58
59
60

1
2
3 analyzed outcomes.
4

5 This systematic review indicated that patients who received broad-spectrum
6 antibiotics and who were admitted to the ICU were associated with the development
7 of candidemia. Patients with *C. albicans* infection had longer ICU stays. In this
8 setting, the choice of early detection and therapeutic intervention strategies for IC
9 should strengthen implementation to optimize patients' management to reduce the risk
10 of infection and potentially save the excessive consumption of medical resources.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **Acknowledgements**

25
26 The medical writing and editorial assistance were provided by Elizabeth Goodwin and
27 Prof. Jerry Tseng of MedCom Asia Inc., China. This assistance was funded by MSD
28 China. The authors initiated the concept for this systematic review and are responsible
29 for the content of the manuscript.
30
31
32
33
34

35 **Competing interests:** The authors declare that they have no competing interests
36

37 **Funding:** None
38

39 **Authors' contributions:**

40
41
42 ZDZ: guarantor of integrity of the entire study; study concepts; study design;
43 definition of intellectual content; manuscript editing; manuscript review.
44
45

46
47 RZ: guarantor of integrity of the entire study; study concepts; study design; definition
48 of intellectual content; manuscript editing; manuscript review.
49
50

51
52 ZGL: guarantor of integrity of the entire study; study concepts; study design;
53 definition of intellectual content; manuscript editing; manuscript review.
54
55

56
57 XCM: guarantor of integrity of the entire study; study concepts; study design;
58 definition of intellectual content; manuscript editing; manuscript review.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data sharing statement: No unpublished data are available.

Patient consent for publication: Not required.

For peer review only

REFERENCES

1. Calandra T, Roberts JA, Antonelli M, et al. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. *Crit Care* 2016;20:125.
2. Pappas PG, Kauffman CA, Andes DR, et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;62:409-17.
3. Bassetti M, Peghin M, Timsit JF. The current treatment landscape: candidiasis. *J Antimicrob Chemother*. 2016;71:ii13-ii22.
4. Yapar N. Epidemiology and risk factors for invasive candidiasis. *Ther Clin Risk Manag*. 2014;10:95-105.
5. Strollo S, Lionakis MS, Adjemian J, et al. Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002-2012. *Emerg Infect Dis*. 2016;23:7-13.
6. Leon C, Ostrosky-Zeichner L, Schuster M. What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. *Intensive Care Med* 2014;40:808-19.
7. Yang SP, Chen YY, Hsu HS, et al. A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study. *BMC Infect Dis* 2013;13:10.
8. Montagna MT, Lovero G, Borghi E, et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. *Eur Rev Med Pharmacol Sci*. 2014;18:661-74.

- 1
2
3 9. Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine
4 research agenda on invasive fungal infection in critically ill patients. *Intensive*
5
6 *Care Med.* 2017;43:1225-38.
7
8
- 9
10 10. Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of
11
12 invasive candidiasis. *Clin Infect Dis.* 2012;54:1123-5.
13
- 14 11. Kullberg BJ, Arendrup MC. Invasive Candidiasis. *N Engl J Med.* 2016;374:794-
15
16 5.
17
- 18 12. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at
19
20 increased risk for candidal infections in the surgical intensive care unit: an
21
22 approach to developing practical criteria for systematic use in antifungal
23
24 prophylaxis trials. *Med Mycol*2005;43:235–43
25
26
- 27 13. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective
28
29 development and validation of a clinical prediction rule for
30
31 nosocomial invasive candidiasis in the intensive care setting. *Eur J*
32
33 *Clin Microbiol Infect Dis.* 2007;26:271-6.
34
35
- 36 14. Liao X, Qiu H, Li R, et al. Risk factors for fluconazole-resistant invasive
37
38 candidiasis in intensive care unit patients: An analysis from the China Survey
39
40 of Candidiasis study. *J Crit Care* 2015;30:862.e861-5.
41
42
- 43 15. Aguilar G, Delgado C, Corrales I, et al. Epidemiology of invasive candidiasis
44
45 in a surgical intensive care unit: an observational study. *BMC Res Notes*
46
47 2015;8:491.
48
49
- 50 16. Ortiz Ruiz G, Osorio J, Valderrama S, et al. Risk factors for candidemia in
51
52 non-neutropenic critical patients in Colombia. *Med Intensiva.*2016;40:139-44.
53
54
- 55 17. Ostrosky-Zeichner L. Clinical prediction rules for invasive candidiasis in the
56
57 ICU: ready for prime time? *Crit Care.* 2011;15:189.
58
59
60

- 1
2
3 18. León C, Ruiz-Santana S, Saavedra P, et al. Contribution of Candida
4 biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU
5 patients with severe abdominal conditions. *Crit Care*. 2016;20:149.
6
7
- 8
9
10 19. Martín-Mazuelos E, Loza A, Castro C, et al. β -D-Glucan and Candida albicans
11 germ tube antibody in ICU patients with invasive candidiasis. *Intensive Care*
12 *Med*. 2015;41:1424-32.
13
14
- 15
16
17 20. Eggimann P, Que YA, Revelly JP, Pagani JL. Preventing invasive candida
18 infections. Where could we do better? *J Hosp Infect*. 2015;89:302-8.
19
20
- 21
22 21. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk
23 of bias in non-randomized studies of interventions. *BMJ*. 2016; 355; i4919.
24
25
- 26
27 22. Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group
28 for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions
29 (ROBINS-I): detailed guidance, updated 12 October 2016. Available from
30 <http://www.riskofbias.info>.
31
32
33
- 34
35 23. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The
36 methodological quality assessment tools for preclinical and clinical studies,
37 systematic review and meta-analysis, and clinical practice guideline: a
38 systematic review. *J Evid Based Med*, 2015, 8(1):2-10.)
39
40
41
42
43
- 44
45 24. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
46 deviation from the sample size, median, range and/or interquartile range. *BMC*
47 *Med Res Methodol*. 2014;14:135.
48
49
50
- 51
52 25. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and
53 interpreting funnel plot asymmetry in meta-analyses of randomised controlled
54 trials. *BMJ*. 2011 Jul 22;343:d4002.
55
56
57
58
59
60

- 1
2
3 26. Yang Y, Guo F, Kang Y, et al. Epidemiology, clinical characteristics, and risk
4 factors for mortality of early- and late-onset invasive candidiasis in intensive
5 care units in China. *Medicine (Baltimore)*. 2017;96:e7830.
6
7
- 8
9
10 27. Fochtman A, Forstner C, Haggmann M, et al. Predisposing factors for
11 candidemia in patients with major burns. *Burns*. 2015;41:326-32.
12
13
- 14 28. Klingspor L, Tortorano AM, Peman J, et al. Invasive *Candida* infections in
15 surgical patients in intensive care units: a prospective, multicentre survey
16 initiated by the European Confederation of Medical Mycology (ECMM) (2006-
17 2008). *Clin Microbiol Infect*. 2015;21:87.e81-7.e10.
18
19
- 20 29. Chakrabarti A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and
21 outcome of ICU-acquired candidemia in India. *Intensive Care
22 Med*. 2015;41:285-95.
23
24
- 25 30. Gupta A, Gupta A, Varma A. *Candida glabrata* candidemia: An emerging threat
26 in critically ill patients. *Indian J Crit Care Med*. 2015;19:151-4.
27
28
- 29 31. Karacaer Z, Oncul O, Turhan V, Gorenk L, Ozyurt M. A surveillance of
30 nosocomial candida infections: epidemiology and influences on mortality in
31 intensive care units. *Pan Afr Med J*. 2014;19:398.
32
33
- 34 32. Colombo AL, Guimaraes T, Sukienik T, et al. Prognostic factors and historical
35 trends in the epidemiology of candidemia in critically ill patients: an analysis of
36 five multicenter studies sequentially conducted over a 9-year period. *Intensive
37 Care Med*. 2014;40:1489-98.
38
39
- 40 33. Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the
41 intensive care unit: a multicentre, prospective, observational study in Italy
42 (2006-2008). *Mycoses*. 2012;55:73-9.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 34. Ylipalosaari P, Ala-Kokko TI, Karhu J, et al. Comparison of the epidemiology,
4 risk factors, outcome and degree of organ failures of patients with candidemia
5 acquired before or during ICU treatment. Crit Care. 2012;16:R62.
6
7
- 8
9
10 35. Pasero D, De Rosa FG, Rana NK, et al. Candidemia after cardiac surgery in the
11 intensive care unit: an observational study. Interact CardiovascThorac
12 Surg.2011;12:374-8.
13
14
- 15
16
17 36. Han SS, Yim JJ, Yoo CG, et al. Clinical characteristics and risk factors for
18 nosocomial candidemia in medical intensive care units: experience in a single
19 hospital in Korea for 6.6 years. J Korean Med Sci.2010;25:671-6.
20
21
- 22
23
24 37. Pratikaki M, Platsouka E, Sotiropoulou C, et al. Epidemiology, risk factors for
25 and outcome of candidaemia among non-neutropenic patients in a Greek
26 intensive care unit. Mycoses.2011;54:154-61.
27
28
- 29
30
31 38. Playford EG, Lipman J, Kabir M, et al. Assessment of clinical risk predictive
32 rules for invasive candidiasis in a prospective multicentre cohort of ICU
33 patients. Intensive Care Med.2009;35:2141-5.
34
35
- 36
37
38 39. Holley A, Dulhunty J, Blot S, et al. Temporal trends, risk factors and outcomes
39 in albicans and non-albicanscandidaemia: an international epidemiological
40 study in four multidisciplinary intensive care units. Int J Antimicrob
41 Agents.2009;33:554.e551-7.
42
43
- 44
45
46 40. Choi HK, Jeong SJ, Lee HS, et al. Blood stream infections by *Candida*
47 *glabrata* and *Candida krusei*: A single-center experience. Korean J Intern
48 Med. 2009;24:263-9.
49
50
- 51
52
53 41. Chow JK, Golan Y, Ruthazer R, et al. Risk factors for albicans and non-
54 albicanscandidemia in the intensive care unit. Crit Care Med.2008;36:1993-8.
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
42. Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. *Intensive Care Med.*2008;34:292-9.
 43. Girão E, Levin AS, Basso M, et al. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital. *Med Mycol.*2008;46:581-8.
 44. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. *Candida albicans* versus non-*albicans* intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. *AnesthAnalg.*2008;106:523-9.
 45. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. *Eur J ClinMicrobiol Infect. Dis.*2007;26:377-84.
 46. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. *Chest.*2003;124:2244-55.
 47. Gong X, Luan T, Wu X, et al. Invasive candidiasis in intensive care units in China: Risk factors and prognoses of *Candida albicans* and non-*albicans* *Candida* infections. *Am J Infect Control.* 2016;44:e59-63.
 48. Hu B, Du Z, Kang Y, et al. Catheter-related *Candida* bloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study. *BMC Infect Dis.*2014;14:594.


- 1
2
3 49. Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in
4
5 China: a multicentre prospective observational study. *J Antimicrob*
6
7 *Chemother.*2013;68:1660-8.
8
9
10 50. Yap HY, Kwok KM, Gomersall CD, et al. Epidemiology and outcome of
11
12 *Candida* bloodstream infection in an intensive care unit in Hong Kong. *Hong*
13
14 *Kong Med J.*2009;15:255-61.
15
16
17 51. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of
18
19 antibiotics in primary health care settings in China. *JAMA Intern*
20
21 *Med.* 2014;174:1914-20.
22
23
24 52. Agrawal C, Biswas D, Gupta A, Chauhan BS. Antibiotic overuse as a risk
25
26 factor for candidemia in an Indian pediatric ICU. *Indian J Pediatr.* 2015;82:530-
27
28 6.
29
30
31 53. Cheng MF, Yang YL, Yao TJ, et al. Risk factors for fatal candidemia caused by
32
33 *Candida albicans* and non-*albicans Candida* species. *BMC Infect*
34
35 *Dis.*2005;5:22.
36
37
38 54. Cheng MF, Yu KW, Tang RB, et al. Distribution and antifungal susceptibility
39
40 of *Candida* species causing candidemia from 1996 to 1999. *DiagnMicrobiol*
41
42 *Infect Dis.*2004;48:33-7.
43
44
45 55. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of *Candida*
46
47 species to amphotericin B and fluconazole: the emergence of fluconazole
48
49 resistance in *Candida tropicalis*. *Infect Control Hosp Epidemiol.*2004;25:60-4.
50
51
52 56. Yang YL, Cheng HH, Lo HJ. In vitro activity of voriconazole against *Candida*
53
54 species isolated in Taiwan. *Int J Antimicrob Agents.*2004;24:294-6.
55
56
57
58
59
60

1
2
3
4 **Figure legends**
5
6
7

8 **Figure 1.** PRISMA flow diagram of study selection
9

10
11 **Figure 2.** Meta-analysis of *C. albicans* vs. non-*C. albicans* for A) length of hospital
12
13
14 stay; B) ICU length of stay; and C) Overall mortality
15
16

17
18 **Figure 3.** Funnel plot for A) length of hospital stay; B) ICU length of stay; C)
19
20 duration of ICU admission prior to candidemia onset
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



680x397mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Unable to Convert Image

The dimensions of this image (in pixels) are too large to be converted. For this image to convert, the total number of pixels (height x width) must be less than 40,000,000 (40 megapixels).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3A




Figure 3B





Figure 3C



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Supplementary Table S1. A supplementary information of heterogeneity test for overall studies or given subgroup for Table 3.

Comparison	Length of hospital stay, days				ICU length of stay, days				Duration of ICU admission prior to candidemia onset, days				Length of stay prior to ICU admission, days				Overall mortality rate			
	Degrees of freedom				Degrees of freedom				Degrees of freedom				Degrees of freedom				Degrees of freedom			
	of	Q	I ²	P-value	of	Q	I ²	P-value	of	Q	I ²	P-value	of	Q	I ²	P-value	of	Q	I ²	P-value
Overall	16	20197.0	99.92	<0.001	27	2690.9	99.00	<0.001	30	4686.2	99.36	<0.001	4	311.2	98.71	<0.001	39	26981.1	99.86	<0.001
Overall optional^{abcd}	^a 13	850.7	98.47	<0.001	^b 25	2626.7	99.05	<0.001	^c 26	2649.8	99.02	<0.001					^d 35	24273.9	99.86	<0.001
Subgroups																				
Type of study																				
Prospective	7	568.3	98.77	<0.001	12	662.2	98.19	<0.001	16	1572.3	98.98	<0.001	1	0.9	0.35	<0.001	20	13805.2	99.86	<0.001
Retrospective	8	14000.4	99.94	<0.001	14	893.2	98.43	<0.001	13	2670.7	99.51	<0.001	2	28.39	92.95	<0.001	18	9479.2	99.81	<0.001
Presence of neutropenia																				
Neutropenia	7	6119.9	99.89	<0.001	8	2297.7	99.65	<0.001	11	3099.9	99.65	<0.001	0	-	-	-	11	15935.0	99.93	<0.001
Non-neutropenia	1	1.8	42.97	0.185	0			-	1	0	0	1	0	-	-	-	2	1388.4	99.86	<0.001
Type of ICU																				
ICU	7	11712.8	99.94	<0.001	16	930.6	98.28	<0.001	13	1589.8	99.18	<0.001	1	4.14	75.86	0.042	23	13807.9	99.83	<0.001
SICU				-	1	0.7	0.00	0.404	2	31.2	93.60	<0.001	0	-	-	-	2	1005.5	99.80	<0.001
MICU	0			-	1	6.2	83.92	0.013-	1	0	0	1-	0	-	-	-	1	14.3	92.99	<0.001
MICU+SICU	7	776.9	99.10	<0.001	6	713.7	99.16	<0.001	11	1539.5	99.29	<0.001	0	-	-	-	10	8098.2	99.88	<0.001

C. Albicans

C. Albicans	2	114.7	98.26	<0.001	2	5.79	65.45	0.055	1	0	0	1	5	1558.5	99.68	<0.001
Non C. Albicans	1	2.262	55.78	0.133	1	5.4	81.37	0.021	0	-	-	-	-	-	-	-

Presence of**IC/candidemia**

Candidemia	13	651.6	98.01	<0.001	23	2620.0	99.12	<0.001	24	2517.8	99.05	<0.001	3	302.3	99.01	<0.001	32	18755.6	99.83	<0.001
IC	2	2588.9	99.92	<0.001	3	17.0	82.33	0.001	5	1169.4	99.57	<0.001	0	-	-	-	6	3922.9	99.85	<0.001

Region

Asia	8	5464.6	99.85	<0.001	11	738.6	98.51	<0.001	11	2189.9	99.50	<0.001	1	1.4	26.82	0.242	16	8966.6	99.82	<0.001
Europe	3	226.5	98.68	<0.001	8	346.7	97.69	<0.001	10	907.3	98.90	<0.001	2	37.9	94.72	<0.001	13	7933.8	99.84	<0.001
South America	0	-	-	-	0	-	-	-	2	19.6	89.80	<0.001	-	-	-	-	4	1960.7	99.80	<0.001

Note: Certain subgroups have only 1 study (degree of freedom = 0).

^a Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^b Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^c Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

^d Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

Dash indicates no available.

1
2
3
4 **ZMR060116**

5 Date of Issue: **December 2, 2019**

6
7
8 **CERTIFICATION**

9
10
11 This is to certify that a medical editor who is a native English speaker
12
13
14 associated with MedCom Asia, Inc., has edited the manuscript entitled

15
16
17
18 **“The risk of invasive candidiasis with prolonged duration of ICU stay and**
19
20
21 **broad-spectrum antibiotic use: a systematic review and meta-analysis”**
22

23
24
25
26 This manuscript has been sent back to the author on **December 2, 2019**. If
27
28
29 there is any change on the manuscript by the author after the
30
31
32 above-mentioned date, this certificate is invalid. The medical editor who edited
33
34
35 the manuscript has been a professional editor and writer for several years and
36
37
38 is a member of American Medical Writers Association.
39
40

41
42 ***MedCom Asia, Inc.***

43
44
45
46
47 5F., No. 182, Songjiang Rd., Zhongshan Dist., Taipei City 104, Taiwan (R.O.C.)

48 TEL: +886-2-25211886

49 FAX: +886-2-25211386

50 E-mail: service@medcomasia.net

51 Web: <http://www.asiamedcom.com/eng/>



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	9



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	34
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	33
Synthesis of results	21	Present the main results of the review. If meta-analyses done, include for each, confidence intervals and measures of consistency.	28
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	38
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	34
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	38
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	41
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	41
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	42

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

BMJ Open

The risk of invasive candidiasis with prolonged duration of ICU stay and broad-spectrum antibiotic use: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036452.R1
Article Type:	Original research
Date Submitted by the Author:	17-Feb-2020
Complete List of Authors:	Zhang, Zhidan; the First Hospital of China Medical University, Department of Critical Care Medicine Zhu, Ran; the First Hospital of China Medical University, Department of Critical Care Medicine Luan, Zhenggang; the First Hospital of China Medical University, Department of Critical Care Medicine Ma, Xiaochun; the First Hospital of China Medical University, Department of Critical Care Medicine
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Intensive care
Keywords:	ACCIDENT & EMERGENCY MEDICINE, INTENSIVE & CRITICAL CARE, Adult intensive & critical care < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **The risk of invasive candidiasis with prolonged duration of ICU stay and**
4 **broad-spectrum antibiotic use: a systematic review and meta-analysis**
5
6
7
8
9
10

11 **Running title:** Duration of ICU prior to candidemia
12

13
14 Zhidan Zhang MD, Ran Zhu MD, Zhenggang Luan MD, Xiaochun Ma MD
15

16
17 Department of Critical Care Medicine, the First Hospital of China Medical University,
18
19 Shenyang 110001, Liaoning, China
20
21

22
23
24
25 **Corresponding author:** Xiaochun Ma
26

27
28 Department of Critical Care Medicine, the First Hospital of China Medical University,
29
30 Shenyang 110001, Liaoning, China
31
32

33
34 Tel: 008613840192939;
35

36
37 E-mail: XCMA2972@sina.com
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: This study aimed to evaluate the duration of intensive care unit (ICU) stay prior to onset of invasive candidiasis (IC)/candidemia.

Design: Systematic review and meta-analysis.

Data Sources: Pubmed, Cochrane, Embase, and Web of Science databases were searched through June, 2019 to identify the relevant studies.

Eligibility Criteria: Adult patients who had been admitted to the ICU and developed an invasive candidiasis infection.

Data extraction and synthesis: The following data were extracted from each article: ICU length of stay in hospital, length of stay prior to ICU admission, duration of ICU stay prior to candidemia onset, antibiotic therapy prior to candidemia onset, duration of antibiotic therapy prior to candidemia onset, and overall mortality. In addition to traditional meta-analyses, meta-regression was also used to explore possible mediators that might further explain heterogeneity.

Results: The mean age of patients ranged from 28 to 76 years across studies. The pooled mean duration of ICU stay before the onset of candidemia was 12.9 days (95% confidence interval [CI]: 11.7 – 14.2). The pooled mean duration of ICU admission prior to the onset of candidemia ranged from 4 to 47 days. The pooled mean duration of hospital stay was 36.3±5.3 days (95% CI: 25.8 – 46.7) and the pooled mean mortality rate was 49.3±2.2% (95% CI: 45.0% – 53.5%). There was no significant difference in duration of hospital stay ($P = 0.528$) or overall mortality ($P=0.111$) between patients with or without *C. albicans*, yet a significant difference was demonstrated in mean length of ICU stay (2.8 days, $P < 0.001$). The meta-regression

1
2
3 analysis found that South American countries had significantly longer mean duration
4 of ICU admission prior to candidemia onset compared with Asian, European,
5
6 Australian, and North American countries.
7
8
9

10 **Conclusions:** Patients with IC are possibly associated with the use of broad-spectrum
11 antibiotics and length of ICU stay, with the shortest duration of IC onset in Asia. Thus,
12 the current findings demonstrate that a more proactive strategy for the diagnosis of IC
13
14 should be considered in these patients, especially relevant for Asian physicians.
15
16
17
18
19
20
21

22 **KEYWORDS:** Invasive candidiasis, candidemia, intensive care unit, length of stay,
23 antibiotic, mortality
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This meta-analysis is one of few that investigated the association of IC with the length of ICU stay, using data published worldwide and adhering to the PRISMA guideline.
- Extensive subgroup analyses were performed and meta-regression was made to examine possible causes of heterogeneity in the results.
- Although this meta-analysis was performed methodically, it lacked a pre-specified protocol and preliminary registration.
- Heterogeneity exists in some subgroup and overall analyses.
- Due to a lack of sufficient published data, relationship between prolonged exposure to broad-spectrum antibiotics and ICU-acquired candidemia could not be assessed.

INTRODUCTION

Candida species account for 70% to 90% of invasive fungal infections and are the most frequent cause of fungal infections in patients admitted to the intensive care unit (ICU) [1]. Invasive candidiasis (IC) is associated with a high mortality rate (range: 40% to 60%) [1, 2]. Over recent decades, the incidence of IC has been gradually increasing in most regions [3], ranging from 0.5 to 32 cases per 1,000 ICU admissions. It has been found that there is a significant difference in the incidence of IC among several countries in Latin America and North America; however, data from Asia-Pacific countries are still relatively rare [4]. Candidemia has been described as the most common manifestation of IC, and the further infection of the liver, spleen, heart valves, or eye might also occur after a bloodstream infection [5]. In the past, the main *Candida* species isolated from patients with IC was *C. albicans*. However, non-*C. albicans* species has seen a rising proportion and now account for approximately 50% of all cases of IC in the past two decades [1,6-8].

Diagnosis and management of IC remains challenging for physicians in the ICU [1, 2]. The early initiation of empiric antifungal treatment has been demonstrated to improve the prognosis of invasive candidiasis [2, 9]. However, there is difficulty in the diagnosis of IC which can delay timely antifungal treatment [2, 10]. Blood culture remains the gold standard for the diagnosis of invasive candidiasis, but its sensitivity is variable (21% to 71%) [11].

In order to improve the diagnosis of IC, and to identify the patients who may best benefit from prophylactic, preemptive, or empirical therapy prior to, or at an early stage of ICU admission several methods in predicting the development of IC based on their associated risk factors have been developed [12, 13]. The risk factors in the

1
2
3 various predictive models include broad-spectrum antibiotic use, central venous
4 catheter placement, total parenteral nutrition, hemodialysis (days 1–3 in the ICU), any
5 surgery, immunosuppressive use, pancreatitis prior to ICU admission, and steroid use.
6
7 However, different risk factors are included in the different predictive models. In
8 addition, potential risk factors such as *Candida* colonization [14] and mechanical
9 ventilation [15] have not been included in these models.
10
11
12
13
14
15

16
17 Long-term ICU stay has been reported as a risk factor for IC [11, 14-16]. Only a
18 few studies have examined the interval between ICU admission or initiation of
19 broad-spectrum antibiotics and the diagnosis of IC. However, the specific duration of
20 long-term ICU stays and the prolonged use of broad-spectrum antibiotics are often
21 arbitrarily defined and inconsistent among studies [6, 12, 15, 17-19]. Furthermore, a
22 large majority of severe candidiasis cases are caused by endogenous colonization.
23 This may be the primary reason for causing a delay of 7 to 10 days between exposure
24 to risk factors and the development of IC [20].
25
26
27
28
29
30
31
32
33
34

35 Thus, the objective of this systematic review was to evaluate the risk factors
36 associated with the development of candidemia, specifically the length of ICU stay
37 and the use of broad-spectrum antibiotics.
38
39
40
41
42
43
44

45 **METHODS**

46 **Search strategy**

47
48 The study was performed in accordance with guidance from the Preferred
49 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed,
50 Cochrane, Embase, and Web of Science databases were searched through June, 2019
51 using the following terms: invasive candidiasis, critical care, critical illness, risk
52 factors, candidemia, and antibiotic agents. Studies identified by the search strategy
53
54
55
56
57
58
59
60

1
2
3 were reviewed for inclusion and data were extracted by two independent reviewers.
4
5 Where there was uncertainty regarding study eligibility, a third reviewer was
6
7 consulted. A flow chart of the study selection is shown in Figure 1.
8
9
10
11

12 **Study selection criteria and data extraction**

13
14 Randomized controlled trials (RCTs), cohort studies, case-controlled, and
15
16 cross-sectional studies were included. All studies included adult patients who were
17
18 critically ill, who had been admitted to the ICU, and who were tested positive for
19
20 *Candida* species using blood culture analyses. Studies had to have reported
21
22 quantitative outcomes of interest and no author was contacted. Letters, comments,
23
24 editorials, case reports, proceedings, personal communications, and case series were
25
26 excluded. Studies in which patients were diagnosed with candidiasis prior to ICU
27
28 admission were excluded. Studies that did not evaluate the incidence of candidiasis as
29
30 a primary objective, or that were not designed to evaluate risk factors/prognostic
31
32 factors of patients with candidiasis were also excluded.
33
34
35
36

37
38 The following information / data was extracted from studies that met the
39
40 inclusion criteria: the name of the first author, year of publication, country, study
41
42 design, type of ICU, number of participants in each group, participants' age and
43
44 gender, the presence of *C. albicans*, the presence of neutropenia, and antifungal
45
46 treatment (especially the use of broad-spectrum antibiotics). The following data were
47
48 also extracted from each article: length of stay in hospital/ICU, length of stay prior to
49
50 ICU admission, duration of ICU stay prior to candidemia onset, antibiotic therapy
51
52 prior to candidemia onset, duration of antibiotic therapy prior to candidemia onset,
53
54 and overall mortality.
55
56
57
58
59
60

Quality assessment

We used the Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool to assess the quality of the included studies [21]. ROBINS-I is based on the Cochrane RoB tool and is suited for evaluating non-randomized studies that compare the health effects of different interventions. ROBINS-I covers 7 different bias domains: bias due to confounding, bias in selection of participants into the study, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes, and bias in the selection of reported results [22-23]. In this systematic review, 2 independent reviewers performed the quality assessment, with a third reviewer consulted for any uncertainties.

Patient and public involvement

Since no patients and/or members of the public were involved in the process of designing, planning and completing this study, ethical approval, informed consent, and institutional review board's review were not required.

Statistical analysis

Study characteristics were summarized as mean \pm standard deviations (SD), mean (range), median (range), or median (IQR) for age or duration of antifungal treatment; and percentage (%) for sex, rate of *C. albicans* isolated, neutropenia, and antifungal treatment used in each study.

Clinical outcomes, including hospital stay, ICU length of stay, length of stay prior to ICU admission, duration of ICU admission prior to candidemia onset, and duration of antibiotic therapy prior to candidemia onset were represented as mean

1
2
3 (range: [min. – max.]), median (range), or median (IQR [interquartile range: 1st – 3rd
4 quartiles]). The rate of antibiotic therapy prior to candidemia onset and overall
5 mortality rate were presented as a percentage (%), according to the data extracted
6 from the study. All the clinical outcomes were further summarized for overall studies,
7 or subgroups of studies (with studies' number ≥ 2) given type of study, presence of
8 neutropenia, type of ICU, type of *Candida* isolated, presence of IC/candidemia, and
9 region/country, and meta-regression analyses were further used to investigate
10 statistical importance of the potential moderators. Before summarizing, studies that
11 reported quantitative data with median (range) and/or median interquartile range (IQR)
12 were transformed into mean \pm SD according to Wan et al. [24]
13
14
15
16
17
18
19
20
21
22
23
24
25

26
27 The outcomes selected for the analysis were length of hospital stay, ICU length
28 of stay, duration of ICU admission prior to candidemia onset, and overall mortality
29 compared between subgroups, *C. albicans* and non-*C. albicans*. The effect size was
30 calculated as mean difference with 95% CI (Lower, Upper limit) and significance of
31 *p*-values in length of days, or rate ratio with 95% CI and *p*-values in overall mortality
32 for each given study, and then a pooling effect was derived thereafter. A difference in
33 means of length days < 0 (or rate ratio of overall mortality rate > 1) indicated the
34 pooling effect favored non- *C. albicans* subgroup, whereas difference in means of
35 length days > 0 (or rate ratio of overall mortality rate < 1) indicated the pooling effect
36 favored *C. albicans* subgroup. A difference in means of length days = 0 (or rate ratio
37 of overall mortality rate = 1) indicated the pooling effect was similar between *C.*
38 *albicans* and non-*C. albicans* subgroups. Heterogeneity was evaluated using a
39 χ^2 -based Cochran's Q statistic and I^2 , that the random effect model
40 (DerSimonian-Laird method) and meta-regression analyses with potential moderators
41 were considered for the meta-analysis if either Q statistic with P values < 0.10 or
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 $I^2 > 50\%$ were derived; otherwise, a fixed effect model (Mantel-Haenszel method) was
4 considered for the meta-analysis. For the Q statistic, P values < 0.10 were considered
5 statistically significant for heterogeneity. For the I^2 statistic, heterogeneity was
6 assessed as follows: no heterogeneity ($I^2 = 0 - 25\%$), moderate heterogeneity ($I^2 = 25 -$
7 50%), large heterogeneity ($I^2 = 50 - 75\%$), and extreme heterogeneity ($I^2 = 75 - 100\%$).
8 A two-sided P value of < 0.05 was considered significant.
9

10
11
12
13
14
15
16
17 Countries were grouped based on their continents, but since meta-analysis of this
18 particular topic has not yet been seen in China, research from China will be separately
19 examined and discussed.
20
21
22

23
24 The publication bias was assessed using the funnel plot with Egger's test and
25 Classical fail-safe N test for all enrolled studies (except for subgroups). The absence
26 of publication bias was indicated by the data points forming a symmetric
27 funnel-shaped distribution and a 1-tailed significance level of $P > 0.05$ in an Egger's
28 test.[25] All analyses were performed using Comprehensive Meta-Analysis statistical
29 software, version 3.3.070 (Biostat, Englewood, NJ, USA).
30
31
32
33
34
35
36
37
38
39

40 RESULTS

41 Literature search results

42
43
44 A total of 1875 articles were retrieved by the primary search, and 1800 articles were
45 excluded after the title and abstract were screened based on the inclusion/exclusion
46 criteria (Figure 1). Seventy-five articles underwent full-text review, and 34 articles
47 were excluded for having irrelevant objectives or study designs ($n=19$), containing
48 patients in neonatal or pediatric intensive care unit ($n=5$), not designed for invasive
49 candidiasis ($n=4$), and not reporting outcomes of interest ($n=6$). Thus, 41 articles were
50 included in the systematic review and meta-analysis.
51
52
53
54
55
56
57
58
59
60

Study characteristics

The characteristics of the 41 studies are summarized in Table 1 and Table 2 [14-16, 26, 27-29, 30-63]. A total of 10,692 patients were included across the studies, with the number of patients in each study ranging from 12 to 1,400. The mean age of the patients ranged from 28 to 76 years. Majority of the patients were males (range: 20% to 75.9%). These studies were conducted in different countries: 19 in Europe, 14 in Asia, 1 in the US, 4 in South America, 2 in Australia and 1 multinational study (Australia, Belgium, Greece, Brazil).

Table 1. Characteristics of studies included in this systematic review

Studies 1 st Author (year)	Country	Study design	Type of ICU	Total IC and Candidemia number of patients	No. of patients	Age (years)	Male (%)	<i>C.Albica</i> <i>ns</i> isolated (%)	Neutropen ia (%)	Antifungal treatment	
										Duration of treatment	Antifungal treatment used
Zhao H (2018) [51]	China	retrospective cohort	ICU	Candidemia	95	69.3±16.5	57.9 %	59	—	—	17.90%
Ding R (2018) [52]	China	retrospective cohort	ICU	Candidemia	72	62.5 (49.8, 77.0)§	62.5 %	15	—	—	Fluconazole 30.6% Voriconazole 9.7% Echinocandin 44.4%
Yang et al. (2017) [26]	China	Retrospectiv e cohort study (China-SCA N)	ICU	Early-onset IC	105	56.9 (19.9)§	64.8 %	47.7	1.9%	—	Fluconazole (39.3%) Caspofungin(21.3%) Voriconazole (19.1%) Micafungin(10.1%) Itraconazole(5.6%) Amphotericin B (3.4%) Combined therapy (1.1%)
				Late-onset IC	201	64.0 (19.7)§	70.6 %	36.1	1.5%	—	Fluconazole (36.9%) Caspofungin(25.1%) Voriconazole (17.9%) Micafungin(7.8%) Itraconazole(9.5%) Amphotericin B (1.7%) Combined therapy (1.1%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Gong et al. (2016) [47]	China	Prospective, cohort study (China-SCAN)	MICU, SICU, Integrated ICU	306	Candidemia (<i>C. albicans</i>)	98	62.2±17.3	62.2 %	100	3.1%	12.85 days	Triazole (64.7%) Echinocandin (31.8%) Polyenes (0%)
					Candidemia (Non- <i>C. albicans</i>)	146	61.4±21.4	72.6 %	—	1.4%	20.4 days	Triazole (62.8%) Echinocandin (34.1%) Polyenes (2.3%)
Playford EG (2016) [57]	Australia	prospective cohort	MICU, SICU	6,714	ICU-acquired IC	96	—	—	66	—	—	—
					Control (no IC)	6618	—	—	—	—	—	—
Pinhati HM (2016) [58]	Brazil	cross-sectional	ICU	40	fluconazole-resistant <i>C. parapsilosis</i> (FRCP)	21	70 (23 - 91)†	66.7 %	—	—	—	any: (33.3) fluconazole: (19.0)
					fluconazole-susceptible <i>Candida</i> species (FSC)	19	76 (35 - 90)†	57.9 %	—	—	—	any: (15.8) fluconazole: (15.8)
Aguilar et al. (2015) [15]	Spain	Prospective cohort study	SICU	22	IC	22	66 (53.7-74.2) §	72.7 %	59.1	—	10 (5.0-16.5) days	Echinocandins (86.4%) Fluconazole (13.6%)
Fochtman et al. (2015) [27]	Austria	Retrospective cohort study	Burn ICU	174	Candidemia	20	39 (17-88) †	60%	60	—	—	Triazoles (70%)
					Control	154	58 (17-94) †	61%	—	—	—	Echinocandins (30%)

1													
2													
3													
4													
5	Klingsporet al.(2015) [28]	14 countries in Europe	Prospective cohort study	SICU	807	IC	779	63(0–91)†	62.5%	54	—	—	Fluconazole (60%) Caspofungin (18.7%) Amphotericin B (13%) Voriconazole (4.8%)
6													
7													
8													
9													
10	Chakrabarti et al. (2015) [29]	India	Prospective cohort study	MICU, SICU	1400	Candidemia	1400	49.7 ± 17.7	—	20.9	1.3%	9.0 (5-15)§	Azoles (72.0%) Echinocandins (18.3%) Amphotericin B (14.4%)
11													
12													
13													
14	Liao et al. (2015) [14]	China	Prospective cohort study (China-SCAN)	MICU, SICU, Mix ICU	306	Flu-S	129	62.4±19.5	68.2%	60.5	3.1%	—	Monoantifungaltherapy (64.5%) Fungal drug adjustment (35.7%) Completely improved(34.6%)
15													
16													
17													
18													
19													
20													
21													
22													
23													
24													
25													
26													
27	Kautzky S (2015) [59]	Austria	prospective cohort	MICU	65	IC (invasive <i>Candida</i> infection)	5	28.2 ± 97	20%	—	0%	15.40 ± 13.9	100%
28													
29													
30													
31													
32													
33													
34													
35													
36													
37	Karacaer et al. (2014) [31]	Turkey	Prospective cohort study	ICU service	burn 2362	IC	63	70.2 ± 19.5	54%	64	—	—	—
38													
39													
40													
41													
42													
43													
44													
45													
46													

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

(14-95)

Colombo et al. (2014) [32]	Brazil	Retrospective cohort study	ICU	1,392	Candidemia	647	66 (18-97) †	50.7	44	2.5%	—	Amphotericin B (period 1:27.8%; period 2: 13.4%) Echinocandins(period 1: 5.9%; period 2: 18.0%)
Hu et al.(2014) [48]	China	Prospective cohort study (China-SCAN)	ICU	294	CRCBSI	29	69.4 ± 19.1	75.9 %	28.6	—	19.0 ± 13.3 days	Fluconazole (39.3%) Caspofungin(25.0%) Voriconazole(14.3%) Miconazole (10.70%) Itraconazole(10.7%) Amphotericin B (0%) Two-drug combination (0%)
												Non-CRCBSI
Lortholary O (2014) [60]	France	prospective cohort	ICU	2507	ICU-aquired candidemia	1206	60 ± 17	62.0 %	57.10	—	—	Fluconazole(55.4 %) Echinocandins(26.2 %) Others (including combination)(12.6 %)
												non-ICU aquired candidemia

1														
2														
3														
4														
5	Yapar N	Turkey	retrospective cohort	ICU	1076	Candidemia	66	54.4 ± 23.9	53%	53	—	—	9%	
6	(2014) [61]													
7														
8														
9														
10														
11														
12														
13	Guo et al.(2013) [49]	China	Prospective cohort study (China-SCA N)	MICU SICU General Emergency Neurologic ICU	306	Candidemia	306	61.5±20.0	68.6 %	40.2	1.6%	14 (0-104)† days	Fluconazole (37.7%) Caspofungin (23.9%) Voriconazole (18.3%)	
14														
15														
16														
17														
18	Giri S (2013) [30]	India	prospective cohort	ICU	5,976	Candidemia	39	35.14 (3days-79 % y)	61.5 %	4				
19														
20														
21														
22														
23	Tortorano et al.(2012) [33]	Italy	Prospective cohort study	MICU, SICU	384	Candidemia	276	—	—	60.9	—	—	Fluconazole (63%) Amphotericin B (22%) Caspofungin (7%) Voriconazole (6%)	
24														
25														
26														
27														
28	Ylipalosaari et al. (2012) [34]	Finland	Retrospective cohort study	MICU,SICU	82	ICU-acquired candidemia	38	63 (45-69) §	71%	76.3	—	Median: 22 days	Fluconazole (73%) Amphotericin B (34%) Echinocandins (31%)	
29														
30														
31														
32														
33														
34														
35														
36	Pasero D et al. (2011) [35]	Italy	Prospective cohort study	SICU	349	Candidemia	26	60±21	61.5 %	73	—	—	—	
37														
38														
39														
40														
41														
42														
43														
44														
45														
46														

Author (Year) [ref]	Country	Study Design	Setting	n	Pathogen	n	APACHE II	SOFA	Mortality %	Survival %	LOS (days)	Treatment
Yap et al (2009) [50]	China Hong Kong	Retrospective cohort study	MICU SICU	128	Candidemia (<i>C. glabrata</i> , <i>C. krusei</i>)	128	54 (43-68) §	63.3 %	56	11%	—	Amphotericin B (39.1%) Fluconazole (38%) Amphotericin B+fluconazole (13%) Caspofungin or voriconazole (9.8%)
Chow et al. (2008) [41]	US	Case-control study	MICU, SICU	926	Candidemia (Non- <i>Candida albicans</i>)	67	62.3±14.5	57%	—	—	—	Fluconazole (84.8%) Amphotericin B (23.9%) Caspofungin (10.9%) Voriconazole (4.3%)
					Candidemia (<i>C. albicans</i>)	79	57±17.0	60%	100	—	—	Fluconazole (63%) Amphotericin B (33.3%) Caspofungin (11.1%) Voriconazole (0%)
					Control	780	62.3±17.4	56%	—	—	—	Fluconazole (100%) Amphotericin B (14.3%) Caspofungin (0%) Voriconazole (0%)
Bougnoux et al. (2008) [42]	France	Prospective cohort study	MICU SICU HU BU	290	Candidemia	57	56.1±18.2	67%	54.2	19.3%	13.2±10.3 days	Fluconazole (78.3%) Amphotericin B (52.2%) Flucytosine (15.2%)
Girão et al. (2008) [43]	Brazil	Prospective cohort study	ICU	73	Candidemia (Non- <i>Candida</i>)	40	51 (12-86) *	60%	—	—	—	—

						<i>albicans</i>)							
						Candidemia (<i>C. albicans</i>)	33	51(15-86)*	40%	100	—	—	—
	Dimopoulos et al. (2008) [44]	Greece	Prospective cohort study	MICU, SICU	56	Candidemia (<i>C. albicans</i>)	36	60.5 ± 14.9	44.4 %	100	0% (excluded)	Response rate: (80.6%)	Fluconazole as prophylaxis: Amphotericin B (75%) Caspofungin (25%)
												No fluconazole as prophylaxis: Amphotericin B (60%) Caspofungin (40%)	
						Candidemia (Non- <i>Candida albicans</i>)	20	64.5± 16.8	55%	—		Response rate: (45%)	Amphotericin B (100%)
	Dimopoulos et al. (2007) [45]	Greece	Prospective cohort study	MICU, SICU	24	Candidemia	24	—	—	62.5	—	16.5 (14-24)*days	<i>C. albicans</i> : fluconazole Non- <i>albicans</i> : amphotericin B
	Jordà-Marcos R (2007) [62]	Spain	prospective cohort	MICU, SICU	1765	Candidemia	63	63 (48 - 70)†	71.4 %	57.10	6.3%	—	7.90%
						Control (non-Candidemia)	1072	63 (46 - 71)†	66.5 %	—	2.8%	—	5.60%
	Piazza O (2004) [63]	Italy	retrospective cohort	ICU	478	Candidemia	12	57.58± 22.07	58.3 %	67	—	—	—

Table 2. Length of stay, antibiotic therapy prior to candidemia onset, and overall mortality

Studies 1 st Author (year)	Hospital stay (days)	ICU length of stay (days)	Length of stay prior to ICU admission (days)	Duration of ICU admission prior to candidemia onset (days)	Rate of antibiotic therapy prior to candidemia onset	Duration of antibiotic therapy prior to candidemia onset (days)	Overall mortality rate
Zhao H (2018) ^[51]	N/A	24 (12-57)†	N/A	N/A	N/A	N/A	58%
Ding R (2018) ^[52]	N/A	N/A	N/A	N/A	Broad-spectrum antibiotics: 98.6%	N/A	31.90%
Yang et al. (2017) ^[26]	(prior to IC diagnosis) Early-onset IC:4 (2, 7)§ Late-onset IC: 26 (16, 50)§	N/A	N/A	Early-onset IC: 4 (1, 7)§ Late-onset IC: 17 (10, 33)§	Early-onset IC: 62 (59.0%) Late-onset IC: 179 (89.1%)	N/A	Early-onset IC: 28.6% Late-onset IC: 40.8%
Tigen E (2017) ^[53]	N/A	22 (18-30)† 5.5 (2.25-15.75)†	N/A	N/A	Broad-spectrum antibiotic: 100% Broad-spectrum antibiotic: 59.5%	N/A	83.30%
Baldesi O (2017) ^[54]	N/A	29 (18; 49) § 7 (4; 13) §	N/A	N/A	antimicrobials: 82.2% antimicrobials: 55.1%	N/A	52.40% 17.80%
Rudramurt hy SM (2017) ^[55]	N/A	N/A	N/A	10 (4.7 – 22.2)§ 7 (3 – 13)§	N/A	N/A	41.90% 27%

1								
2								
3								
4								
5	Kawano Y (2017) [56]	N/A	N/A	N/A	13 (1 – 73)†	Broad-spectrum antimicrobial: 84%	N/A	72%
6								
7	OrtízRuiz et al. (2016) [16]	35.4±3.0	21.9±1.7	N/A	Median 25	Broad-spectrum antibiotic: 93.8 vs. 69.8% (case vs. control)	N/A	39.51%
8								
9								
10								
11	Gong et al. (2016) [47]	<i>Candida albicans</i> : Median: 32 Non- <i>C. albicans</i> : Median: 44	<i>Candida albicans</i> : Median: 18 Non- <i>C. albicans</i> : Median: 29	N/A	N/A	<i>Candida albicans</i> (before diagnosis): 76 (77.6%) Non- <i>albicans</i> (before diagnosis): 121 (82.9%)	N/A	<i>Candida albicans</i> (before diagnosis): 29.6% Non- <i>albicans</i> (befor e diagnosis): 26.7%
12								
13								
14								
15								
16								
17	Playford EG (2016) [57]	51 (34 – 89)§ 23 (13 – 40)§	21 (14 – 32)§ 8 (5 – 12)§	N/A	10 (5 – 15.25)†	N/A	N/A	26% 18.3%
18								
19								
20								
21	Pinhati HM (2016) [58]	N/A	N/A	N/A	22 (0 – 83)† 25 (7 – 134)†	any: 47.6% any: 42.1%	N/A	42.9% 47.4%
22								
23								
24								
25	Aguilar et al. (2015) [15]	N/A	N/A	N/A	20 (5, 37.5) §	Antibiotic therapy:21 (95.4 %)	10 (5.0–16.5)†	13.60%
26								
27								
28	Fochtman et al. (2015) [27]	N/A	60 (13–176) †	N/A	16 (6–89) †	Broad-spectrum antibiotic treatment in most patients	16 (6–89)†	30%
29								
30								
31								
32	Klingspore t al.(2015) [28]	N/A	23 (0–329) †	2 (0-744) †	12 (0–190) †	Broad-spectrum antibiotics in the last 2 weeks: 511 (78.4%)	N/A	38.80%
33								
34								
35								
36	Chakrabart i et al.	N/A	N/A	N/A	8 (4, 15) §	Candidemia patients received: antibiotics:93.0%	16.0 (7–36) days§	44.70%
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

(2015) [29]

Liao et al. (2015) [14]	Flu-S: 34.5 (18, 65) Flu-R: 48.0 (21, 90)	Flu-S: 22.5 (10.0, 40.0) Flu-R: 29.0 (17, 59)	N/A	Flu-S: 8.0 (3.0, 17.0)§ Flu-R: 10.5 (4.0, 27.0)§	≥5 d before diagnosis: Flu-S: 101 (78.3%) Flu-R: 73 (81.1%)	N/A	Flu-S: 31.8% Flu-R: 41.1%
Kautzky S (2015) [59]	N/A	46 (14 - 74)† 21 (10 - 77)†	17 (1 - 21)† 3 (1 - 66)†	17.4 ± 14.5	100% 90%	N/A	80% 21.7%
Karacaer et al. (2014) [31]	46.8±36.7 (5-190)	32.9±36.9 (0-190)	N/A	N/A	N/A	15 ± 13.8	77.70%
Colombo et al. (2014) [32]	N/A	N/A	N/A	20 (0-188) †	Prior antibiotic expose: 96.1%	N/A	70.30%
Hu et al. (2014) [48]	54.0 (26.0-91.0) §	34.0 (18.0-71.0) §	N/A	11.0 (4.0, 26.0)§	CRCBSI: 100% N CRCBSI:99.5%	CRCBSI: 11.4 ± 4.2 days; N CRCBSI:10.6 ±6.5 day	44.80%
Lortholary O (2014) [60]	N/A	N/A	N/A	N/A	N/A	N/A	51.00% 30.70%
Yapar N (2014) [61]	N/A	30.9±33 12.9±13	N/A	N/A	96.9% 78.3%	N/A	43.9% 32.2%
Guo et al. (2013) [49]	N/A	N/A	N/A	10 (0-330)†	Treatment before diagnostic confirm: 74 (27.6%)	N/A	36.60%
Giri S (2013) [30]	N/A	mean 26.4 (range 9-86) days	N/A	N/A	66.70%	mean 19.45 (range 4-31) days	24%

1								
2								
3								
4								
5	Tortorano et al.(2012) ^[33]	N/A	N/A	N/A	22.8 (2–190)†	broad spectrum antibiotic treatment: 85%	N/A	46.20%
6								
7								
8	Ylipalosaari et al. (2012) ^[34]	38.0 (22- 59) §	16.0 (11-30) §	1 (0-2) §	8.0 (1.0, 12.0) §	Previous antibacterial treatment (%): 97.4-95.5%	N/A	65.80%
9								
10								
11								
12	Pasero D et al. (2011) ^[35]	N/A	21±7	N/A	20 (8, 49) §	A significantly higher administration of > 2 antibiotics for >72 hours.	N/A	47%
13								
14								
15								
16	Han SS et al. (2010) ^[36]	38 (2-141)§	22 (1-141)§	8 (0-92) §	17 (0-117) †	All patients were treated with antibiotics prior to candidaemia onset	16 (1-92) †	96.00%
17								
18								
19								
20	Pratikaki M et al. (2009) ^[37]	N/A	25 (14-46)§	14 (1-20) §	10 (3, 22) §	All patients received antimicrobial agents prior to candidaemia onset	N/A	60.60%
21								
22								
23								
24	Playford et al.(2009) ^[38]	N/A	NA	N/A	10 (4, 16) §	Antibiotic receipt on days 1–3: 83.4%; Broad-spectrum antibiotic receipt on days 1–3: 82.0%	N/A	10.60%
25								
26								
27								
28	Holleyetal. (2009) ^[39]	N/A	<i>C. albicans</i> : 29.0±18.5 non- <i>C. albicans</i> : 29.2±28.2	N/A	N/A	All patients received antimicrobial agents prior to candidaemia onset	<i>C. albicans</i> : 13 (median) non- <i>C. albicans</i> : 15 (median)	<i>C. albicans</i> : 52.9% non- <i>C. albicans</i> : 64.7%
29								
30								
31								
32	Choi et al. (2009) ^[40]	(prior to fungemia) <i>Candida albicans</i> : 42±47 Non- <i>C. albicans</i> : 38±33	<i>Candida albicans</i> : 19±41 Non- <i>C. albicans</i> : 25±50	N/A	<i>Candida albicans</i> : 11±25 Non- <i>C. albicans</i> : 15±31	N/A	N/A	<i>Candida albicans</i> : 48% Non- <i>C. albicans</i> : 67%
33								
34								
35								
36								
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

1								
2								
3								
4								
5	Yap et al	28 (17-54) §	14 (5-23) §	N/A	6 (1-13)§	Antibiotics > 48 hours before candidaemia: <i>C. albicans</i> : 70 (97.0%) <i>non-C. albicans</i> : 56 (100%)	N/A	70%
6	(2009) [50]							
7								
8								
9	Chow et al.	<i>Candida albicans</i> : 28 (20–42)§	<i>Candida albicans</i> : 22 (15–33)§	N/A	<i>Candida albicans</i> : 11 (9, 17) § Non- <i>C. albicans</i> : 10 (4, 21) §	Non- <i>C. albicans</i> : 0.75 (0–2) §	2.21 (1.4–2.7)§	<i>Candida albicans</i> : 58% Non- <i>albicans</i> : 57%;
10	(2008) [41]	Non- <i>C. albicans</i> : 37 (24–57)§	Non- <i>C. albicans</i> : 25 (14–40)§					
11								
12								
13								
14	Bougnoux et al.	N/A	43.1 ± 45.2	N/A	19.0 ± 2.9 or (13.0; 2-145)§	No antibiotic treatment is reported	N/A	61.80%
15	(2008)							
16	[42]							
17								
18	Girão et al.	N/A	N/A	N/A	<i>C. albicans</i> : 15 (mean) Non- <i>C. albicans</i> : 18 (mean)	The hospital is restricted the use of several antibiotics	N/A	<i>C. albicans</i> : 72% non- <i>C. albicans</i> : 80%
19	(2008)							
20	[43]							
21								
22	Dimopoulou et al.	<i>C. albicans</i> : 22 ± 7.6	N/A	N/A	<i>C. albicans</i> : 12 ± 2.2 non- <i>C. albicans</i> : 10 ± 2.4	100% of patients received broad spectrum antibiotic treatment for >3 days during the ICU stay.	N/A	<i>C. albicans</i> : 52.8% non- <i>C. albicans</i> : 90%
23	(2008) [44]	non- <i>C. albicans</i> : 25 ± 8.4						
24								
25								
26								
27	Dimopoulou et al.	N/A	N/A	N/A	9 (5–11) †	100% of patients received broad spectrum antibiotic treatment	N/A	N/A
28	(2007)							
29	[45]							
30								
31	Jordà-Marcos R	48 (26 – 69)	28 (17 – 45)	N/A	23.5 ± 54.7	100%	N/A	17.2%
32	(2007) [62]	35 (22 – 57)	18 (12 – 28)			96.5%		13.2%
33								
34								
35	Piazza O	N/A	N/A	N/A	median 13 days	N/A	N/A	67%
36	(2004) [63]							
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

1						
2						
3						
4						
5	Michalopoulos et al.	N/A	27.1 ± 7.5	N/A	15 (11-23) †	Empiric antibiotic therapy with 2 N/A or more broad-spectrum agents for all patients
6	(2003) [46]					N/A
7						
8						

9 Abbreviation: ARDS, acute respiratory distress syndrome; CPB, cardiopulmonary bypass; CRCBSI, Candida catheter-related bloodstream infection; Flu-R, fluconazole-resistant; Flu-S, fluconazole-sensitive; IC, invasive candidiasis; IMV, invasive mechanical ventilation; N/A, not available; SAPS II, Simplified Acute Physiology Score II; TPN, total parenteral nutrition.

12 § Data are presented as median (interquartile range; IQR).

14 † Data are presented as median (range).

For peer review only

1
2
3 Five studies reported the mean ICU stay prior to onset of candidemia. In 4 studies,
4
5 the median ICU stay was ≤ 10 days, including the early-onset group in the study by
6
7 Yang et al [26] and Flu-S group in the study by Liao et al. [14] with the overall
8
9 mortality ranged from 28.6% to 70.0%. Three studies reported that the median ICU
10
11 stay was >10 days prior to candidemia onset with the overall mortality ranged from
12
13 40.8% to 44.8%.
14
15

16
17 Similar to other countries, most of the patients with IC in China received
18
19 antibiotic treatment prior to candidemia onset in the ICU, which was ranged from
20
21 59.0% of patients in the early-onset group [26] to 100% in the CRCBSI group and
22
23 non-*C. albicans* group [49, 51]. Only one study reported the median duration of
24
25 antibiotic therapy prior to candidemia onset, which was ranged from 10.6 to 11.4 days
26
27 [49].
28
29
30
31
32

33 **Meta-analysis**

34 ***Summary of the clinical outcomes for overall studies or given subgroups***

35
36 The summary of variables such as hospital length of stay, ICU length of stay, duration
37
38 of ICU admission prior to candidemia onset, length of stay prior to ICU admission,
39
40 and overall mortality was presented in Table 3. Five studies [14, 26, 47-49] were from
41
42 China by using China-SCAN patient data, in which four studies were excluded to
43
44 avoid using repeating data.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 3. Summary for length of hospital stay, length of ICU stay, duration of ICU admission prior to candidemia onset, and overall mortality for overall or given subgroups^{†‡}

Comparison	Length of hospital stay, days	ICU length of stay, days	Duration of ICU admission prior to candidemia onset, days	Length of stay prior to ICU admission, days	Overall mortality
	Mean (95%CI.)	Mean (95%CI.)	Mean (95%CI.)	Mean (95%CI.)	Rate (95%CI.)
Overall	36.3(25.8, 46.7)	25.8(23.6, 28.1)	12.9(11.7, 14.2)	11.7(0.4, 23.1)	49.3(45.0, 53.5)
Overall optional^{abcd}	^a 37.5(33.3, 41.6)	^b 25.9(23.5, 28.3)	^c 13.7(12.5, 15.0)	—	^d 51.0(46.6, 55.4)
Subgroups					
Type of study					
Prospective	41.0(32.9, 49.1)	27.4(24.6, 30.3)	12.9(11.5, 14.4)	19.2(17.2, 21.3)	42.7(37.9, 47.4)
Retrospective/ Cross-sectional	31.9(18.2, 45.5)	23.9(21.1, 26.6)	13.7(11.2, 16.2)	7.4 (-3.7, 18.4)	56.5(48.0, 65.0)
Presence of neutropenia					
Neutropenia	34.9(19.8, 50.1)	25.42(19.33, 31.50)	11.64(9.53, 13.75)	—	49.6(40.8, 58.3)
Non-neutropenia	22.9(20.9, 25.0)	—	10.0(9.3, 10.7)	—	41.3(7.9, 74.7)
Type of ICU					
ICU	37.7(21.7, 53.7)	27.3(24.9, 29.7)	14.3(5.7, 6.0)	17.2(11.9, 22.4)	49.8(44.3, 55.3)
SICU	—	21.7(19.5, 23.9)	17.3(11.9, 22.7)	—	33.1(15.2, 51.1)

MICU	—	32.7(10.3, 55.2)	17.0(16.2, 17.8)	—	88.4(72.8, 104.1)
MICU+SICU	34.6(28.2, 41.1)	22.5(18.4, 26.6)	10.9(9.6, 12.3)	—	45.7(36.4, 55.0)
<i>C. Albicans</i>					
<i>C. Albicans</i>	34.2(33.1, 35.3)	25.9(22.3, 29.5)	11.0(10.7, 11.3)	—	52.2(40.0, 64.4)
Non <i>C. Albicans</i>	27.0(24.3, 29.8)	25.0(18.0, 31.9)	—	—	—
Presence of IC/candidemia					
Candidemia	36.3(32.9, 39.8)	25.8(23.2, 28.3)	13.2(12.0, 14.5)	10.8(-2.0,23.6)	51.4(47.1, 55.8)
IC	33.9(-3.7, 71.4)	26.4(20.7, 32.1)	11.5(7.7, 15.3)	—	38.9(27.8, 50.1)
Region					
Asia	36.9(23.0, 50.8)	25.0(20.9, 29.0)	17.4(14.6, 20.2)	19.3(17.2, 21.4)	51.2(44.7, 57.7)
Europe/US/Australia	33.3(20.8, 45.8)	27.7(23.3, 32.1)	18.5(15.3, 21.7)	9.6 (-1.2, 20.4)	48.6(42.4, 54.7)
South America	—	—	45.8(27.8, 63.7) *	—	54.4(38.0, 70.7)

Note: Certain subgroups have only 1 study (degree of freedom = 0).

^a Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^b Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^c Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

^d Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

Dash indicates no available

[†] The range width of 95% CI is related to the accuracy of the estimation. The narrower the range, the higher the accuracy of the estimation. If both the upper and lower limits are positive, the clinical outcome estimate for this group of participants is obviously positive, if the lower limit negative and the upper limit is positive, indicating that the clinical outcome estimate for this type of participants is not significantly greater than 0.

[‡] Meta-regression is used to assess the relationship between study level covariates and effect size when obvious heterogeneity in subgroups.

* Meta-regression analysis illustrated the South American countries were significantly longer than the Asian, European, Australian, and North American countries in the mean of duration of ICU admission prior to candidemia onset (Asia as reference group, South America $\beta = 25.83$, $p = 0.0308$, $R^2 = 0.097$). Other meta-regression analysis in subgroups in this table did not reach statistical significance.

For overall studies, the length of hospital stay, length of ICU stay, duration of ICU admission prior to candidemia onset, length of stay prior to ICU admission and overall mortality rate were derived as a mean of 36.3 days (95% CI: 25.8 - 46.7), 25.8 days (95% CI: 23.6 - 28.1), 12.9 days (95% CI: 11.7 - 14.2), 11.7 days (95% CI: 0.37 - 23.1), and rate of 49.3% (95% CI: 45.0% - 53.5%), respectively. When the four China-SCANE studies were excluded from the analysis, length of hospital stay, length of ICU stay, duration of ICU admission prior to candidemia onset were derived as a mean of 37.5 days (95% CI: 33.3 - 41.6), 25.9 days (95% CI: 23.5 - 28.3), 13.7 days (95% CI: 12.5 - 15.0), and the overall mortality was 50.99% (95% CI: 46.6% - 55.4%), respectively (Table 3).

The clinical outcomes were also summarized for subgroups of studies (with studies' number ≥ 2) given the type of study, presence of neutropenia, type of ICU, type of *C.*

Albicans isolated, presence of IC/candidemia, and region of countries. The interval

1
2
3 estimate showed the summarized statistics of subgroups were all significant except for
4 length of hospital stay of patients with IC present, length of stay prior to ICU
5 admission of patients selected from retrospective or cross-sectional type of studies and
6 patients with candidemia presents (95% CI included zero) (Table 3).
7
8
9

10
11
12 According to the summarized statistics, those studies with neutropenic patients
13 had a greater length of hospital stay (mean=34.9 vs. 22.9 days), a longer duration of
14 ICU admission prior to candidemia onset (mean=11.6 vs. 10.0 days), and a higher
15 overall mortality rate (rate: 49.6% vs. 41.3%) compared to those with non-neutropenic
16 patients. The duration of ICU admission prior to candidemia onset had a mean of 17.3
17 days, 17 days, 14.3 days, and 10.9 days for studies with patients in surgical ICU
18 (SICU), medical ICU (MICU), ICU, and MICU+SICU, respectively. Patients with
19 candidemia had a greater length of hospital stay (mean=36.3 vs. 33.9), longer duration
20 of ICU admission prior to candidemia onset (mean=13.2 vs. 11.5), and a higher
21 overall mortality rate (51.4% vs. 38.9%) compared with patients without IC. However,
22 patients with candidemia had a shorter length of ICU stay (mean=25.8 vs. 26.4 days)
23 and length of stay prior to ICU admission (mean=10.8 vs. 15.2 days) than patients
24 with IC. Furthermore, patients with *C. albicans* also had a higher duration of ICU
25 admission prior to candidemia onset compared to patients with other species of *C.*
26 *albicans* (mean=11 vs. 10 days). The mean duration of ICU admission prior to
27 candidemia onset in patients in hospitals was 18.5 days (95% CI=15.3 – 21.7 days) in
28 Europe, 17.4 days (95% CI: 14.6 – 20.2 days) in Asia, and 45.8 days (95% CI: 27.8 –
29 63.7 days) in South America. Data from Giro et al.[43] and Gong et al.[47] were
30 excluded from the summarized analysis due to a lack of standard deviations for mean
31 values and unavailability of data ranges.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ***Broad-spectrum antibiotic use prior to candidemia onset, length of stay prior to***
4
5 ***ICU admission, and overall mortality***
6
7

8 In order to compare whether there is a differences in the proportion of broad-spectrum
9 antibiotic use between IC patients and non-IC patients, we reviewed the identified
10 publications and excluded studies containing control groups (non-invasive candida
11 infection) and studies with a clear number of broad-spectrum antibiotics utilized.
12
13
14

15
16 After pooling the study data, there is no statistically significant difference in IC
17 patients' use of broad-spectrum antibiotics (89.1%, 95% CI: 82.7%-93.4%) prior to IC
18 onset vs. that of non-IC patients (77.4%, 95% CI: 52.3%-91.4%). The mean duration
19 of antibiotic therapy prior to candidemia onset was 17.8 days (95% CI: 9.3 - 26.3), but
20 the duration of broad-spectrum antibiotic use prior to the infection was not included
21 due to insufficient data. Only five studies reported length of stay prior to ICU
22 admission and the mean was 11.7 days (95% CI: 0.4 - 23.1). The overall mortality rate
23 was increased from 49.3% to 51.0% after excluding four China-SCAN studies (Table
24 3).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 ***Comparing the effect between *Candida albicans* vs. non-*Candida albicans****
41

42 A meta-analysis was performed to compare the effect of length of hospital stay, ICU
43 length of stay, and overall mortality between studies of patients infected with *C.*
44 *albicans* and different strains of *Candida*. Three studies examined length of hospital
45 stay (Choi et al 2009, Chow et al. 2008, Dimopoulos et al 2008), three studies
46 examined ICU length of stay (Holley et al 2009, Choi et al 2009, Chow et al. 2008),
47 and six studies examined overall mortality (Gong et al 2016, Holley et al 2009, Choi
48 et al 2009, Chow et al. 2008, Giral et al 2008, Dimopoulos et al 2008) and were
49 selected for the meta-analysis. According to the heterogeneity test, a random effect
50
51
52
53
54
55
56
57
58
59
60

1
2
3 model was applied for length of hospital stay (Q value=25.47, I-squared value =
4
5 92.1%, $p<0.001$) and overall mortality rate (Q-value=399, I-squared value=98.7%,
6
7 $p<0.001$) and a fixed effect model for ICU length of stay (Q value = 1.56, I-squared
8
9 value = 0%, $p=0.458$). The pooled effect demonstrated that there was no significant
10
11 difference in length of stay between patients with and without *C. albicans* (Figure 2A,
12
13 $p>0.05$); however, there was a significant difference in mean length of ICU stay
14
15 (difference in means = 2.8 days, Figure 2B, $P<0.001$). There was also no significant
16
17 difference in overall mortality between patients with and without *C. albicans* (Figure
18
19 2C, $p>0.05$).
20
21
22
23
24
25
26

27 ***Quality assessment***

28
29 The results of the quality assessment are shown in Table 4. For the results of
30
31 ROBINS-I, 9 studies had serious bias due to confounding because no baseline
32
33 confounding or appropriate analysis methods were used to adjust for important
34
35 baseline confounding. Five studies had serious bias in the selection of participants due
36
37 to unclear inclusion and exclusion criteria. Most of studies had low or moderate bias
38
39 in classification of interventions. No studies provided the information of systematic
40
41 differences between experimental intervention and comparator groups due to lack of
42
43 comparison of two intervention groups. All studies had low or moderate bias due to
44
45 missing data, bias in measurement of outcomes and bias in selection of the reported
46
47 result. Overall, 28 studies had moderate risk of bias, thirteen had serious risk of bias,
48
49 and one had unclear information regarding the risk of bias.
50
51
52
53
54

55 ***Meta-regression of clinical outcomes***

56
57 A meta-regression analysis demonstrated that South American countries were
58
59 significantly longer than the Asian, European, Australian, and North American
60

1
2
3 countries for mean duration of ICU admission prior to candidemia onset (Asia as
4 reference group, South America $\beta = 25.83$, $p = 0.0308$, $R^2 = 0.097$). Other
5
6 meta-regression analysis in subgroups did not reach statistical significance (Table 3).
7
8 The level of risk of bias (moderate/serious or no information) was also included in the
9
10 meta-regression analysis and the coefficient was not found to achieve statistically
11
12 significant results.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 4. Quality assessment of included studies using ROBINS-I

1st Author (year)	Bias due to confounding	Bias in selection of participants into the study	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported result	Overall risk of bias
Ding et al. (2018) ^[52]	low	moderate	low	no information	moderate	low	low	moderate
Zhao et al. (2018) ^[51]	low	low	no information	no information	low	low	low	moderate
Baldesi et al. (2017) ^[54]	low	moderate	no information	no information	low	low	low	moderate
Kawano et al. (2017) ^[56]	serious	moderate	low	no information	low	low	low	serious
Rudramurthy et al. (2017) ^[55]	low	low	low	no information	low	low	low	moderate
Tigen et al. (2017) ^[53]	serious	moderate	low	no information	low	low	low	serious
Yang et al. (2017) ^[26]	low	low	low	no information	low	low	moderate	moderate
Gong et al. (2016) ^[47]	serious	moderate	low	no information	low	low	low	serious
OrtizRuiz et al. (2016) ^[16]	low	low	low	no information	low	low	low	moderate
Pinhati et al. (2016) ^[58]	moderate	moderate	low	no information	low	low	low	moderate
Playford et al. (2016) ^[57]	low	moderate	no information	no information	low	low	low	moderate
Aguilar et al. (2015) ^[15]	no information	moderate	low	no information	low	low	low	moderate
Chakrabarti et al. (2015) ^[29]	serious	low	low	no information	low	low	low	serious

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Fochtmann et al. (2015) [27]	low	moderate	low	no information	low	low	low	moderate
Kautzky et al. (2015) ^[59]	serious	low	no information	no information	low	low	low	serious
Klingspor et al.(2015) [28]	low	moderate	low	no information	low	low	low	moderate
Liao et al. (2015) ^[14]	low	moderate	low	no information	low	low	low	moderate
Karacaer et al. (2014) ^[31]	moderate	moderate	low	no information	low	low	low	moderate
Colombo et al. (2014) [32]	low	moderate	low	no information	low	low	low	moderate
Hu et al.(2014) ^[48]	low	moderate	low	no information	low	low	low	moderate
Lortholary et al. (2014) [60]	low	serious	low	no information	low	low	moderate	serious
Yapar et al. (2014) ^[61]	moderate	moderate	low	no information	low	low	low	moderate
Giri et al. (2013) ^[30]	serious	moderate	low	no information	low	low	low	serious
Guo et al.(2013) ^[49]	low	low	low	no information	low	low	low	moderate
Tortorano et al.(2012) [33]	serious	moderate	low	no information	low	low	low	serious
Ylipalosaari et al. (2012) [34]	moderate	moderate	low	no information	low	low	low	moderate
Pasero et al. (2011) ^[35]	low	low	low	no information	low	low	low	moderate
Han et al. (2010) ^[36]	low	serious	no information	no information	low	low	low	serious
Pratikaki et al. (2009) ^[37]	moderate	low	low	no information	low	low	low	moderate

1									
2									
3									
4									
5	Playford et al.(2009) ^[38]	no information	low	no information	no information	low	low	low	no information
6	Holley et al.(2009) ^[39]	low	serious	low	no information	low	low	low	serious
7	Choi et al. (2009) ^[40]	low	serious	low	no information	low	low	low	serious
8	Yap et al. (2009) ^[50]	no information	moderate	low	no information	low	low	low	moderate
9	Chow et al. (2008) ^a	low	low	low	no information	low	low	low	moderate
10	Chow et al. (2008) ^b	low	moderate	low	no information	low	low	low	moderate
11	Bougnoux et al. (2008) ^[42]	no information	low	low	no information	low	low	low	moderate
12	Girão et al. (2008) ^[43]	no information	serious	low	no information	low	low	low	moderate
13	Dimopoulos et al. (2008) ^[44]	low	low	low	no information	low	low	low	moderate
14	Dimopoulos et al. (2007) ^[45]	serious	low	low	no information	low	low	low	serious
15	Jordà-Marcos et al. (2007) ^[62]	low	moderate	low	no information	low	low	low	moderate
16	Piazza et al. (2004) ^[63]	serious	low	moderate	no information	moderate	low	low	serious
17	Michalopoulos et al. (2003) ^[46]	low	low	no information	no information	low	low	low	moderate

^a, Chow JK¹, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S.

Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008 Apr 15;46(8):1206-13.

doi: 10.1086/529435.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

^b, Chow JK¹, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, Chawla V, Young JA, Hadley S. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med. 2008 Jul;36(7):1993-8. doi: 10.1097/CCM.0b013e31816fc4cd.

For peer review only

Publication bias

Egger's test showed potential publication bias for length of hospital stay (1-tailed $P < 0.001$) and duration of ICU admission prior to candidemia onset (1-tailed $P = 0.004$), and no significant publication bias for length of ICU stay (1-tailed $P = 0.37$) and overall mortality (1-tailed $P = 0.38$). The classic fail-safe N tests indicated that the number of missing studies which would be needed to make the P-values of the summary effect become insignificant was 65,685 for length of stay, 2,304 for ICU length of stay, 89,242 for duration of ICU admission prior to candidemia onset, and 34,263 for overall mortality. These results indicated that the significance of the observed effects of the meta-analyses would not be influenced by the inclusion of additional studies (Figure 3A-C).

Data sharing

No additional data is available.

DISCUSSION

The current meta-analysis demonstrated that the pooled mean of duration of ICU admission prior to candidemia varied from approximately 17 days within hospital settings in Asia, to 19 days in Europe, to 46 days in South America. Most of the IC patients had received broad-spectrum antibiotics (89%), and the mean duration of antibiotic therapy prior to candidemia onset was nearly 18 days. The pooled mean mortality rate was approximately 49%. There was no significant difference in length of stay or overall mortality between patients with and without *C. albicans*, but the mean length of ICU stay was greater for patients with *C. albicans* compared to those patients without *C. albicans*.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Seven studies were performed in hospitals in China (Table 1). Two studies evaluated patients with *Candida albicans* vs. non-*Candida albicans* candidemia. One study compared patients with catheter-related *Candida* bloodstream infection (CRCBSI) vs. non-CRCBSI, and the other study compared patients with a fluconazole-resistant vs. fluconazole-sensitive (Flu-S) infection. The mean length of hospital stay ranged from 4 (early-onset group) to 54 days, and the mean length of ICU stay ranged from 14 to 34 days. The majority of studies (n=29) were performed in countries other than China. Of these, 7 were case-control or cross-sectional studies, and 34 were retrospective or prospective cohort studies. Eleven were designed to compare patients with and without candidemia. Five studies compared patients with candidemia based on *C. Albicans* vs. another *Candida* strain, and only 1 study compared ICU-acquired candidemia vs. non-ICU acquired candidemia [34]. Most of the studies (n=24) were conducted in general ICUs, and the others in SICUs or in cardio-surgical/cardiothoracic ICUs (CICU) [47], or medical ICUs [36], suggesting that invasive candidiasis is a common problem in critically ill patients regardless of the type of ICU. The mean length of hospital stay ranged from 22 to 51 days, and the mean length of ICU stay ranged from 7 days to 60 days (Table 2). In 9 studies, the median length of ICU stay was ≤ 10 days prior to onset of IC, and the overall mortality in ICU patients with candidemia in those studies ranged from 10.6% to 65.8%. In the other studies with a median ICU length of stay > 10 days prior to onset of IC, the overall mortality ranged from 13.6% to 96.0%.

The duration of ICU stay varied widely prior to candidemia onset which indicated that the onset of IC may be initiated by distinct risk factors in the ICU, and the time point to encounter these risk factors was different among critically ill patients. As we have mentioned previously, the major cause of severe candidiasis has been the

1
2
3 endogenous colonization of *Candida* species that requires a 7 to 10-day period for the
4 development of IC after exposure to risk factors [20]. In addition, the median time for
5 obtaining positive blood cultures was 2–3 days (possibly up to ≥ 7 days) [2].
6
7

8
9
10 Therefore, for patients with a confirmed diagnosis of candidemia onset at 8 days after
11 ICU admission, the endogenous colonization of *Candida* species may have occurred
12 in patients on the first day of ICU admission. Similarly, for the patients with a
13 confirmed diagnosis of candidemia at 12-13 days after ICU admission, the
14 endogenous colonization of *Candida* species may have also occurred 3-5 days after
15 ICU admission.
16
17
18
19
20
21
22
23

24 The main risk factor for candidemia was systemic antibiotic use [16]. In a
25 previously reported study in pediatric ICUs, it was reported that treatment with
26 vancomycin or anti-anaerobic antibiotics for >3 days were independently associated
27 with the development of candidemia [2], but only in an unadjusted analysis [16]. A
28 study in Hong Kong found that candidemia occurred in patients within 6 days of
29 being admitted to the ICU, and more than 97.0% of patients infected with fungi of
30 *Candida* species had received >48 hours of antibiotic treatment [64]. Overuse and
31 prolonged exposure to broad-spectrum antibiotics have been found that closely
32 associates them with candidemia in both China and India [65, 66], so it's reasonable to
33 suspect a link between overuse of broad-spectrum antibiotics and early-onset of
34 candidemia after ICU admission. Regardless of geographical differences, most
35 patients with IC received broad-spectrum antibiotic treatment prior to candidemia
36 onset in the ICU. However, due to a lack of sufficient data, potential correlation
37 between prolonged exposure to broad-spectrum antibiotics and the time of candidemia
38 onset after ICU admission, as well as further explanation of the longer duration of
39 ICU admission prior to candidemia onset in South America than in
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Asia/Europe/US/Australia could not be established in this systematic review.
4

5 The current results demonstrated that there was no significant difference in length
6 of hospital stay prior to the development of IC or overall mortality between patients
7 with and without *C. albicans* IC. This may be due to the clinical presentation and the
8 treatment of patients with candidemia caused by *C. albicans* and non-*C. albicans* were
9 indistinguishable [67]. Although it was found that the mortality rates in patients with
10 *C. albicans* and non-*C. albicans* was similar, the susceptibilities of these strains to
11 anti-fungal agents were different [21, 68, 69].
12
13
14
15
16
17
18
19
20
21

22 This systematic review had several limitations. This systematic review was
23 lacking a pre-specified protocol and its preliminary registration, the biased post hoc
24 decisions in review methods may occur. A number of the trials reported outcomes
25 using median (range) and/or median (IQR). In order to combine results, the sample
26 mean and standard deviation for such trials was estimated using a method proposed by
27 Wan et al. [24]. This method was based under the assumption that the data were
28 normally distributed. Across the meta-analysis, however, medians and quartiles were
29 often reported when data did not follow a normal distribution [23]. This possibility
30 may have confounded the results. The results of the quality assessment indicated that
31 potential biases from confounders may be present. High heterogeneity had existed in
32 the overall and subgroup analyses, suggesting the complexity of the risk factors
33 causing IC and candidemia (Supplementary Table S1).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Although meta-regression analysis in different design, country, and risk of bias et
50 al, which may be find the heterogeneity between groups were assessed in this study,
51 there may still be other potential factors that explain heterogeneity that requires
52 further study. Besides the factors analyzed in the subgroup analyses, there may be
53 other factors influencing heterogeneity such as comorbidities, severity of illness, and
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

invasive procedures (e.g., hemodialysis, invasive mechanical ventilation, total parenteral nutrition, surgery, and immunosuppression), which were not taken into account in this analysis. Publication bias may have also possibly existed in some analyzed outcomes.

This systematic review indicated that patients who received broad-spectrum antibiotics and who were admitted to the ICU were associated with the development of candidemia. Patients with *C. albicans* infection had longer ICU stays. In this setting, the choice of early detection and therapeutic intervention strategies for IC should strengthen implementation to optimize patients' management to reduce the risk of infection and potentially save the excessive consumption of medical resources.

Acknowledgements

The medical writing and editorial assistance were provided by Elizabeth Goodwin and Prof. Jerry Tseng of MedCom Asia Inc., China. This assistance was funded by MSD China. The authors initiated the concept for this systematic review and are responsible for the content of the manuscript.

Competing interests: The authors declare that they have no competing interests

Funding: None

Authors' contributions:

ZDZ: guarantor of integrity of the entire study; study concepts; study design; definition of intellectual content; manuscript editing; manuscript review.

RZ: guarantor of integrity of the entire study; study concepts; study design; definition of intellectual content; manuscript editing; manuscript review.

ZGL: guarantor of integrity of the entire study; study concepts; study design; definition of intellectual content; manuscript editing; manuscript review.

1
2
3 XCM: guarantor of integrity of the entire study; study concepts; study design;
4
5 definition of intellectual content; manuscript editing; manuscript review.
6
7

8 **Data sharing statement:** No additional data are available.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Calandra T, Roberts JA, Antonelli M, et al. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. *Crit Care* 2016;20:125.
2. Pappas PG, Kauffman CA, Andes DR, et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;62:409-17.
3. Bassetti M, Peghin M, Timsit JF. The current treatment landscape: candidiasis. *J Antimicrob Chemother*. 2016;71:ii13-ii22.
4. Yapar N. Epidemiology and risk factors for invasive candidiasis. *Ther Clin Risk Manag*. 2014;10:95-105.
5. Strollo S, Lionakis MS, Adjemian J, et al. Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002-2012. *Emerg Infect Dis*. 2016;23:7-13.
6. Leon C, Ostrosky-Zeichner L, Schuster M. What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. *Intensive Care Med* 2014;40:808-19.
7. Yang SP, Chen YY, Hsu HS, et al. A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study. *BMC Infect Dis* 2013;13:10.
8. Montagna MT, Lovero G, Borghi E, et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. *Eur Rev Med Pharmacol Sci*. 2014;18:661-74.

- 1
2
3 9. Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine
4
5 research agenda on invasive fungal infection in critically ill patients. *Intensive*
6
7 *Care Med.* 2017;43:1225-38.
8
9
- 10 10. Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of
11
12 invasive candidiasis. *Clin Infect Dis.* 2012;54:1123-5.
13
14
- 15 11. Kullberg BJ, Arendrup MC. Invasive Candidiasis. *N Engl J Med.*
16
17 2016;374:794-5.
18
- 19 12. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at
20
21 increased risk for candidal infections in the surgical intensive care unit: an
22
23 approach to developing practical criteria for systematic use in antifungal
24
25 prophylaxis trials. *Med Mycol*2005;43:235–43
26
27
- 28 13. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective
29
30 development and validation of a clinical prediction rule for
31
32 nosocomial invasive candidiasis in the intensive care setting. *Eur J*
33
34 *Clin Microbiol Infect Dis.* 2007;26:271-6.
35
36
- 37 14. Liao X, Qiu H, Li R, et al. Risk factors for fluconazole-resistant invasive
38
39 candidiasis in intensive care unit patients: An analysis from the China Survey
40
41 of Candidiasis study. *J Crit Care* 2015;30:862.e861-5.
42
43
44
- 45 15. Aguilar G, Delgado C, Corrales I, et al. Epidemiology of invasive candidiasis in
46
47 a surgical intensive care unit: an observational study. *BMC Res Notes*
48
49 2015;8:491.
50
- 51 16. Ortiz Ruiz G, Osorio J, Valderrama S, et al. Risk factors for candidemia in
52
53 non-neutropenic critical patients in Colombia. *Med Intensiva.*2016;40:139-44.
54
55
- 56 17. Ostrosky-Zeichner L. Clinical prediction rules for invasive candidiasis in the
57
58 ICU: ready for prime time? *Crit Care.* 2011;15:189.
59
60

- 1
2
3 18. León C, Ruiz-Santana S, Saavedra P, et al. Contribution of Candida biomarkers
4 and DNA detection for the diagnosis of invasive candidiasis in ICU patients
5 with severe abdominal conditions. *Crit Care*. 2016;20:149.
6
7
- 8
9
10 19. Martín-Mazuelos E, Loza A, Castro C, et al. β -D-Glucan and Candida albicans
11 germ tube antibody in ICU patients with invasive candidiasis. *Intensive Care*
12 *Med*. 2015;41:1424-32.
13
14
- 15
16
17 20. Eggimann P, Que YA, Revelly JP, Pagani JL. Preventing invasive candida
18 infections. Where could we do better? *J Hosp Infect*. 2015;89:302-8.
19
20
- 21
22 21. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk
23 of bias in non-randomized studies of interventions. *BMJ*. 2016; 355; i4919.
24
25
- 26
27 22. Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for
28 ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions
29 (ROBINS-I): detailed guidance, updated 12 October 2016. Available from
30 <http://www.riskofbias.info>.
31
32
33
- 34
35
36 23. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The
37 methodological quality assessment tools for preclinical and clinical studies,
38 systematic review and meta-analysis, and clinical practice guideline: a
39 systematic review. *J Evid Based Med*, 2015, 8(1):2-10.)
40
41
42
43
- 44
45 24. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
46 deviation from the sample size, median, range and/or interquartile range. *BMC*
47 *Med Res Methodol*. 2014;14:135.
48
49
- 50
51
52 25. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and
53 interpreting funnel plot asymmetry in meta-analyses of randomised controlled
54 trials. *BMJ*. 2011 Jul 22;343:d4002.
55
56
57
58
59
60

- 1
2
3 26. Yang Y, Guo F, Kang Y, et al. Epidemiology, clinical characteristics, and risk
4 factors for mortality of early- and late-onset invasive candidiasis in intensive
5 care units in China. *Medicine (Baltimore)*. 2017;96:e7830.
6
7
8
9
10 27. Fochtmann A, Forstner C, Haggmann M, et al. Predisposing factors for
11 candidemia in patients with major burns. *Burns*. 2015;41:326-32.
12
13
14 28. Klingspor L, Tortorano AM, Peman J, et al. Invasive *Candida* infections in
15 surgical patients in intensive care units: a prospective, multicentre survey
16 initiated by the European Confederation of Medical Mycology (ECMM)
17 (2006-2008). *Clin Microbiol Infect*. 2015;21:87.e81-7.e10.
18
19
20
21
22
23 29. Chakrabarti A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and
24 outcome of ICU-acquired candidemia in India. *Intensive Care*
25 *Med*. 2015;41:285-95.
26
27
28
29
30 30. Giri S, Kindo AJ, Kalyani J. Candidemia in intensive care unit patients: a
31 one-year study from a tertiary center in South India. *J Postgrad Med*.
32 2013;59(3):190-5.
33
34
35
36
37 31. Karacaer Z, Oncul O, Turhan V, Gorenek L, Ozyurt M. A surveillance of
38 nosocomial candida infections: epidemiology and influences on mortality in
39 intensive care units. *Pan Afr Med J*. 2014;19:398.
40
41
42
43
44 32. Colombo AL, Guimaraes T, Sukienik T, et al. Prognostic factors and historical
45 trends in the epidemiology of candidemia in critically ill patients: an analysis of
46 five multicenter studies sequentially conducted over a 9-year period. *Intensive*
47 *Care Med*. 2014;40:1489-98.
48
49
50
51
52
53 33. Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the
54 intensive care unit: a multicentre, prospective, observational study in Italy
55 (2006-2008). *Mycoses*. 2012;55:73-9.
56
57
58
59
60

- 1
2
3 34. Ylipalosaari P, Ala-Kokko TI, Karhu J, et al. Comparison of the epidemiology,
4 risk factors, outcome and degree of organ failures of patients with candidemia
5 acquired before or during ICU treatment. Crit Care. 2012;16:R62.
6
7
8
9
10 35. Pasero D, De Rosa FG, Rana NK, et al. Candidemia after cardiac surgery in the
11 intensive care unit: an observational study. Interact CardiovascThorac
12 Surg.2011;12:374-8.
13
14
15
16
17 36. Han SS, Yim JJ, Yoo CG, et al. Clinical characteristics and risk factors for
18 nosocomial candidemia in medical intensive care units: experience in a single
19 hospital in Korea for 6.6 years. J Korean Med Sci.2010;25:671-6.
20
21
22
23
24 37. Pratikaki M, Platsouka E, Sotiropoulou C, et al. Epidemiology, risk factors for
25 and outcome of candidaemia among non-neutropenic patients in a Greek
26 intensive care unit. Mycoses.2011;54:154-61.
27
28
29
30
31 38. Playford EG, Lipman J, Kabir M, et al. Assessment of clinical risk predictive
32 rules for invasive candidiasis in a prospective multicentre cohort of ICU
33 patients. Intensive Care Med.2009;35:2141-5.
34
35
36
37
38 39. Holley A, Dulhunty J, Blot S, et al. Temporal trends, risk factors and outcomes
39 in albicans and non-albicanscandidaemia: an international epidemiological
40 study in four multidisciplinary intensive care units. Int J Antimicrob
41 Agents.2009;33:554.e551-7.
42
43
44
45
46
47 40. Choi HK, Jeong SJ, Lee HS, et al. Blood stream infections by *Candida*
48 *glabrata* and *Candida krusei*: A single-center experience. Korean J Intern
49 Med. 2009;24:263-9.
50
51
52
53
54 41. Chow JK, Golan Y, Ruthazer R, et al. Risk factors for albicans and
55 non-albicanscandidemia in the intensive care unit. Crit Care
56 Med.2008;36:1993-8.
57
58
59
60

- 1
2
3 42. Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY. Candidemia and
4
5 candiduria in critically ill patients admitted to intensive care units in France:
6
7 incidence, molecular diversity, management and outcome. *Intensive Care*
8
9 *Med.*2008;34:292-9.
10
11
12 43. Girão E, Levin AS, Basso M, et al. Seven-year trend analysis of nosocomial
13
14 candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care
15
16 Units at a Brazilian University Hospital. *Med Mycol.*2008;46:581-8.
17
18
19 44. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. *Candida*
20
21 *albicans* versus non-*albicans* intensive care unit-acquired bloodstream
22
23 infections: differences in risk factors and outcome.
24
25 *AnesthAnalg.*2008;106:523-9.
26
27
28 45. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in
29
30 immunocompromised and immunocompetent critically ill patients: a
31
32 prospective comparative study. *Eur J ClinMicrobiol Infect.*
33
34 *Dis.*2007;26:377-84.
35
36
37 46. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of
38
39 candidemia and candidemia-related death in cardiothoracic ICU patients.
40
41 *Chest.*2003;124:2244-55.
42
43
44 47. Gong X, Luan T, Wu X, et al. Invasive candidiasis in intensive care
45
46 units in China: Risk factors and prognoses of *Candida albicans* and
47
48 non-*albicans Candida* infections. *Am J Infect Control.* 2016;44:e59-63.
49
50
51 48. Hu B, Du Z, Kang Y, et al. Catheter-related *Candida* bloodstream infection in
52
53 intensive care unit patients: a subgroup analysis of the China-SCAN study.
54
55 *BMC Infect Dis.*2014;14:594.
56
57
58
59
60

- 1
2
3 49. Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in
4
5 China: a multicentre prospective observational study. *J Antimicrob*
6
7 *Chemother.*2013;68:1660-8.
8
9
- 10 50. Yap HY, Kwok KM, Gomersall CD, et al. Epidemiology and outcome of
11
12 *Candida* bloodstream infection in an intensive care unit in Hong Kong. *Hong*
13
14 *Kong Med J.*2009;15:255-61.
15
16
- 17 51. Zhao H, Wong C, Wu P, et al. An analysis of mortality and clinical
18
19 characteristics of ICU-acquired candidemia patients. *Chin Crit Care*
20
21 *Med.*2018;30(10):929-32.
22
23
- 24 52. Ding R, Ji Y, Liu B, et al. Risk factors for mortality in cases of intensive care
25
26 unit-acquired candidemia: a 5.5-year, single-center, retrospective study. *Int J*
27
28 *Clin Exp Med.*2018;11(9):9950-7.
29
30
- 31 53. Tigen ET, Bilgen H, Gurun HP, et al. Risk factors, characteristics, and outcomes
32
33 of candidemia in an adult intensive care unit in Turkey. *Am J Infec*
34
35 *Control.*2017;45:e61-3.
36
37
- 38 54. Baldesi O, Bailey S, Ruckly S, et al. ICU-acquired candidemia in France:
39
40 epidemiology and temporal trends, 2004-2013-a study from REA-RAISIN
41
42 network. *J Infection.*2017;75:59-67.
43
44
- 45 55. Rudramurthy SM, Chakrabarti A, Paul RA, et al. *Candida auris* candidemia in
46
47 Indian ICUs: analysis of risk factors. *J Antimicrob*
48
49 *Chemother.*2017;72:1794-1801.
50
51
- 52 56. Kawano Y, Togawa A, Nakamura Y, et al. Prognostic factors for candidemia in
53
54 intensive care unit patients: a retrospective analysis. *Singapore Med*
55
56 *J.*2017;58(4):196-200.
57
58
59
60

- 1
2
3 57. Playford EG, Lipman J, Jones M, et al. Problematic dichotomization of risk for
4
5 intensive care unit (ICU)-acquired invasive candidiasis: results using a
6
7 risk-predictive model to categorize 3 levels of risk from a multi-center
8
9 prospective cohort of Australian ICU patients. *Clin Infect*
10
11 *Dis.*2016;63(11):1463-9.
12
13
14 58. Pinhati HM, Casulari LA, Souza AC, et al. *BMC Infect Dis.*2016;16(433):1-6.
15
16
17 59. Kautzky S, Staudinger T, Presteri E. Invasive candida infection in patients of a
18
19 medical intensive care unit. *Wien Klin Wochenschr.*2015;127: 132-42.
20
21
22 60. Lortholary O, Renaudat C, Sitbon K, et al. The risk and clinical outcome of
23
24 candidemia depending on underlying malignancy. *Intensive Care*
25
26 *Med.*2017;43:652-662.
27
28
29 61. Yapar N, Akan M, Avkan-Oguz V, et al. Risk factors, incidence and outcome of
30
31 candidemia in a Turkish intensive-care unit: a five-year retrospective cohort
32
33 study. *Anaesth Pain Intensive Care.*2014;18(3): 265-71.
34
35
36 62. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidemia
37
38 in critically ill patients: a prospective surveillance study.
39
40 *Mycoses.*2007;50:302-10.
41
42
43 63. Piazza O, Boccia MC, Iasiello A, et al. Candidemia in intensive care patients.
44
45 *Minerva Anesthesiol.*2003;70:63-9.
46
47
48 64. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics
49
50 in primary health care settings in China. *JAMA Intern Med.* 2014;174:1914-20.
51
52
53 65. Agrawal C, Biswas D, Gupta A, Chauhan BS. Antibiotic overuse as a risk factor
54
55 for candidemia in an Indian pediatric ICU. *Indian J Pediatr.* 2015;82:530-6.
56
57
58
59
60


- 1
2
3 66. Cheng MF, Yang YL, Yao TJ, et al. Risk factors for fatal candidemia caused by
4
5 Candida albicans and non-albicans Candida species. BMC Infect
6
7 Dis.2005;5:22.
8
9
10 67. Cheng MF, Yu KW, Tang RB, et al. Distribution and antifungal susceptibility of
11
12 Candida species causing candidemia from 1996 to 1999. DiagnMicrobiol Infect
13
14 Dis.2004;48:33-7.
15
16
17 68. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of Candida species
18
19 to amphotericin B and fluconazole: the emergence of fluconazole resistance in
20
21 Candida tropicalis. Infect Control Hosp Epidemiol.2004;25:60-4.
22
23
24 69. Yang YL, Cheng HH, Lo HJ. In vitro activity of voriconazole against Candida
25
26 species isolated in Taiwan. Int J Antimicrob Agents.2004;24:294-6.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Figure legends**
5
6
7

8 **Figure 1.** PRISMA flow diagram of study selection
9

10
11 **Figure 2.** Meta-analysis of *C. albicans* vs. non-*C. albicans* for A) length of hospital
12
13
14 stay; B) ICU length of stay; and C) Overall mortality
15
16

17
18 **Figure 3.** Funnel plot for A) length of hospital stay; B) ICU length of stay; C)
19
20 duration of ICU admission prior to candidemia onset
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



264x283mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Unable to Convert Image

The dimensions of this image (in pixels) are too large to be converted. For this image to convert, the total number of pixels (height x width) must be less than 40,000,000 (40 megapixels).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3A




Figure 3B





Figure 3C



130x242mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Supplementary Table S1. A supplementary information of heterogeneity test for overall studies or given subgroup for Table 3.

Comparison	Length of hospital stay, days				ICU length of stay, days				Duration of ICU admission prior to candidemia onset, days				Length of stay prior to ICU admission, days				Overall mortality rate			
	Degrees of freedom				Degrees of freedom				Degrees of freedom				Degrees of freedom				Degrees of freedom			
	Q	I ²	P-value		Q	I ²	P-value		Q	I ²	P-value		Q	I ²	P-value		Q	I ²	P-value	
Overall	16	20197.0	99.92	<0.001	27	2690.9	99.00	<0.001	30	4686.2	99.36	<0.001	4	311.2	98.71	<0.001	39	26981.1	99.86	<0.001
Overall optional^{abcd}	^a 13	850.7	98.47	<0.001	^b 25	2626.7	99.05	<0.001	^c 26	2649.8	99.02	<0.001					^d 35	24273.9	99.86	<0.001
Subgroups																				
Type of study																				
Prospective	7	568.3	98.77	<0.001	12	662.2	98.19	<0.001	16	1572.3	98.98	<0.001	1	0.9	0.35	<0.001	20	13805.2	99.86	<0.001
Retrospective	8	14000.4	99.94	<0.001	14	893.2	98.43	<0.001	13	2670.7	99.51	<0.001	2	28.39	92.95	<0.001	18	9479.2	99.81	<0.001
Presence of neutropenia																				
Neutropenia	7	6119.9	99.89	<0.001	8	2297.7	99.65	<0.001	11	3099.9	99.65	<0.001	0	-	-	-	11	15935.0	99.93	<0.001
Non-neutropenia	1	1.8	42.97	0.185	0			-	1	0	0	1	0	-	-	-	2	1388.4	99.86	<0.001
Type of ICU																				
ICU	7	11712.8	99.94	<0.001	16	930.6	98.28	<0.001	13	1589.8	99.18	<0.001	1	4.14	75.86	0.042	23	13807.9	99.83	<0.001
SICU				-	1	0.7	0.00	0.404	2	31.2	93.60	<0.001	0	-	-	-	2	1005.5	99.80	<0.001
MICU	0			-	1	6.2	83.92	0.013-	1	0	0	1-	0	-	-	-	1	14.3	92.99	<0.001
MICU+SICU	7	776.9	99.10	<0.001	6	713.7	99.16	<0.001	11	1539.5	99.29	<0.001	0	-	-	-	10	8098.2	99.88	<0.001

C. Albicans

C. Albicans	2	114.7	98.26	<0.001	2	5.79	65.45	0.055	1	0	0	1	5	1558.5	99.68	<0.001
Non C. Albicans	1	2.262	55.78	0.133	1	5.4	81.37	0.021	0	-	-	-	-	-	-	-

Presence of**IC/candidemia**

Candidemia	13	651.6	98.01	<0.001	23	2620.0	99.12	<0.001	24	2517.8	99.05	<0.001	3	302.3	99.01	<0.001	32	18755.6	99.83	<0.001
IC	2	2588.9	99.92	<0.001	3	17.0	82.33	0.001	5	1169.4	99.57	<0.001	0	-	-	-	6	3922.9	99.85	<0.001

Region

Asia	8	5464.6	99.85	<0.001	11	738.6	98.51	<0.001	11	2189.9	99.50	<0.001	1	1.4	26.82	0.242	16	8966.6	99.82	<0.001
Europe	3	226.5	98.68	<0.001	8	346.7	97.69	<0.001	10	907.3	98.90	<0.001	2	37.9	94.72	<0.001	13	7933.8	99.84	<0.001
South America	0	-	-	-	0	-	-	-	2	19.6	89.80	<0.001	-	-	-	-	4	1960.7	99.80	<0.001

Note: Certain subgroups have only 1 study (degree of freedom = 0).

^a Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^b Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^c Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

^d Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

Dash indicates no available.



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	9



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	34
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	33
Synthesis of results	21	Present the main results of the review. If meta-analyses done, include for each, confidence intervals and measures of consistency.	28
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	38
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	34
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	38
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	41
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	41
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	42

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

BMJ Open

The risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036452.R2
Article Type:	Original research
Date Submitted by the Author:	12-Mar-2020
Complete List of Authors:	Zhang, Zhidan; the First Hospital of China Medical University, Department of Critical Care Medicine Zhu, Ran; the First Hospital of China Medical University, Department of Critical Care Medicine Luan, Zhenggang; the First Hospital of China Medical University, Department of Critical Care Medicine Ma, Xiaochun; the First Hospital of China Medical University, Department of Critical Care Medicine
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Intensive care
Keywords:	ACCIDENT & EMERGENCY MEDICINE, INTENSIVE & CRITICAL CARE, Adult intensive & critical care < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **The risk of invasive candidiasis with prolonged duration of ICU stay: a systematic**
4 **review and meta-analysis**
5
6
7
8
9

10
11 **Running title:** Duration of ICU prior to candidemia
12

13
14 Zhidan Zhang MD, Ran Zhu MD, Zhenggang Luan MD, Xiaochun Ma MD
15

16
17 Department of Critical Care Medicine, the First Hospital of China Medical University,
18
19 Shenyang 110001, Liaoning, China
20
21

22
23
24
25 **Corresponding author:** Xiaochun Ma
26

27
28 Department of Critical Care Medicine, the First Hospital of China Medical University,
29
30 Shenyang 110001, Liaoning, China
31
32

33
34 Tel: 008613840192939;
35

36
37 E-mail: XCMA2972@sina.com
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: This study aimed to evaluate the duration of intensive care unit (ICU) stay prior to onset of invasive candidiasis (IC)/candidemia.

Design: Systematic review and meta-analysis.

Data Sources: Pubmed, Cochrane, Embase, and Web of Science databases were searched through June, 2019 to identify relevant studies.

Eligibility Criteria: Adult patients who had been admitted to the ICU and developed an invasive candidiasis infection.

Data extraction and synthesis: The following data were extracted from each article: the length of hospital stay, the length of ICU stay, duration of ICU admission prior to the candidemia onset, percentages of patients who received antibiotics and duration of their antibiotic therapy prior to candidemia onset, and overall mortality. In addition to the traditional meta-analyses, meta-regression was performed to explore possible mediators which might have contributed to the heterogeneity.

Results: The mean age of patients ranged from 28 to 76 years across selected studies. The pooled mean duration of ICU admission before onset of candidemia was 12.9 days (95% confidence interval [CI]: 11.7 – 14.2). The pooled mean duration of hospital stay was 36.3±5.3 days (95% CI: 25.8 – 46.7) and the pooled mean mortality rate was 49.3±2.2% (95% CI: 45.0% – 53.5%). There was no significant difference in duration of hospital stay ($P = 0.528$) or overall mortality ($P=0.111$), but a significant difference was observed in the mean length of ICU stay (2.8 days, $P < 0.001$) between patients with and without *C. albicans*. Meta-regression analysis found that South American patients had longer duration of ICU admission prior to candidemia onset than patients elsewhere, while those in Asia had the shortest duration.

1
2
3 **Conclusions:** Patients with IC are associated with longer ICU stay, with the shortest
4 duration of ICU admission prior to the candidemia onset in Asia. This shows a more
5 proactive strategy for the diagnosis of IC should be considered in caring ICU patients.
6
7
8
9

10
11
12 **KEYWORDS:** Invasive candidiasis, candidemia, intensive care unit, length of stay,
13 antibiotic, mortality
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- This meta-analysis is one of few that investigated the association of IC with the length of ICU stay, using data published worldwide and adhering to the PRISMA guideline.
- Extensive subgroup analyses were performed and meta-regression was made to examine possible causes of heterogeneity in the results.
- Although this meta-analysis was performed methodically, it lacked a pre-specified protocol and preliminary registration.
- Heterogeneity exists in some subgroup and overall analyses.
- Due to a lack of sufficient published data, relationship between prolonged exposure to broad-spectrum antibiotics and ICU-acquired candidemia could not be assessed.

INTRODUCTION

Candida species account for approximately 70% to 90% of invasive fungal infections and are the most frequent cause of fungal infections in patients admitted to the intensive care unit (ICU) [1]. Invasive candidiasis (IC) is associated with a high mortality rate (range: 40% to 60%) [1, 2]. Over recent decades, the incidence of IC has been gradually increasing in most regions [3], ranging from 0.5 to 32 cases per 1,000 ICU admissions. It has been found that there is a significant difference in the incidence of IC among several countries in Latin America and North America; however, data from Asia-Pacific countries are still relatively rare [4]. Candidemia has been described as the most common manifestation of IC, and the further infection of the liver, spleen, heart valves, or eye might also occur after a bloodstream infection [5]. In the past, the main *Candida* species isolated from patients with IC was *C. albicans*. However, non-*C. albicans* species has seen a rising proportion and now account for approximately 50% of all cases of IC in the past two decades [1,6-8].

Diagnosis and management of IC remains challenging for physicians in the ICU [1, 2]. The early initiation of empiric antifungal treatment has been demonstrated to improve the prognosis of invasive candidiasis [2, 9]. However, there is difficulty in the diagnosis of IC which can delay timely antifungal treatment [2, 10]. Blood culture remains the gold standard for the diagnosis of invasive candidiasis, but its sensitivity is variable (21% to 71%) [11].

In order to improve the diagnosis of IC, and to identify the patients who may best benefit from prophylactic, preemptive, or empirical therapy prior to, or at an early stage of ICU admission several methods in predicting the development of IC based on their associated risk factors have been developed [12, 13]. The risk factors in the

1
2
3 various predictive models include broad-spectrum antibiotic use, central venous
4 catheter placement, total parenteral nutrition, hemodialysis (days 1–3 in the ICU), any
5 surgery, immunosuppressive use, pancreatitis prior to ICU admission, and steroid use.
6
7 However, different risk factors are included in different predictive models. In addition,
8 potential risk factors such as *Candida* colonization [14] and mechanical ventilation
9 [15] have not been included in these models.

10
11
12
13
14
15
16
17 Long-term ICU stay has been reported as a risk factor for IC [11, 14-16]. Only a
18 few studies have examined the interval between ICU admission or initiation of
19 broad-spectrum antibiotics and the diagnosis of IC. However, the specific duration of
20 long-term ICU stays and the prolonged use of broad-spectrum antibiotics are often
21 arbitrarily defined and inconsistent among studies [6, 12, 15, 17-19]. Furthermore, a
22 large majority of severe candidiasis cases are caused by endogenous colonization.
23 This may be the primary reason for causing a delay of 7 to 10 days between exposure
24 to risk factors and the development of IC [20].
25
26
27
28
29
30
31
32
33
34

35 Thus, the objective of this systematic review was to evaluate several possible risk
36 factors associated with the development of candidemia, including the length of
37 hospitalization and ICU stay, as well as regional difference in those factors.
38
39
40
41
42
43
44

45 **METHODS**

46 **Search strategy**

47
48
49
50 The study was performed in accordance with guidance from the Preferred
51 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed,
52 Cochrane, Embase, and Web of Science databases were searched from the inception
53 through June, 2019 using the following terms: candidiasis, candidemia, intensive care
54 unit or ICU, and risk factors (Supplementary table S1). Studies identified by the
55
56
57
58
59
60

1
2
3 search strategy were reviewed for inclusion and data were extracted by two
4
5 independent reviewers. Where there was uncertainty regarding study eligibility, a
6
7 third reviewer was consulted. A flow chart of the study selection is shown in Figure 1.
8
9

10 11 12 **Study selection criteria**

13
14 Randomized controlled trials (RCTs), cohort studies, case-controlled, and
15
16 cross-sectional studies were included. All studies included adult patients who were
17
18 critically ill, who had been admitted to the ICU, and who were tested positive for
19
20 *Candida* species using blood culture analyses. Studies had to have reported
21
22 quantitative outcomes of interest and no author was contacted. Letters, comments,
23
24 editorials, case reports, proceedings, personal communications, and case series were
25
26 excluded. Studies in which patients were diagnosed with candidiasis prior to ICU
27
28 admission were excluded. Studies that did not evaluate the incidence of candidiasis as
29
30 a primary objective, or that were not designed to evaluate risk factors/prognostic
31
32 factors of patients with candidiasis were also excluded.
33
34
35
36
37
38
39

40 **Data extraction**

41
42 The following information / data was extracted from studies that met the
43
44 inclusion criteria: the name of the first author, year of publication, country, study
45
46 design, type of ICU, number of participants in each group, participants' age and
47
48 gender, the presence of *C. albicans*, the presence of neutropenia, and antifungal
49
50 treatment (especially the use of broad-spectrum antibiotics). The following data were
51
52 also extracted from each article: length of stay in hospital/ICU, length of stay prior to
53
54 ICU admission, duration of ICU stay prior to candidemia onset, antibiotic therapy
55
56 prior to candidemia onset, duration of antibiotic therapy prior to candidemia onset,
57
58
59
60

1
2
3 and overall mortality.
4
5
6

7 8 **Quality assessment** 9

10 We used the Risk of Bias In Non-randomized Studies of Interventions
11 (ROBINS-I) tool to assess the quality of the included studies [21]. ROBINS-I is based
12 on the Cochrane RoB tool and is suited for evaluating non-randomized studies that
13 compare the health effects of different interventions. ROBINS-I covers 7 different
14 bias domains: bias due to confounding, bias in selection of participants into the study,
15 bias in classification of interventions, bias due to deviations from intended
16 interventions, bias due to missing data, bias in measurement of outcomes, and bias in
17 the selection of reported results [22-23]. In this systematic review, 2 independent
18 reviewers performed the quality assessment, with a third reviewer consulted for any
19 uncertainty.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 38 **Patient and public involvement** 39

40 No patients and/or members of the public were involved in the process of
41 designing, planning and completing this study.
42
43
44

45 46 **Statistical analysis** 47

48 Study characteristics were summarized as mean±standard deviations (SD), mean
49 (range), median (range), or median (IQR) for age or duration of antifungal treatment,
50 and percentage (%) for sex, rate of *C. albicans* isolated, neutropenia, and antifungal
51 treatment used in each study.
52
53
54
55
56

57 Clinical outcomes, including the length of hospital stay, length of ICU stay,
58 length of hospital stay prior to ICU admission, duration of ICU admission prior to
59
60

1
2
3 candidemia onset, and duration of antibiotic therapy prior to candidemia onset were
4 represented as mean (range: [min. – max.]), median (range), or median (IQR
5 [interquartile range: 1st – 3rd quartiles]). The rate of antibiotic therapy prior to
6 candidemia onset and overall mortality rate were presented as percentages. All
7 clinical outcomes were further summarized for subgroups of studies (with studies'
8 number ≥ 2). Types of study, presence of neutropenia, types of ICU, type of *Candida*
9 isolated, presence of IC/candidemia, and regions/countries were listed for comparison
10 as well. Meta-regression analyses were performed to investigate statistical importance
11 of potential moderators. Quantitative data reported with median (range) and/or median
12 interquartile range (IQR) were converted to mean \pm SD, according to the method
13 described by Wan et al. [24]
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 The outcomes selected for the analysis were the length of hospital stay, the
30 length of ICU stay, duration of ICU admission prior to candidemia onset, and overall
31 mortality between patients who were diagnosed with *C. albicans* and those with
32 non-*C. albicans*. The effect size was calculated as mean difference with 95% CI
33 (Lower, Upper limit) in length of days, or rate ratio with 95% CI in overall mortality
34 for each given study, and then a pooling effect was derived thereafter. A difference in
35 means of length in days < 0 (or rate ratio of overall mortality rate > 1) indicated the
36 pooling effect favoring non- *C. albicans* subgroup, whereas difference in means of
37 length in days > 0 (or rate ratio of overall mortality rate < 1) indicated the pooling
38 effect favoring *C. albicans* subgroup. A difference in means of length in days = 0 (or
39 rate ratio of overall mortality rate = 1) indicated that the pooling effect was similar
40 between *C. albicans* and non-*C. albicans* subgroups. Heterogeneity was evaluated
41 using a χ^2 -based Cochran's Q statistic and I^2 . The random effect model
42 (DerSimonian-Laird method) and meta-regression analyses with potential moderators
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 were used for the meta-analysis if either Q statistic with P values < 0.10 or $I^2 > 50\%$;
4
5 otherwise, a fixed effect model (Mantel-Haenszel method) was used instead. For the
6
7 Q statistic, P values < 0.10 were considered statistically significant for heterogeneity.
8
9 For the I^2 statistic, heterogeneity was assessed as follows: no heterogeneity ($I^2 = 0 -$
10
11 25%), moderate heterogeneity ($I^2 = 25 - 50\%$), large heterogeneity ($I^2 = 50 - 75\%$), and
12
13 extreme heterogeneity ($I^2 = 75 - 100\%$). A two-sided P value of <0.05 was considered
14
15 statistically significant.
16
17

18
19 Countries were grouped based on their continents, but since meta-analysis of this
20
21 particular topic has not yet been seen in China, research articles from China will be
22
23 separately examined and discussed.
24
25

26 The publication bias was assessed using the funnel plot with Egger's test and
27
28 Classical fail-safe N test for all enrolled studies (except for subgroups). The absence
29
30 of publication bias was indicated by the data points forming a symmetric
31
32 funnel-shaped distribution and a 1-tailed significance level of $P > 0.05$ in an Egger's
33
34 test.[25] All analyses were performed using Comprehensive Meta-Analysis statistical
35
36 software, version 3.3.070 (Biostat, Englewood, NJ, USA).
37
38
39
40
41
42

43 **RESULTS**

44 **Literature search results**

45
46 A total of 1875 articles were retrieved from databases, and 1800 articles were
47
48 excluded after their titles and abstracts were screened based on the inclusion/exclusion
49
50 criteria (Figure 1). Seventy-five articles underwent full-text review, and 34 articles
51
52 were excluded for having irrelevant objectives or study designs (n=19), containing
53
54 patients in neonatal or pediatric intensive care unit (n=5), not having invasive
55
56
57
58
59
60

1
2
3 candidiasis (n=4), and not reporting outcomes of interest (n=6). The remaining 41
4
5 articles were included in the systematic review and meta-analysis.
6
7
8
9

10 **Study characteristics**

11
12
13 Characteristics of the 41 studies are summarized in Table 1 and Table 2 [14-16, 26-29,
14
15 30-63]. A total of 10,692 patients were included in those studies, with the number of
16
17 patients in each study ranging from 12 to 1,400. Mean age of the patients ranged from
18
19 28 to 76 years. Majority of the patients were males (range: 20% to 75.9%). These
20
21 studies were conducted in different countries, with 19 in Europe, 14 in Asia, 1 in the
22
23 US, 4 in South America, 2 in Australia and one multinational study (Australia,
24
25 Belgium, Greece, Brazil).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1. Characteristics of studies included in this systematic review

Studies 1 st Author (year)	Country	Study design	Type of ICU	Total IC and Candidemia number of patients	No. of patients	Age (years)	Male (%)	<i>C.Albica</i> <i>ns</i> isolated (%)	Neutropen ia (%)	Antifungal treatment	
										Duration of treatment	Antifungal treatment used
Zhao H (2018) [51]	China	retrospective cohort	ICU	95	95	69.3±16.5	57.9%	59	—	—	17.90%
Ding R (2018) [52]	China	retrospective cohort	ICU	72	72	62.5 (49.8, 77.0)§	62.5%	15	—	—	Fluconazole 30.6% Voriconazole 9.7% Echinocandin 44.4%
Yang et al. (2017) [26]	China	Retrospective cohort study (China-SCAN)	ICU	306	105	56.9 (19.9)§	64.8%	47.7	1.9%	—	Fluconazole (39.3%) Caspofungin(21.3%) Voriconazole (19.1%) Micafungin(10.1%) Itraconazole(5.6%) Amphotericin B (3.4%) Combined therapy (1.1%)
					201	64.0 (19.7)§	70.6%	36.1	1.5%	—	Fluconazole (36.9%) Caspofungin(25.1%) Voriconazole (17.9%) Micafungin(7.8%) Itraconazole(9.5%) Amphotericin B (1.7%) Combined therapy (1.1%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Gong et al. (2016) [47]	China	Prospective, cohort study (China-SCAN)	MICU, SICU, Integrated ICU	306	Candidemia (<i>C. albicans</i>)	98	62.2±17.3	62.2	100	3.1%	12.85 days	Triazole (64.7%) Echinocandin (31.8%) Polyenes (0%)
					Candidemia (Non- <i>C. albicans</i>)	146	61.4±21.4	72.6	—	1.4%	20.4 days	Triazole (62.8%) Echinocandin (34.1%) Polyenes (2.3%)
Playford EG (2016) [57]	Australia	prospective cohort	MICU, SICU	6,714	ICU-acquired IC	96	—	—	66	—	—	—
					Control (no IC)	6618	—	—	—	—	—	—
Pinhati HM (2016) [58]	Brazil	cross-sectional	ICU	40	fluconazole-resistant <i>C. parapsilosis</i> (FRCP)	21	70 (23–91)†	66.7	—	—	—	any: (33.3) fluconazole: (19.0)
					fluconazole-susceptible <i>Candida</i> species (FSC)	19	76 (35–90)†	57.9	—	—	—	any: (15.8) fluconazole: (15.8)
Aguilar et al. (2015) [15]	Spain	Prospective cohort study	SICU	22	IC	22	66 (53.7–74.2) §	72.7	59.1	—	10 (5.0–16.5) days	Echinocandins (86.4%) Fluconazole (13.6%)
Fochtman et al. (2015) [27]	Austria	Retrospective cohort study	Burn ICU	174	Candidemia	20	39 (17–88) †	60%	60	—	—	Triazoles (70%)
					Control	154	58 (17–94) †	61%	—	—	—	Echinocandins (30%)

1													
2													
3													
4													
5	Klingsporet al.(2015) [28]	14 countries in Europe	Prospective cohort study	SICU	807	IC	779	63(0–91)†	62.5%	54	—	—	Fluconazole (60%) Caspofungin (18.7%) Amphotericin B (13%) Voriconazole (4.8%)
6													
7													
8													
9													
10	Chakrabarti et al. (2015) [29]	India	Prospective cohort study	MICU, SICU	1400	Candidemia	1400	49.7 ± 17.7	—	20.9	1.3%	9.0 (5-15)§ days	Azoles (72.0%) Echinocandins (18.3%) Amphotericin B (14.4%)
11													
12													
13													
14	Liao et al. (2015) [14]	China	Prospective cohort study (China-SCAN)	MICU, SICU, Mix ICU	306	Flu-S	129	62.4±19.5	68.2%	60.5	3.1%	—	Monoantifungaltherapy (64.5%) Fungal drug adjustment (35.7%) Completely improved(34.6%)
15													
16													
17													
18													
19													
20													
21													
22													
23													
24													
25													
26													
27	Kautzky S (2015) [59]	Austria	prospective cohort	MICU	65	IC (invasive <i>Candida</i> infection)	5	28.2 ± 97	20%	—	0%	15.40 ± 13.9	100%
28													
29													
30													
31													
32													
33													
34													
35													
36													
37	Karacaer et al. (2014) [31]	Turkey	Prospective cohort study	ICU service	burn 2362	IC	63	70.2 ± 19.5	54%	64	—	—	—
38													
39													
40													
41													
42													
43													
44													
45													
46													

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

(14-95)

Colombo et al. (2014) [32]	Brazil	Retrospective cohort study	ICU	1,392	Candidemia	647	66 (18-97) †	50.7	44	2.5%	—	Amphotericin B (period 1:27.8%; period 2: 13.4%) Echinocandins(period 1: 5.9%; period 2: 18.0%)
Hu et al.(2014) [48]	China	Prospective cohort study (China-SCAN)	ICU	294	CRCBSI	29	69.4 ± 19.1	75.9 %	28.6	—	19.0 ± 13.3 days	Fluconazole (39.3%) Caspofungin(25.0%) Voriconazole(14.3%) Miconazole (10.70%) Itraconazole(10.7%) Amphotericin B (0%) Two-drug combination (0%)
												Non-CRCBSI
Lortholary O (2014) [60]	France	prospective cohort	ICU	2507	ICU-aquired candidemia	1206	60 ± 17	62.0 %	57.10	—	—	Fluconazole(55.4 %) Echinocandins(26.2 %) Others (including combination)(12.6 %)
												non-ICU aquired candidemia

1														
2														
3														
4														
5	Yapar N	Turkey	retrospective cohort	ICU	1076	Candidemia	66	54.4 ± 23.9	53%	53	—	—	9%	
6	(2014) [61]													
7														
8														
9														
10														
11														
12														
13	Guo et al.(2013) [49]	China	Prospective cohort study (China-SCA N)	MICU SICU General Emergency Neurologic ICU	306	Candidemia	306	61.5±20.0	68.6 %	40.2	1.6%	14 (0-104)† days	Fluconazole (37.7%) Caspofungin (23.9%) Voriconazole (18.3%)	
14														
15														
16														
17														
18	Giri S (2013) [30]	India	prospective cohort	ICU	5,976	Candidemia	39	35.14 (3days-79 % y)	61.5 %	4				
19														
20														
21														
22														
23	Tortorano et al.(2012) [33]	Italy	Prospective cohort study	MICU, SICU	384	Candidemia	276	—	—	60.9	—	—	Fluconazole (63%) Amphotericin B (22%) Caspofungin (7%) Voriconazole (6%)	
24														
25														
26														
27														
28	Ylipalosaari et al. (2012) [34]	Finland	Retrospective cohort study	MICU, SICU	82	ICU-acquired candidemia	38	63 (45-69) §	71%	76.3	—	Median: 22 days	Fluconazole (73%) Amphotericin B (34%) Echinocandins (31%)	
29														
30														
31														
32														
33														
34														
35														
36	Pasero D et al. (2011) [35]	Italy	Prospective cohort study	SICU	349	Candidemia	26	60±21	61.5 %	73	—	—	—	
37														
38														
39														
40														
41														
42														
43														
44														
45														
46														

					Control	323	67±16	65.3%	—	—	—		
	Han SS et al. (2010) [36]	Korea	Case-control study	MICU	52	Candidemia	49	57.6±14.1	—	65	25%	11 (1-45)†	Amphotericin B (71.4%)
						Control	147	57.4±14.0	—	—	8%	days	Fluconazole (28.6%)
	Pratikaki M et al. (2009) [37]	Greece	Case-control study	Multi-disciplinary ICU	855	Candidemia	33	57±18	64%	33.3	0%		Amphotericin B (57.1%)
						Control	132	58±18	70%	—	0%	>14 days	Voriconazole(17.9%), Caspofungin (14.3%) Fluconazole (10.7%)
	Playford et al.(2009) [38]	Australia	Prospective cohort study	MICU, SICU	615	IC	15	NA	NA	73.3	0%	—	—
	Holleyetal.(2009) [39]	Australia, Belgium, Greece, Brazil	Retrospective cohort study	Multi-disciplinary ICU	189	Candidemia (<i>C. albicans</i>)	104	56.5±17.1	63.5%	100	—	1(1-32)†days	Fluconazole (37%) Amphotericin B (31%)
						Candidemia (Non- <i>Candida albicans</i>)	85	58.9±16.3	44.7%	—	—		Fluconazole and amphotericin B (15%)
	Choi et al. (2009) [40]	Korea	Retrospective cohort study	ICU	497	Candidemia (<i>C. albicans</i>)	54	49±23	44.4%	100	13%	—	Amphotericin B (77.8%) Fluconazole (16.7%)
						Candidemia	27	48±25	44.4%	—	19%	—	Fluconazole and amphotericin B (5.6%)

Author (Year) [ref]	Country	Study Design	Setting	n	Infection	n	APACHE II	SOFA	Mortality %	Survival %	LOS (days)	Treatment
Yap et al (2009) [50]	China Hong Kong	Retrospective cohort study	MICU SICU	128	Candidemia (<i>C. glabrata</i> , <i>C. krusei</i>)	128	54 (43-68)	63.3 %	56	11%	—	Amphotericin B (39.1%) Fluconazole (38%) Amphotericin B+fluconazole (13%) Caspofungin or voriconazole (9.8%)
Chow et al. (2008) [41]	US	Case-control study	MICU, SICU	926	Candidemia (Non- <i>Candida albicans</i>)	67	62.3±14.5	57%	—	—	—	Fluconazole (84.8%) Amphotericin B (23.9%) Caspofungin (10.9%) Voriconazole (4.3%)
					Candidemia (<i>C. albicans</i>)	79	57±17.0	60%	100	—	—	Fluconazole (63%) Amphotericin B (33.3%) Caspofungin (11.1%) Voriconazole (0%)
					Control	780	62.3±17.4	56%	—	—	—	Fluconazole (100%) Amphotericin B (14.3%) Caspofungin (0%) Voriconazole (0%)
Bougnoux et al. (2008) [42]	France	Prospective cohort study	MICU SICU HU BU	290	Candidemia	57	56.1±18.2	67%	54.2	19.3%	13.2±10.3 days	Fluconazole (78.3%) Amphotericin B (52.2%) Flucytosine (15.2%)
Girão et al. (2008) [43]	Brazil	Prospective cohort study	ICU	73	Candidemia (Non- <i>Candida</i>)	40	51 (12-86)	60%*	—	—	—	—

						<i>albicans</i>)							
						Candidemia (<i>C. albicans</i>)	33	51(15-86)*	40%	100	—	—	—
	Dimopoulos et al. (2008) [44]	Greece	Prospective cohort study	MICU, SICU	56	Candidemia (<i>C. albicans</i>)	36	60.5 ± 14.9	44.4 %	100	0% (excluded)	Response rate: (80.6%)	Fluconazole as prophylaxis: Amphotericin B (75%) Caspofungin (25%)
												No fluconazole as prophylaxis: Amphotericin B (60%) Caspofungin (40%)	
						Candidemia (Non- <i>Candida albicans</i>)	20	64.5± 16.8	55%	—		Response rate: (45%)	Amphotericin B (100%)
	Dimopoulos et al. (2007) [45]	Greece	Prospective cohort study	MICU, SICU	24	Candidemia	24	—	—	62.5	—	16.5 (14-24)*days	<i>C. albicans</i> : fluconazole Non- <i>albicans</i> : amphotericin B
	Jordà-Marcos R (2007) [62]	Spain	prospective cohort	MICU, SICU	1765	Candidemia	63	63 (48 - 70)†	71.4 %	57.10	6.3%	—	7.90%
						Control (non-Candidemia)	1072	63 (46 - 71)†	66.5 %	—	2.8%	—	5.60%
	Piazza O (2004) [63]	Italy	retrospective cohort	ICU	478	Candidemia	12	57.58± 22.07	58.3 %	67	—	—	—

Table 2. Length of hospital and ICU stay, percentages of patients receiving antibiotics duration of antibiotic therapy prior to candidemia onset, and overall mortality

Studies 1 st Author (year)	Length of hospital stay (days)	Length of ICU stay (days)	Length of hospital stay prior to ICU admission (days)	Duration of ICU admission prior to candidemia onset (days)	Percentages of patients receiving antibiotic therapy prior to candidemia onset	Duration of antibiotic therapy prior to candidemia onset (days)	Overall mortality rate
Zhao H (2018) [51]	N/A	24 (12-57)†	N/A	N/A	N/A	N/A	58%
Ding R (2018) [52]	N/A	N/A	N/A	N/A	Broad-spectrum antibiotics: 98.6%	N/A	31.90%
Yang et al. (2017) [26]	(prior to IC diagnosis) Early-onset IC:4 (2, 7)§ Late-onset IC: 26 (16, 50)§	N/A	N/A	Early-onset IC: 4 (1, 7)§ Late-onset IC: 17 (10, 33)§	Early-onset IC: 62 (59.0%) Late-onset IC: 179 (89.1%)	N/A	Early-onset IC: 28.6% Late-onset IC: 40.8%
Tigen E (2017) [53]	N/A	22 (18-30)† 5.5 (2.25-15.75)†	N/A	N/A	Broad-spectrum antibiotic: 100% Broad-spectrum antibiotic: 59.5%	N/A	83.30%
Baldesi O (2017) [54]	N/A	29 (18; 49) § 7 (4; 13) §	N/A	N/A	antimicrobials: 82.2% antimicrobials: 55.1%	N/A	52.40% 17.80%
Rudramurt hy SM (2017) [55]	N/A	N/A	N/A	10 (4.7 – 22.2)§ 7 (3 – 13)§	N/A	N/A	41.90% 27%

1								
2								
3								
4								
5	Kawano Y (2017) [56]	N/A	N/A	N/A	13 (1 – 73)†	Broad-spectrum antimicrobial: 84%	N/A	72%
6								
7	OrtízRuiz et al. (2016) [16]	35.4±3.0	21.9±1.7	N/A	Median 25	Broad-spectrum antibiotic: 93.8 vs. 69.8% (case vs. control)	N/A	39.51%
8								
9								
10								
11	Gong et al. (2016) [47]	<i>Candida albicans</i> : Median: 32 Non- <i>C. albicans</i> : Median: 44	<i>Candida albicans</i> : Median: 18 Non- <i>C. albicans</i> : Median: 29	N/A	N/A	<i>Candida albicans</i> (before diagnosis): 76 (77.6%) Non- <i>albicans</i> (before diagnosis): 121 (82.9%)	N/A	<i>Candida albicans</i> (before diagnosis): 29.6% Non- <i>albicans</i> (before diagnosis): 26.7%
12								
13								
14								
15								
16								
17	Playford EG (2016) [57]	51 (34 – 89)§ 23 (13 – 40)§	21 (14 – 32)§ 8 (5 – 12)§	N/A	10 (5 – 15.25)†	N/A	N/A	26% 18.3%
18								
19								
20								
21	Pinhati HM (2016) [58]	N/A	N/A	N/A	22 (0 – 83)† 25 (7 – 134)†	any: 47.6% any: 42.1%	N/A	42.9% 47.4%
22								
23								
24								
25	Aguilar et al. (2015) [15]	N/A	N/A	N/A	20 (5, 37.5) §	Antibiotic therapy:21 (95.4 %)	10 (5.0–16.5)†	13.60%
26								
27								
28	Fochtman et al. (2015) [27]	N/A	60 (13–176) †	N/A	16 (6–89) †	Broad-spectrum antibiotic treatment in most patients	16 (6–89)†	30%
29								
30								
31								
32	Klingspore t al.(2015) [28]	N/A	23 (0–329) †	2 (0-744) †	12 (0–190) †	Broad-spectrum antibiotics in the last 2 weeks: 511 (78.4%)	N/A	38.80%
33								
34								
35								
36	Chakrabart i et al.	N/A	N/A	N/A	8 (4, 15) §	Candidemia patients received: antibiotics:93.0%	16.0 (7–36) days§	44.70%
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

(2015) [29]

Liao et al. (2015) [14]	Flu-S: 34.5 (18, 65) Flu-R: 48.0 (21, 90)	Flu-S: 22.5 (10.0, 40.0) Flu-R: 29.0 (17, 59)	N/A	Flu-S: 8.0 (3.0, 17.0)§ Flu-R: 10.5 (4.0, 27.0)§	≥5 d before diagnosis: Flu-S: 101 (78.3%) Flu-R: 73 (81.1%)	N/A	Flu-S: 31.8% Flu-R: 41.1%
Kautzky S (2015) [59]	N/A	46 (14 - 74)† 21 (10 - 77)†	17 (1 - 21)† 3 (1 - 66)†	17.4 ± 14.5	100% 90%	N/A	80% 21.7%
Karacaer et al. (2014) [31]	46.8±36.7 (5-190)	32.9±36.9 (0-190)	N/A	N/A	N/A	15 ± 13.8	77.70%
Colombo et al. (2014) [32]	N/A	N/A	N/A	20 (0-188) †	Prior antibiotic expose: 96.1%	N/A	70.30%
Hu et al. (2014) [48]	54.0 (26.0-91.0) §	34.0 (18.0-71.0) §	N/A	11.0 (4.0, 26.0)§	CRCBSI: 100% N CRCBSI:99.5%	CRCBSI: 11.4 ± 4.2 days; N CRCBSI:10.6 ±6.5 day	44.80%
Lortholary O (2014) [60]	N/A	N/A	N/A	N/A	N/A	N/A	51.00% 30.70%
Yapar N (2014) [61]	N/A	30.9±33 12.9±13	N/A	N/A	96.9% 78.3%	N/A	43.9% 32.2%
Guo et al. (2013) [49]	N/A	N/A	N/A	10 (0-330)†	Treatment before diagnostic confirm: 74 (27.6%)	N/A	36.60%
Giri S (2013) [30]	N/A	mean 26.4 (range 9-86) days	N/A	N/A	66.70%	mean 19.45 (range 4-31) days	24%

1								
2								
3								
4								
5	Tortorano et al.(2012) ^[33]	N/A	N/A	N/A	22.8 (2–190)†	broad spectrum antibiotic treatment: 85%	N/A	46.20%
6								
7								
8	Ylipalosaari et al. (2012) ^[34]	38.0 (22- 59) §	16.0 (11-30) §	1 (0-2) §	8.0 (1.0, 12.0) §	Previous antibacterial treatment (%): 97.4-95.5%	N/A	65.80%
9								
10								
11								
12	Pasero D et al. (2011) ^[35]	N/A	21±7	N/A	20 (8, 49) §	A significantly higher administration of > 2 antibiotics for >72 hours.	N/A	47%
13								
14								
15								
16	Han SS et al. (2010) ^[36]	38 (2-141)§	22 (1-141)§	8 (0-92) §	17 (0-117) †	All patients were treated with antibiotics prior to candidaemia onset	16 (1-92) †	96.00%
17								
18								
19								
20	Pratikaki M et al. (2009) ^[37]	N/A	25 (14-46)§	14 (1-20) §	10 (3, 22) §	All patients received antimicrobial agents prior to candidaemia onset	N/A	60.60%
21								
22								
23								
24	Playford et al.(2009) ^[38]	N/A	NA	N/A	10 (4, 16) §	Antibiotic receipt on days 1–3: 83.4%; Broad-spectrum antibiotic receipt on days 1–3: 82.0%	N/A	10.60%
25								
26								
27								
28	Holleyetal. (2009) ^[39]	N/A	<i>C. albicans</i> : 29.0±18.5 non- <i>C. albicans</i> : 29.2±28.2	N/A	N/A	All patients received antimicrobial agents prior to candidaemia onset	<i>C. albicans</i> : 13 (median) non- <i>C. albicans</i> : 15 (median)	<i>C. albicans</i> : 52.9% non- <i>C. albicans</i> : 64.7%
29								
30								
31								
32	Choi et al. (2009) ^[40]	(prior to fungemia) <i>Candida albicans</i> : 42±47 Non- <i>C. albicans</i> : 38±33	<i>Candida albicans</i> : 19±41 Non- <i>C. albicans</i> : 25±50	N/A	<i>Candida albicans</i> : 11±25 Non- <i>C. albicans</i> : 15±31	N/A	N/A	<i>Candida albicans</i> : 48% Non- <i>C. albicans</i> : 67%
33								
34								
35								
36								
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

1								
2								
3								
4								
5	Yap et al	28 (17-54) §	14 (5-23) §	N/A	6 (1-13)§	Antibiotics > 48 hours before candidaemia: <i>C. albicans</i> : 70 (97.0%) <i>non-C. albicans</i> : 56 (100%)	N/A	70%
6	(2009) [50]							
7								
8								
9	Chow et al.	<i>Candida albicans</i> : 28 (20–42)§	<i>Candida albicans</i> : 22 (15–33)§	N/A	<i>Candida albicans</i> : 11 (9, 17) § Non- <i>C. albicans</i> : 10 (4, 21) §	Non- <i>C. albicans</i> : 0.75 (0–2) §	2.21 (1.4–2.7)§	<i>Candida albicans</i> : 58% Non- <i>albicans</i> : 57%;
10	(2008) [41]	Non- <i>C. albicans</i> : 37 (24–57)§	Non- <i>C. albicans</i> : 25 (14–40)§					
11								
12								
13								
14	Bougnoux et al.	N/A	43.1 ± 45.2	N/A	19.0 ± 2.9 or (13.0; 2-145)§	No antibiotic treatment is reported	N/A	61.80%
15	(2008)							
16	[42]							
17								
18	Girão et al.	N/A	N/A	N/A	<i>C. albicans</i> : 15 (mean) Non- <i>C. albicans</i> : 18 (mean)	The hospital is restricted the use of several antibiotics	N/A	<i>C. albicans</i> : 72% non- <i>C. albicans</i> : 80%
19	(2008)							
20	[43]							
21								
22	Dimopoulou et al.	<i>C. albicans</i> : 22 ± 7.6	N/A	N/A	<i>C. albicans</i> : 12 ± 2.2 non- <i>C. albicans</i> : 10 ± 2.4	100% of patients received broad spectrum antibiotic treatment for >3 days during the ICU stay.	N/A	<i>C. albicans</i> : 52.8% non- <i>C. albicans</i> : 90%
23	(2008) [44]	non- <i>C. albicans</i> : 25 ± 8.4						
24								
25								
26								
27	Dimopoulou et al.	N/A	N/A	N/A	9 (5–11) †	100% of patients received broad spectrum antibiotic treatment	N/A	N/A
28	(2007)							
29	[45]							
30								
31	Jordà-Marcos R	48 (26 – 69)	28 (17 – 45)	N/A	23.5 ± 54.7	100%	N/A	17.2%
32	(2007) [62]	35 (22 – 57)	18 (12 – 28)			96.5%		13.2%
33								
34								
35	Piazza O	N/A	N/A	N/A	median 13 days	N/A	N/A	67%
36	(2004) [63]							
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								

1						
2						
3						
4						
5	Michalopoulos et al.	N/A	27.1 ± 7.5	N/A	15 (11-23) †	Empiric antibiotic therapy with 2 N/A or more broad-spectrum agents for all patients
6	(2003) [46]					N/A
7						
8						

Abbreviations: ARDS, acute respiratory distress syndrome; CPB, cardiopulmonary bypass; CRCBSI, catheter-related bloodstream *Candida* infection; Flu-R, fluconazole-resistant; Flu-S, fluconazole-sensitive; IC, invasive candidiasis; IMV, invasive mechanical ventilation; N/A, not available; SAPS II, Simplified Acute Physiology Score II; TPN, total parenteral nutrition.

§ Data are presented as median (interquartile range; IQR).

† Data are presented as median (range).

For peer review only

1
2
3
4
5 Among studies that reported mean length of ICU admission being ≤ 10 days prior to candidemia onset, including the early-onset group in the
6
7 study by Yang et al [26] and Flu-S group in the study by Liao et al. [14], the overall mortality ranged from 28.6% to 70.0% (Table 2). Among
8
9 studies that reported the median length of ICU admission being >10 days prior to candidemia onset, the overall mortality ranged from 40.8% to
10
11 44.8%.
12

13
14 Similar to other countries, most patients with IC in China received antibiotic treatment prior to candidemia onset in the ICU, which ranged
15
16 from 59.0% of the early-onset group [26] to 100% in the CRCBSI and non-*C. albicans* groups [49, 51]. Only one study reported the median
17
18 duration of antibiotic therapy prior to candidemia onset, which ranged from 10.6 to 11.4 days [49].
19
20
21
22

23 **Meta-analysis**

24 *Summary of the clinical outcomes for overall studies or given subgroups*

25
26 The summary of variables such as the length of hospital stay, length of ICU stay, duration of ICU admission prior to candidemia onset, length of
27
28 hospital stay prior to ICU admission, and overall mortality was presented in Table 3. Five studies [14, 26, 47-49] were from China by using
29
30 China-SCAN patient data, in which four studies were excluded to avoid overlapping data.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 3. Summary for length of hospital stay, length of ICU stay, duration of ICU admission and hospital stay prior to candidemia onset, and overall mortality for overall or given subgroups^{†‡}

Comparison	Length of hospital stay, days	Length of ICU stay, days	Duration of ICU admission prior to candidemia onset, days	Length of hospital stay prior to ICU admission, days	Overall mortality
	Mean (95%CI.)	Mean (95%CI.)	Mean (95%CI.)	Mean (95%CI.)	Rate (95%CI.)
Overall	36.3(25.8, 46.7)	25.8(23.6, 28.1)	12.9(11.7, 14.2)	11.7(0.4, 23.1)	49.3(45.0, 53.5)
Overall optional^{abcd}	^a 37.5(33.3, 41.6)	^b 25.9(23.5, 28.3)	^c 13.7(12.5, 15.0)	—	^d 51.0(46.6, 55.4)
Subgroups					
Type of study					
Prospective	41.0(32.9, 49.1)	27.4(24.6, 30.3)	12.9(11.5, 14.4)	19.2(17.2, 21.3)	42.7(37.9, 47.4)
Retrospective/ Cross-sectional	31.9(18.2, 45.5)	23.9(21.1, 26.6)	13.7(11.2, 16.2)	7.4 (-3.7, 18.4)	56.5(48.0, 65.0)
Presence of neutropenia					
Neutropenia	34.9(19.8, 50.1)	25.4(19.3, 31.5)	11.6(9.5, 13.8)	—	49.6(40.8, 58.3)
Non-neutropenia	22.9(20.9, 25.0)	—	10.0(9.3, 10.7)	—	41.3(7.9, 74.7)
Type of ICU					
ICU	37.7(21.7, 53.7)	27.3(24.9, 29.7)	14.3(5.7, 6.0)	17.2(11.9, 22.4)	49.8(44.3, 55.3)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

SICU	—	21.7(19.5, 23.9)	17.3(11.9, 22.7)	—	33.1(15.2, 51.1)
MICU	—	32.7(10.3, 55.2)	17.0(16.2, 17.8)	—	88.4(72.8, 104.1)
MICU+SICU	34.6(28.2, 41.1)	22.5(18.4, 26.6)	10.9(9.6, 12.3)	—	45.7(36.4, 55.0)
<i>C. albicans</i>					
<i>C. albicans</i>	34.2(33.1, 35.3)	25.9(22.3, 29.5)	11.0(10.7, 11.3)	—	52.2(40.0, 64.4)
Non <i>C. albicans</i>	27.0(24.3, 29.8)	25.0(18.0, 31.9)	—	—	—
Presence of IC/candidemia					
Candidemia	36.3(32.9, 39.8)	25.8(23.2, 28.3)	13.2(12.0, 14.5)	10.8(-2.0,23.6)	51.4(47.1, 55.8)
IC	33.9(-3.7, 71.4)	26.4(20.7, 32.1)	11.5(7.7, 15.3)	—	38.9(27.8, 50.1)
Region(s)					
Asia	36.9(23.0, 50.8)	25.0(20.9, 29.0)	17.4(14.6, 20.2)	19.3(17.2, 21.4)	51.2(44.7, 57.7)
Europe/US/Australia	33.3(20.8, 45.8)	27.7(23.3, 32.1)	18.5(15.3, 21.7)	9.6 (-1.2, 20.4)	48.6(42.4, 54.7)
South America	—	—	45.8(27.8, 63.7) *	—	54.4(38.0, 70.7)

Note: Certain subgroups have only 1 study (degree of freedom = 0).

^a Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^b Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^c Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

^d Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

Dash indicates no available

[†] The range width of 95% CI is related to the accuracy of the estimation. The narrower the range, the higher the accuracy of the estimation. If both the upper and lower limits are positive, the clinical outcome estimate for this group of participants is positive, if the lower limit is negative and the upper limit is positive, indicating that the clinical outcome estimate for this type of participants is not significantly greater than 0.

[‡] Meta-regression is used to assess relationship between the study-level covariates and effect size when obvious heterogeneity exists in subgroups.

* Meta-regression analysis illustrated South American patients had significantly longer duration of ICU admission prior to candidemia onset than their counterparts in Asia, Australia, Europe and North America (using Asia as the reference group, for South America: $\beta = 25.83$, $p = 0.0308$, $R^2 = 0.097$). Other meta-regression analyses in subgroups in this table did not reach statistical significance.

Across all studies, the mean length of hospital stay, mean length of ICU stay, mean duration of ICU admission prior to candidemia onset, mean length of hospital stay prior to ICU admission and mean overall mortality rate were found to be 36.3 days (95% CI: 25.8 - 46.7), 25.8 days (95% CI: 23.6 - 28.1), 12.9 days (95% CI: 11.7 - 14.2), 11.7 days (95% CI: 0.37 - 23.1), and rate of 49.3% (95% CI: 45.0% - 53.5%), respectively. After four China-SCAN studies were excluded from the analysis, the mean length of hospital stay, mean length of ICU stay, mean duration of ICU admission prior to candidemia onset and the mean overall mortality rate were found to be 37.5 days (95% CI: 33.3 - 41.6), 25.9 days (95% CI: 23.5 - 28.3), 13.7 days (95% CI: 12.5 - 15.0) and 50.99% (95% CI: 46.6% - 55.4%), respectively (Table 3).

Other outcomes including types of study, presence of neutropenia, types of ICU, types of *C. Albicans* isolated, presence of IC/candidemia, and regions/countries were also summarized for subgroups of studies (with studies' number ≥ 2). The interval estimate showed the summarized statistics of subgroups were all significant except for length

1
2
3 of hospital stay of patients with IC, length of hospital stay prior to ICU admission of
4 patients selected from retrospective or cross-sectional type of studies, and patients
5 with candidemia (95% CI included zero) (Table 3).
6
7
8

9
10 According to the summarized statistics in Table 3, neutropenic patients had a
11 greater length of hospital stay (mean=34.9 vs. 22.9 days), a longer duration of ICU
12 admission prior to candidemia onset (mean=11.6 vs. 10.0 days), and a higher overall
13 mortality rate (rate: 49.6% vs. 41.3%) than non-neutropenic patients. The mean
14 durations of ICU admission prior to candidemia onset were 17.3 days, 17 days, 14.3
15 days, and 10.9 days for patients in surgical ICU (SICU), medical ICU (MICU), ICU,
16 and MICU+SICU, respectively. Patients with candidemia had a greater length of
17 hospital stay (mean=36.3 vs. 33.9), longer duration of ICU admission prior to
18 candidemia onset (mean=13.2 vs. 11.5), and a higher overall mortality rate (51.4% vs.
19 38.9%) than patients without IC. However, patients with candidemia had a shorter
20 length of ICU stay (mean=25.8 vs. 26.4 days) and a shorter length of hospital stay
21 prior to ICU admission (mean=10.8 vs. 15.2 days) than patients with IC. Furthermore,
22 patients with *C. albicans* also had a higher duration of ICU admission prior to
23 candidemia onset compared to patients with other species of *C. albicans* (mean=11 vs.
24 10 days). The mean durations of ICU admission prior to candidemia onset in
25 hospitalized patients were 18.5 days (95% CI=15.3 – 21.7 days) in Europe, 17.4 days
26 (95% CI: 14.6 – 20.2 days) in Asia, and 45.8 days (95% CI: 27.8 – 63.7 days) in
27 South America. Data from Girão et al.[43] and Gong et al.[47] were excluded from
28 the summarized analysis due to absence of standard deviations for mean values and
29 data ranges.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ***Broad-spectrum antibiotic use prior to candidemia onset, length of hospital stay***
4
5 ***prior to ICU admission, and overall mortality***
6
7

8 In order to compare the broad-spectrum antibiotic use between IC patients and non-IC
9 patients, we reviewed and excluded studies containing control groups with
10 non-invasive candida infection and/or with a clear number of broad-spectrum
11 antibiotics use. After pooling all data, the difference in IC patients' use of
12 broad-spectrum antibiotics (89.1%, 95% CI: 82.7%-93.4%) prior to IC onset vs. that
13 of non-IC patients (77.4%, 95% CI: 52.3%-91.4%) did not reach statistical
14 significance. The mean duration of antibiotic therapy prior to candidemia onset was
15 17.8 days (95% CI: 9.3 - 26.3), but the duration of broad-spectrum antibiotic use prior
16 to the infection could not be determined due to insufficient data. Only five studies
17 reported length of hospital stay prior to ICU admission and the mean was 11.7 days
18 (95% CI: 0.4 - 23.1). The overall mortality rate increased from 49.3% to 51.0% after
19 excluding four China-SCAN studies (Table 3).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 ***Comparing the effect between *Candida albicans* vs. non-*Candida albicans****
39

40 A meta-analysis was performed to compare effect of the length of hospital stay, length
41 of ICU stay, and overall mortality between patients infected with *C. albicans* and
42 those infected with different strains of *Candida*. Three studies examined the length of
43 hospital stay [40, 41, 44], three studies examined the length of ICU stay [39-41], and
44 six studies examined overall mortality [39-41, 43, 44, 47]; these were selected for the
45 meta-analysis. According to the heterogeneity test, a random effect model was applied
46 for the length of hospital stay ($Q = 25.47$, $I^2 = 92.1\%$, $p < 0.001$) and overall mortality
47 rate ($Q = 399$, $I^2 = 98.7\%$, $p < 0.001$), while a fixed effect model was applied for the
48 length of ICU stay ($Q = 1.56$, $I^2 = 0\%$, $p = 0.458$). The pooled effect demonstrated no
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 significant difference in length of hospital stay between patients with and without *C.*
4
5 *albicans* (Figure 2A, $p>0.05$); however, there was a significant difference in mean
6
7 length of ICU stay (difference in means = 2.8 days, Figure 2B, $P<0.001$). There was
8
9 also no significant difference in overall mortality between patients with and without *C.*
10
11 *albicans* (Figure 2C, $p>0.05$).
12
13
14
15
16

17 ***Quality assessment***

18
19 Results of the quality assessment are shown in Table 4. For the results of ROBINS-I,
20
21 9 studies had serious bias due to confounding because no baseline confounding or
22
23 appropriate analysis methods were used to adjust for important baseline confounding.
24
25 Five studies had serious bias in the selection of participants due to unclear inclusion
26
27 and exclusion criteria. Most of studies had low or moderate bias in classification of
28
29 interventions. No study provided the information of systematic difference between
30
31 experimental intervention and comparator groups due to a lack of comparison of two
32
33 intervention groups. All studies had low or moderate bias in missing data, in
34
35 measurement of outcomes, and in selection of the reported result. Overall, 28 studies
36
37 had moderate risk of bias, thirteen had serious risk of bias, and one had unclear
38
39 information regarding the risk of bias.
40
41
42
43
44
45

46 ***Meta-regression of clinical outcomes***

47
48 A meta-regression analysis demonstrated that South American patients had
49
50 significantly longer mean duration of ICU admission prior to candidemia onset than
51
52 patients in Asia, Australian, Europe and North America (using Asia as the reference
53
54 group, South America had $\beta = 25.83$, $p = 0.0308$, $R^2 = 0.097$). Other subgroup
55
56 meta-regression analyses did not reach statistical significance (Table 3). The level of
57
58 risk of bias (moderate/serious or no information) was also included in the
59
60

1
2
3 meta-regression analyses and the coefficient was not found to achieve statistical
4
5 significance.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 4. Quality assessment of included studies using ROBINS-I

1st Author (year)	Bias due to confounding	Bias in selection of participants into the study	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported result	Overall risk of bias
Ding et al. (2018) ^[52]	low	moderate	low	no information	moderate	low	low	moderate
Zhao et al. (2018) ^[51]	low	low	no information	no information	low	low	low	moderate
Baldesi et al. (2017) ^[54]	low	moderate	no information	no information	low	low	low	moderate
Kawano et al. (2017) ^[56]	serious	moderate	low	no information	low	low	low	serious
Rudramurthy et al. (2017) ^[55]	low	low	low	no information	low	low	low	moderate
Tigen et al. (2017) ^[53]	serious	moderate	low	no information	low	low	low	serious
Yang et al. (2017) ^[26]	low	low	low	no information	low	low	moderate	moderate
Gong et al. (2016) ^[47]	serious	moderate	low	no information	low	low	low	serious
OrtízRuiz et al. (2016) ^[16]	low	low	low	no information	low	low	low	moderate
Pinhati et al. (2016) ^[58]	moderate	moderate	low	no information	low	low	low	moderate
Playford et al. (2016) ^[57]	low	moderate	no information	no information	low	low	low	moderate
Aguilar et al. (2015) ^[15]	no information	moderate	low	no information	low	low	low	moderate
Chakrabarti et al. (2015) ^[29]	serious	low	low	no information	low	low	low	serious

1									
2									
3									
4									
5	Fochtmann et al. (2015) [27]	low	moderate	low	no information	low	low	low	moderate
6									
7									
8	Kautzky et al. (2015) ^[59]	serious	low	no information	no information	low	low	low	serious
9									
10	Klingspor et al.(2015) [28]	low	moderate	low	no information	low	low	low	moderate
11									
12	Liao et al. (2015) ^[14]	low	moderate	low	no information	low	low	low	moderate
13									
14	Karacaer et al. (2014) ^[31]	moderate	moderate	low	no information	low	low	low	moderate
15									
16	Colombo et al. (2014) [32]	low	moderate	low	no information	low	low	low	moderate
17									
18	Hu et al.(2014) ^[48]	low	moderate	low	no information	low	low	low	moderate
19									
20	Lortholary et al. (2014) [60]	low	serious	low	no information	low	low	moderate	serious
21									
22	Yapar et al. (2014) ^[61]	moderate	moderate	low	no information	low	low	low	moderate
23									
24	Giri et al. (2013) ^[30]	serious	moderate	low	no information	low	low	low	serious
25									
26	Guo et al.(2013) ^[49]	low	low	low	no information	low	low	low	moderate
27									
28	Tortorano et al.(2012) [33]	serious	moderate	low	no information	low	low	low	serious
29									
30	Ylipalosaari et al. (2012) [34]	moderate	moderate	low	no information	low	low	low	moderate
31									
32	Pasero et al. (2011) ^[35]	low	low	low	no information	low	low	low	moderate
33									
34	Han et al. (2010) ^[36]	low	serious	no information	no information	low	low	low	serious
35									
36	Pratikaki et al. (2009) ^[37]	moderate	low	low	no information	low	low	low	moderate
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Playford et al.(2009) ^[38]	no information	low	no information	no information	low	low	low	no information
Holley et al.(2009) ^[39]	low	serious	low	no information	low	low	low	serious
Choi et al. (2009) ^[40]	low	serious	low	no information	low	low	low	serious
Yap et al. (2009) ^[50]	no information	moderate	low	no information	low	low	low	moderate
Chow et al. (2008) ^a	low	low	low	no information	low	low	low	moderate
Chow et al. (2008) ^b ^[41]	low	moderate	low	no information	low	low	low	moderate
Bougnoux et al. (2008) ^[42]	no information	low	low	no information	low	low	low	moderate
Girão et al. (2008) ^[43]	no information	serious	low	no information	low	low	low	moderate
Dimopoulos et al. (2008) ^[44]	low	low	low	no information	low	low	low	moderate
Dimopoulos et al. (2007) ^[45]	serious	low	low	no information	low	low	low	serious
Jordà-Marcos et al. (2007) ^[62]	low	moderate	low	no information	low	low	low	moderate
Piazza et al. (2004) ^[63]	serious	low	moderate	no information	moderate	low	low	serious
Michalopoulos et al. (2003) ^[46]	low	low	no information	no information	low	low	low	moderate

^a, Chow JK¹, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008 Apr 15;46(8):1206-13. doi: 10.1086/529435.

1
2
3
4
5 ^b, Chow JK¹, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, Chawla V, Young JA, Hadley S. Risk factors for albicans and non-albicans candidemia in
6 the intensive care unit. Crit Care Med. 2008 Jul;36(7):1993-8. doi: 10.1097/CCM.0b013e31816fc4cd.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Publication bias

Egger's test showed potential publication bias for length of hospital stay (1-tailed $P < 0.001$) and duration of ICU admission prior to candidemia onset (1-tailed $P = 0.004$); there was no significant publication bias for length of ICU stay (1-tailed $P = 0.37$) and overall mortality (1-tailed $P = 0.38$). The classic fail-safe N tests indicated that the number of missing studies which would be needed to make the P -values of the summary effect become insignificant, was 65,685 for length of stay, 2,304 for length of ICU stay, 89,242 for duration of ICU admission prior to candidemia onset, and 34,263 for overall mortality. These results indicated that the significance of the observed effects of the meta-analyses would not be influenced by the inclusion of additional studies (Figure 3A-C).

Data sharing

No additional data is available.

DISCUSSION

The current meta-analysis demonstrated that the pooled mean of duration of ICU admission prior to candidemia varied from approximately 17 days in Asia, to 19 days in Europe and 46 days in South America. Most of the IC patients had received broad-spectrum antibiotics (89%), and the mean duration of antibiotic therapy prior to candidemia onset was nearly 18 days. The pooled mean mortality rate was approximately 49%. There was no significant difference in the length of hospital stay or overall mortality between patients with and without *C. albicans*, but the mean length of ICU stay was greater for patients with *C. albicans* compared to those patients without *C. albicans*.

1
2
3 As for the study design, eight were case-control or cross-sectional studies, and
4
5 the remaining 33 were retrospective or prospective cohort studies (Table 1). Eleven
6
7 studies were designed to compare patients with and without candidemia. Five studies
8
9 compared patients with infection of *C. albicans* vs. those infected with another
10
11 *Candida* strain, and only one study compared ICU-acquired candidemia vs. non-ICU
12
13 acquired candidemia [34]. Eight studies were performed in Chinese hospitals (Table
14
15 1). Two studies evaluated patients with *Candida albicans* vs. non-*Candida albicans*
16
17 infection. One study compared patients with catheter-related *Candida* bloodstream
18
19 infection (CRCBSI) vs. non-CRCBSI, and another study compared patients with a
20
21 fluconazole-resistant vs. fluconazole-sensitive (Flu-S) infection.
22
23
24
25

26 Fewer than half of the studies (n=18) were conducted in general or
27
28 multi-disciplinary ICUs, with the rest in SICUs, in the cardio-surgical/cardiothoracic
29
30 ICUs (CICU) [46], or in medical ICUs [36]. This suggests that invasive candidiasis is
31
32 a common problem in critically ill patients regardless of the ICU type. The mean
33
34 length of hospital stay ranged from 4 (early-onset group) to 54 days, and the mean
35
36 length of ICU stay ranged from 7 days to 60 days (Table 2). In 9 studies, median
37
38 lengths of ICU stay were ≤ 10 days prior to onset of IC, and the overall mortality in
39
40 ICU patients with candidemia in those studies ranged from 10.6% to 65.8%. In those
41
42 studies with median lengths of ICU stay > 10 days prior to onset of IC, the overall
43
44 mortality ranged from 13.6% to 96.0%.
45
46
47
48

49 The durations of ICU stay varied widely prior to candidemia onset which
50
51 indicated the time and circumstances involved in encountering ICU-acquired risk
52
53 factors might differ among critically ill patients. As we have mentioned previously,
54
55 one major cause of severe candidiasis is the endogenous colonization of *Candida*
56
57 species that requires a 7 to 10-day period for the development of IC after exposure to
58
59
60

1
2
3 the risk factors [20]. In addition, the median time for obtaining positive blood cultures
4 was 2–3 days (possibly up to ≥ 7 days) [2]. Thus, for a patient with the confirmed
5
6 diagnosis of candidemia at 8 days after ICU admission, the endogenous colonization
7
8 of *Candida* species might have actually occurred on or before the first day of ICU
9
10 admission. Similarly, for a patient with the confirmed diagnosis of candidemia at
11
12 12-13 days after ICU admission, the endogenous colonization of *Candida* species
13
14 might have occurred 3-5 days after ICU admission.
15
16
17
18

19
20 One main risk factor for candidemia was the systemic antibiotic use [16]. In a
21
22 previous study of pediatric ICUs, it was reported that treatment with vancomycin or
23
24 anti-anaerobic antibiotics for >3 days was independently associated with the
25
26 development of candidemia [2], but only in an unadjusted analysis [16]. A study in
27
28 Hong Kong found that candidemia occurred in patients within 6 days of ICU
29
30 admission, and more than 97.0% of patients infected with fungi of *Candida* species
31
32 had received >48 hours of antibiotic treatment [64]. Overuse and prolonged use of
33
34 broad-spectrum antibiotics have been closely associated with candidemia in China
35
36 and India [65, 66], so it's reasonable to suspect a link between overuse of
37
38 broad-spectrum antibiotics and early-onset of candidemia after ICU admission.
39
40
41 Regardless of geographical differences, most patients with IC received
42
43 broad-spectrum antibiotic treatment prior to candidemia onset in the ICU. However,
44
45 due to a lack of sufficient data, potential correlation between prolonged exposure to
46
47 broad-spectrum antibiotics and the time of candidemia onset after ICU admission
48
49 could not be assessed. Further explanations of the longer duration of ICU admission
50
51 prior to candidemia onset in South America than in Asia/Europe/US/Australia also
52
53 could not be determined in this systematic review.
54
55
56
57

58 Results of this study showed no significant difference in the length of hospital stay
59
60

1
2
3 prior to the development of IC and in the overall mortality between patients with and
4 without invasive infection of *C. albicans*. This may be due to the fact that clinical
5 presentation and the treatment of patients with candidemia caused by *C. albicans* and
6 non-*C. albicans* were indistinguishable [67]. Although it was found that the mortality
7 rates in patients with *C. albicans* and non-*C. albicans* was similar, the susceptibilities
8 of these strains to anti-fungal agents were different [21, 68, 69].
9

10
11 This systematic review had several limitations. Because this systematic review
12 lacks a pre-specified protocol and the preliminary registration, biased post hoc
13 decisions in the reviewing process may occur. In addition, a number of the trials
14 reported outcomes using median (range) and/or median (IQR), and in order to
15 combine these results, the sample means and standard deviations for those trials were
16 estimated using a method proposed by Wan et al. [24], based under the assumption
17 that data were normally distributed. Across the meta-analysis, however, medians and
18 quartiles were often reported when data did not follow a normal distribution [23],
19 which may have confounded the results. Results of the quality assessment also
20 indicated that potential biases from confounders may be present. High heterogeneity
21 existed in both overall and subgroup analyses, suggesting complexity of the risk
22 factors causing IC and candidemia (Supplementary Table S2).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Although different designs, regional differences, and risks of bias may contribute
45 to the heterogeneity between groups, there may be other potential factors that requires
46 further study. Factors such as comorbidities, severity of illness, and invasive
47 procedures (e.g., hemodialysis, invasive mechanical ventilation, total parenteral
48 nutrition, surgery, and immunosuppression), were not taken into account in this
49 analysis. Publication bias may have existed in some analyzed outcomes as well.
50
51
52
53
54
55
56
57

58 This meta analysis finds that patients who had longer length of ICU stay were
59
60

1
2
3 more likely to develop candidemia. Therefore, early detection and therapeutic
4
5 intervention should be considered in the ICU to reduce potential risk of fungal
6
7 infection and its complications, which will help conserving valuable medical
8
9 resources and ultimately saving more lives.
10
11
12
13

14 **Acknowledgements**

15
16
17 The medical writing and editorial assistance were provided by Elizabeth Goodwin and
18
19 Prof. Jerry Tseng of MedCom Asia Inc., China. This assistance was funded by MSD
20
21 China. The authors initiated the concept for this systematic review and are responsible
22
23 for the content of the manuscript.
24
25

26 **Competing interests:** The authors declare that they have no competing interests
27

28 **Funding:** None
29

30 **Authors' contributions:**

31
32
33 ZDZ: guarantor of integrity of the entire study; study concepts; study design;
34
35 definition of intellectual content; manuscript editing; manuscript review.
36
37

38 RZ: guarantor of integrity of the entire study; study concepts; study design; definition
39
40 of intellectual content; manuscript editing; manuscript review.
41
42

43 ZGL: guarantor of integrity of the entire study; study concepts; study design;
44
45 definition of intellectual content; manuscript editing; manuscript review.
46
47

48 XCM: guarantor of integrity of the entire study; study concepts; study design;
49
50 definition of intellectual content; manuscript editing; manuscript review.
51
52

53 **Data sharing statement:** No additional data are available.
54
55
56
57
58
59
60

REFERENCES

1. Calandra T, Roberts JA, Antonelli M, et al. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. *Crit Care* 2016;20:125.
2. Pappas PG, Kauffman CA, Andes DR, et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;62:409-17.
3. Bassetti M, Peghin M, Timsit JF. The current treatment landscape: candidiasis. *J Antimicrob Chemother.* 2016;71:ii13-ii22.
4. Yapar N. Epidemiology and risk factors for invasive candidiasis. *Ther Clin Risk Manag.* 2014;10:95-105.
5. Strollo S, Lionakis MS, Adjemian J, et al. Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002-2012. *Emerg Infect Dis.* 2016;23:7-13.
6. Leon C, Ostrosky-Zeichner L, Schuster M. What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. *Intensive Care Med* 2014;40:808-19.
7. Yang SP, Chen YY, Hsu HS, et al. A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study. *BMC Infect Dis* 2013;13:10.
8. Montagna MT, Lovero G, Borghi E, et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. *Eur Rev Med Pharmacol Sci.* 2014;18:661-74.

- 1
2
3 9. Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine
4
5 research agenda on invasive fungal infection in critically ill patients. *Intensive*
6
7 *Care Med.* 2017;43:1225-38.
8
9
- 10 10. Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of
11
12 invasive candidiasis. *Clin Infect Dis.* 2012;54:1123-5.
13
14
- 15 11. Kullberg BJ, Arendrup MC. Invasive Candidiasis. *N Engl J Med.*
16
17 2016;374:794-5.
18
- 19 12. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at
20
21 increased risk for candidal infections in the surgical intensive care unit: an
22
23 approach to developing practical criteria for systematic use in antifungal
24
25 prophylaxis trials. *Med Mycol*2005;43:235–43
26
27
- 28 13. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective
29
30 development and validation of a clinical prediction rule for
31
32 nosocomial invasive candidiasis in the intensive care setting. *Eur J Clin*
33
34 *Microbiol Infect Dis.* 2007;26:271-6.
35
36
- 37 14. Liao X, Qiu H, Li R, et al. Risk factors for fluconazole-resistant invasive
38
39 candidiasis in intensive care unit patients: An analysis from the China Survey
40
41 of Candidiasis study. *J Crit Care* 2015;30:862.e861-5.
42
43
44
- 45 15. Aguilar G, Delgado C, Corrales I, et al. Epidemiology of invasive candidiasis in
46
47 a surgical intensive care unit: an observational study. *BMC Res Notes*
48
49 2015;8:491.
50
- 51 16. Ortiz Ruiz G, Osorio J, Valderrama S, et al. Risk factors for candidemia in
52
53 non-neutropenic critical patients in Colombia. *Med Intensiva.*2016;40:139-44.
54
55
- 56 17. Ostrosky-Zeichner L. Clinical prediction rules for invasive candidiasis in the
57
58 ICU: ready for prime time? *Crit Care.* 2011;15:189.
59
60

- 1
2
3 18. León C, Ruiz-Santana S, Saavedra P, et al. Contribution of Candida biomarkers
4 and DNA detection for the diagnosis of invasive candidiasis in ICU patients
5 with severe abdominal conditions. *Crit Care*. 2016;20:149.
6
7
8
9
10 19. Martín-Mazuelos E, Loza A, Castro C, et al. β -D-Glucan and Candida albicans
11 germ tube antibody in ICU patients with invasive candidiasis. *Intensive Care*
12 *Med*. 2015;41:1424-32.
13
14
15
16
17 20. Eggimann P, Que YA, Revelly JP, Pagani JL. Preventing invasive *Candida*
18 infections. Where could we do better? *J Hosp Infect*. 2015;89:302-8.
19
20
21 21. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk
22 of bias in non-randomized studies of interventions. *BMJ*. 2016; 355; i4919.
23
24
25
26 22. Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for
27 ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions
28 (ROBINS-I): detailed guidance, updated 12 October 2016. Available from
29 <http://www.riskofbias.info>.
30
31
32
33
34
35 23. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The
36 methodological quality assessment tools for preclinical and clinical studies,
37 systematic review and meta-analysis, and clinical practice guideline: a
38 systematic review. *J Evid Based Med*, 2015, 8(1):2-10.)
39
40
41
42
43
44 24. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
45 deviation from the sample size, median, range and/or interquartile range. *BMC*
46 *Med Res Methodol*. 2014;14:135.
47
48
49
50
51 25. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and
52 interpreting funnel plot asymmetry in meta-analyses of randomised controlled
53 trials. *BMJ*. 2011 Jul 22;343:d4002.
54
55
56
57
58
59
60

- 1
2
3 26. Yang Y, Guo F, Kang Y, et al. Epidemiology, clinical characteristics, and risk
4 factors for mortality of early- and late-onset invasive candidiasis in intensive
5 care units in China. *Medicine (Baltimore)*. 2017;96:e7830.
6
7
8
9
10 27. Fochtmann A, Forstner C, Haggmann M, et al. Predisposing factors for
11 candidemia in patients with major burns. *Burns*.2015;41:326-32.
12
13
14 28. Klingspor L, Tortorano AM, Peman J, et al. Invasive *Candida* infections in
15 surgical patients in intensive care units: a prospective, multicentre survey
16 initiated by the European Confederation of Medical Mycology (ECMM)
17 (2006-2008). *Clin Microbiol Infect*.2015;21:87.e81-7.e10.
18
19
20
21
22
23 29. Chakrabarti A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and
24 outcome of ICU-acquired candidemia in India. *Intensive Care*
25 *Med*.2015;41:285-95.
26
27
28
29
30 30. Giri S, Kindo AJ, Kalyani J. Candidemia in intensive care unit patients: a
31 one-year study from a tertiary center in South India. *J Postgrad Med*.
32 2013;59(3):190-5.
33
34
35
36
37 31. Karacaer Z, Oncul O, Turhan V, Gorenek L, Ozyurt M. A surveillance of
38 nosocomial candida infections: epidemiology and influences on mortality in
39 intensive care units. *Pan Afr Med J*.2014;19:398.
40
41
42
43
44 32. Colombo AL, Guimaraes T, Sukienik T, et al. Prognostic factors and historical
45 trends in the epidemiology of candidemia in critically ill patients: an analysis of
46 five multicenter studies sequentially conducted over a 9-year period. *Intensive*
47 *Care Med*.2014;40:1489-98.
48
49
50
51
52
53 33. Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the
54 intensive care unit: a multicentre, prospective, observational study in Italy
55 (2006-2008). *Mycoses*.2012;55:73-9.
56
57
58
59
60

- 1
2
3 34. Ylipalosaari P, Ala-Kokko TI, Karhu J, et al. Comparison of the epidemiology,
4 risk factors, outcome and degree of organ failures of patients with candidemia
5 acquired before or during ICU treatment. Crit Care. 2012;16:R62.
6
7
8
9
10 35. Pasero D, De Rosa FG, Rana NK, et al. Candidemia after cardiac surgery in the
11 intensive care unit: an observational study. Interact CardiovascThorac
12 Surg.2011;12:374-8.
13
14
15
16
17 36. Han SS, Yim JJ, Yoo CG, et al. Clinical characteristics and risk factors for
18 nosocomial candidemia in medical intensive care units: experience in a single
19 hospital in Korea for 6.6 years. J Korean Med Sci.2010;25:671-6.
20
21
22
23
24 37. Pratikaki M, Platsouka E, Sotiropoulou C, et al. Epidemiology, risk factors for
25 and outcome of candidaemia among non-neutropenic patients in a Greek
26 intensive care unit. Mycoses.2011;54:154-61.
27
28
29
30
31 38. Playford EG, Lipman J, Kabir M, et al. Assessment of clinical risk predictive
32 rules for invasive candidiasis in a prospective multicentre cohort of ICU
33 patients. Intensive Care Med.2009;35:2141-5.
34
35
36
37
38 39. Holley A, Dulhunty J, Blot S, et al. Temporal trends, risk factors and outcomes
39 in *albicans* and non-*albicans* candidaemia: an international epidemiological
40 study in four multidisciplinary intensive care units. Int J Antimicrob
41 Agents.2009;33:554.e551-7.
42
43
44
45
46
47 40. Choi HK, Jeong SJ, Lee HS, et al. Blood stream infections by *Candida*
48 *glabrata* and *Candida krusei*: A single-center experience. Korean J Intern
49 Med. 2009;24:263-9.
50
51
52
53
54 41. Chow JK, Golan Y, Ruthazer R, et al. Risk factors for *albicans* and non-*albicans*
55 candidemia in the intensive care unit. Crit Care Med.2008;36:1993-8.
56
57
58
59
60

- 1
2
3 42. Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY. Candidemia and
4
5 candiduria in critically ill patients admitted to intensive care units in France:
6
7 incidence, molecular diversity, management and outcome. *Intensive Care*
8
9 *Med.*2008;34:292-9.
10
11
12 43. Girão E, Levin AS, Basso M, et al. Seven-year trend analysis of nosocomial
13
14 candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care
15
16 Units at a Brazilian University Hospital. *Med Mycol.*2008;46:581-8.
17
18
19 44. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. *Candida*
20
21 *albicans* versus non-*albicans* intensive care unit-acquired bloodstream
22
23 infections: differences in risk factors and outcome.
24
25 *AnesthAnalg.*2008;106:523-9.
26
27
28 45. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in
29
30 immunocompromised and immunocompetent critically ill patients: a
31
32 prospective comparative study. *Eur J ClinMicrobiol Infect.*
33
34 *Dis.*2007;26:377-84.
35
36
37 46. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of
38
39 candidemia and candidemia-related death in cardiothoracic ICU patients.
40
41 *Chest.*2003;124:2244-55.
42
43
44 47. Gong X, Luan T, Wu X, et al. Invasive candidiasis in intensive care
45
46 units in China: Risk factors and prognoses of *Candida albicans* and
47
48 non-*albicans* *Candida* infections. *Am J Infect Control.* 2016;44:e59-63.
49
50
51 48. Hu B, Du Z, Kang Y, et al. Catheter-related *Candida* bloodstream infection in
52
53 intensive care unit patients: a subgroup analysis of the China-SCAN study.
54
55 *BMC Infect Dis.*2014;14:594.
56
57
58
59
60

- 1
2
3 49. Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in
4
5 China: a multicentre prospective observational study. *J Antimicrob*
6
7 *Chemother.*2013;68:1660-8.
8
9
- 10 50. Yap HY, Kwok KM, Gomersall CD, et al. Epidemiology and outcome of
11
12 *Candida* bloodstream infection in an intensive care unit in Hong Kong. *Hong*
13
14 *Kong Med J.*2009;15:255-61.
15
16
- 17 51. Zhao H, Wong C, Wu P, et al. An analysis of mortality and clinical
18
19 characteristics of ICU-acquired candidemia patients. *Chin Crit Care*
20
21 *Med.*2018;30(10):929-32.
22
23
- 24 52. Ding R, Ji Y, Liu B, et al. Risk factors for mortality in cases of intensive care
25
26 unit-acquired candidemia: a 5.5-year, single-center, retrospective study. *Int J*
27
28 *Clin Exp Med.*2018;11(9):9950-7.
29
30
- 31 53. Tigen ET, Bilgen H, Gurun HP, et al. Risk factors, characteristics, and outcomes
32
33 of candidemia in an adult intensive care unit in Turkey. *Am J Infec*
34
35 *Control.*2017;45:e61-3.
36
37
- 38 54. Baldesi O, Bailey S, Ruckly S, et al. ICU-acquired candidemia in France:
39
40 epidemiology and temporal trends, 2004-2013-a study from REA-RAISIN
41
42 network. *J Infection.*2017;75:59-67.
43
44
- 45 55. Rudramurthy SM, Chakrabarti A, Paul RA, et al. *Candida auris* candidemia in
46
47 Indian ICUs: analysis of risk factors. *J Antimicrob*
48
49 *Chemother.*2017;72:1794-1801.
50
51
- 52 56. Kawano Y, Togawa A, Nakamura Y, et al. Prognostic factors for candidemia in
53
54 intensive care unit patients: a retrospective analysis. *Singapore Med*
55
56 *J.*2017;58(4):196-200.
57
58
59
60

- 1
2
3 57. Playford EG, Lipman J, Jones M, et al. Problematic dichotomization of risk for
4
5 intensive care unit (ICU)-acquired invasive candidiasis: results using a
6
7 risk-predictive model to categorize 3 levels of risk from a multi-center
8
9 prospective cohort of Australian ICU patients. *Clin Infect*
10
11 *Dis.*2016;63(11):1463-9.
12
13
14 58. Pinhati HM, Casulari LA, Souza AC, et al. *BMC Infect Dis.*2016;16(433):1-6.
15
16 59. Kautzky S, Staudinger T, Presteri E. Invasive candida infection in patients of a
17
18 medical intensive care unit. *Wien Klin Wochenschr.*2015;127: 132-42.
19
20
21 60. Lortholary O, Renaudat C, Sitbon K, et al. The risk and clinical outcome of
22
23 candidemia depending on underlying malignancy. *Intensive Care*
24
25 *Med.*2017;43:652-662.
26
27
28 61. Yapar N, Akan M, Avkan-Oguz V, et al. Risk factors, incidence and outcome of
29
30 candidemia in a Turkish intensive-care unit: a five-year retrospective cohort
31
32 study. *Anaesth Pain Intensive Care.*2014;18(3): 265-71.
33
34
35 62. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidemia
36
37 in critically ill patients: a prospective surveillance study.
38
39 *Mycoses.*2007;50:302-10.
40
41
42 63. Piazza O, Boccia MC, Iasiello A, et al. Candidemia in intensive care patients.
43
44 *Minerva Anesthesiol.*2003;70:63-9.
45
46
47 64. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics
48
49 in primary health care settings in China. *JAMA Intern Med.* 2014;174:1914-20.
50
51
52 65. Agrawal C, Biswas D, Gupta A, Chauhan BS. Antibiotic overuse as a risk factor
53
54 for candidemia in an Indian pediatric ICU. *Indian J Pediatr.* 2015;82:530-6.
55
56
57
58
59
60

- 1
2
3 66. Cheng MF, Yang YL, Yao TJ, et al. Risk factors for fatal candidemia caused by
4
5 *Candida albicans* and non-*albicans Candida* species. BMC Infect
6
7 Dis.2005;5:22.
8
9
10 67. Cheng MF, Yu KW, Tang RB, et al. Distribution and antifungal susceptibility of
11
12 *Candida* species causing candidemia from 1996 to 1999. DiagnMicrobiol Infect
13
14 Dis.2004;48:33-7.
15
16
17 68. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of *Candida* species
18
19 to amphotericin B and fluconazole: the emergence of fluconazole resistance in
20
21 *Candida tropicalis*. Infect Control Hosp Epidemiol.2004;25:60-4.
22
23
24 69. Yang YL, Cheng HH, Lo HJ. In vitro activity of voriconazole against *Candida*
25
26 species isolated in Taiwan. Int J Antimicrob Agents.2004;24:294-6.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Figure legends**
5
6
7

8 **Figure 1.** PRISMA flow diagram of study selection
9

10
11 **Figure 2.** Meta-analysis of *C. albicans* vs. non-*C. albicans* for A) length of hospital
12
13
14 stay; B) ICU length of stay; and C) Overall mortality
15
16

17
18 **Figure 3.** Funnel plot for A) length of hospital stay; B) ICU length of stay; C)
19
20 duration of ICU admission prior to candidemia onset
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1


99x106mm (300 x 300 DPI)

Figure 2.

A. Length of hospital stay (days)



B. ICU length of stay (days)



C. Overall mortality




Figure 2

99x112mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3A




Figure 3B





Figure 3C



130x242mm (300 x 300 DPI)

Supplementary Table S1. Literature search through several databases and the results.

Database	Key words and the combination	Articles found through initial search (N)	Articles excluded based on selection criteria or were duplicates (N)	Articles qualified for full text review (N)	Articles selected for meta-analysis (ref. no.)
PubMed*	(candidiasis OR candidemia) AND (intensive care unit OR ICU) AND risk factors	581	522	59	#14, 15, 26-29, 30-35, 37-45, 47, 48, 51, 53-58, 60, 63
Cochrane	(candidiasis OR candidemia) AND (intensive care unit OR ICU) AND risk factors	42	42	0	-
Embase **	(candidiasis OR candidemia) AND (intensive care unit OR ICU) AND risk factors	566	560	6	#36, 52, 59, 61
Web of Science***	(candidiasis OR candidemia) AND (intensive care unit OR ICU) AND risk factors	677	676	1	-
Manual search		9	0	9	#16, 46, 49, 50, 62
Total number		1875	1800	75	41

* PubMed search filters: Abstract available, English, Chinese, Human

** Embase search filters: Abstract, English, Human

*** Web of Science search filters: Articles, English, Human

Supplementary Table S2. A supplementary information of heterogeneity test for overall studies or given subgroup for Table 3.

Comparison	Length of hospital stay, days				Total length of ICU stay, days				Duration of ICU admission prior to candidemia onset, days				Length of hospital stay prior to ICU admission, days				Overall mortality rate			
	Degrees of freedom				Degrees of freedom				Degrees of freedom				Degrees of freedom				Degrees of freedom			
	of	Q	I ²	P-value	of	Q	I ²	P-value	of	Q	I ²	P-value	of	Q	I ²	P-value	of	Q	I ²	P-value
Overall	16	20197.0	99.92	<0.001	27	2690.9	99.00	<0.001	30	4686.2	99.36	<0.001	4	311.2	98.71	<0.001	39	26981.1	99.86	<0.001
Overall optional^{abcd}	^a 13	850.7	98.47	<0.001	^b 25	2626.7	99.05	<0.001	^c 26	2649.8	99.02	<0.001					^d 35	24273.9	99.86	<0.001
Subgroups																				
Type of study																				
Prospective	7	568.3	98.77	<0.001	12	662.2	98.19	<0.001	16	1572.3	98.98	<0.001	1	0.9	0.35	<0.001	20	13805.2	99.86	<0.001
Retrospective	8	14000.4	99.94	<0.001	14	893.2	98.43	<0.001	13	2670.7	99.51	<0.001	2	28.39	92.95	<0.001	18	9479.2	99.81	<0.001
Presence of neutropenia																				
Neutropenia	7	6119.9	99.89	<0.001	8	2297.7	99.65	<0.001	11	3099.9	99.65	<0.001	0	-	-	-	11	15935.0	99.93	<0.001
Non-neutropenia	1	1.8	42.97	0.185	0			-	1	0	0	1	0	-	-	-	2	1388.4	99.86	<0.001
Type of ICU																				
ICU	7	11712.8	99.94	<0.001	16	930.6	98.28	<0.001	13	1589.8	99.18	<0.001	1	4.14	75.86	0.042	23	13807.9	99.83	<0.001
SICU				-	1	0.7	0.00	0.404	2	31.2	93.60	<0.001	0	-	-	-	2	1005.5	99.80	<0.001
MICU	0			-	1	6.2	83.92	0.013-	1	0	0	1-	0	-	-	-	1	14.3	92.99	<0.001
MICU+SICU	7	776.9	99.10	<0.001	6	713.7	99.16	<0.001	11	1539.5	99.29	<0.001	0	-	-	-	10	8098.2	99.88	<0.001
C. Albicans																				
C. Albicans	2	114.7	98.26	<0.001	2	5.79	65.45	0.055	1	0	0	1					5	1558.5	99.68	<0.001

Non C. Albicans	1	2.262	55.78	0.133	1	5.4	81.37	0.021	0	-	-	-	-	-	-	-				
Presence of																				
IC/candidemia																				
Candidemia	13	651.6	98.01	<0.001	23	2620.0	99.12	<0.001	24	2517.8	99.05	<0.001	3	302.3	99.01	<0.001	32	18755.6	99.83	<0.001
IC	2	2588.9	99.92	<0.001	3	17.0	82.33	0.001	5	1169.4	99.57	<0.001	0	-	-	-	6	3922.9	99.85	<0.001
Region																				
Asia	8	5464.6	99.85	<0.001	11	738.6	98.51	<0.001	11	2189.9	99.50	<0.001	1	1.4	26.82	0.242	16	8966.6	99.82	<0.001
Europe	3	226.5	98.68	<0.001	8	346.7	97.69	<0.001	10	907.3	98.90	<0.001	2	37.9	94.72	<0.001	13	7933.8	99.84	<0.001
South America	0	-	-	-	0	-	-	-	2	19.6	89.80	<0.001	-	-	-	-	4	1960.7	99.80	<0.001

Note: Certain subgroups have only 1 study (degree of freedom = 0).

^a Excluded Yang et al. (2017),Gong et al (2016), Liao et al. (2015), and Guo et al. (2013).

^b Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015),and Guo et al. (2013).

^c Excluded Yang et al. (2017),Gong et al (2016), Liao et al. (2015), and Hu et al. (2014).

^d Excluded Yang et al. (2017), Gong et al (2016), Liao et al. (2015),and Hu et al. (2014).

Dash indicates no available.



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	9



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	34
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	33
Synthesis of results	21	Present the main results of the review. If meta-analyses done, include for each, confidence intervals and measures of consistency.	28
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	38
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	34
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	38
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	41
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	41
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	42

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.